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Summary:  
 
Dry eye disease is a common clinical condition whose aetiology and management 
challenges clinicians and researchers alike. Practitioners have a number of dry eye 
tests available to clinically assess dry eye disease, in order to treat their patients 
effectively and successfully.   
 
This thesis set out to determine the most relevant and successful key tests for dry eye 
disease diagnosis/ management. There has been very little research on determining 
the most effective treatment options for these patients; therefore a randomised 
controlled study was conducted in order to see how different artificial treatments 
perform compared to each other, whether the preferred treatment could have been 
predicted from their ocular clinical assessment, and if the preferred treatment 
subjectively related to the greatest improvement in ocular physiology and tear film 
stability. 
 
This research has found: 
 
1. From the plethora of ocular the tear tests available to utilise in clinical practice, 
the tear stability tests as measured by the non-invasive tear break (NITBUT) up 
time and invasive tear break up time (NaFL TBUT) are strongly correlated. The 
tear volume tests are also related as measured by the phenol red thread (PRT) 
and tear meniscus height (TMH). Lid Parallel Conjunctival Folds (LIPCOF) and 
conjunctival staining are significantly correlated to one another. Symptomology 
and osmolarity were also found to be important tests in order to assess for dry 
eye.  
 
2. Artificial tear supplements do work for ocular comfort, as well as the ocular 
surface as observed by conjunctival staining and the reduction LIPCOF. There 
is no strong evidence of one type of artificial tear supplement being more 
effective than others, and the data suggest that these improvements are more 
due to the time than the specific drops. 
 
3. When trying to predict patient preference for artificial tears from baseline 
measurements, the individual category of artificial tear supplements appeared 
to have an improvement in at least 1 tear metric.  Undoubtedly, from the study 
the patients preferred artificial tear supplements’ were rated much higher than 
the other three drops used in the study and their subjective responses were 
statistically significant than the signs. 
 
4. Patients are also willing to pay for a community dry eye service in their area of 
£17.  
 
In conclusion, the dry eye tests conducted in the study correlate with one another and 
with the symptoms reported by the patient. Artificial tears do make a difference 
objectively as well as subjectively. There is no optimum artificial treatment for dry eye, 
however regular consistent use of artificial eye drops will improve the ocular surface. 
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CHAPTER 1 
Introduction 
 
1.0 Introduction 
Dry eye disease is a common condition reported by many patients in clinical practice. 
Patients may attend the practice mentioning that they suffer from gritty, burning, 
irritated, eyes. Other symptoms include, foreign body sensation, blurred vision and 
photophobia, or uncomfortable feeling eyes particularly in the evening (Begley et al., 
2003). The aetiology and management of dry eye disease has challenged clinicians 
and researchers alike. An understanding of dry eye disease has been made over the 
past decade in areas of epidemiology, pathogenesis, clinical appearance, and potential 
treatment (DEWS, 2007). 
Dry eye has been defined by the Dry Eye Workshop (DEWS) as: 
‘a multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability, with potential damage to the 
ocular surface. It is accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface.’ (Lemp, 2007) 
It has been found that 52% of contact lens wearers, 7% of emmetropes and 23% of 
spectacle wearers report dry eyes in clinical practice (Nichols et al., 2005). These 
findings are not unusual for contact lens wearers; however it is novel for spectacle 
wearers. The possible reasons for these findings is that spectacle wearers require 
more frequent eye tests care for their refractive error (unlike the emmetropes). 
Spectacle wearers may also have more of an awareness of their ocular health than an 
individual not requiring refractive correction. In addition, those wearing spectacles may 
have had a previous diagnosis of dry eye disease, which may have influenced their 
self-reported dry eye status (Nichols et al., 2005). An increase in age, a female gender, 
connective tissue disease, various medications and refractive surgery are a few factors 
which affect dry eyes (Lemp, 2007). 
There are a number of tests available to the practitioner to evaluate both the quality 
and quantity of tears, in order to provide the appropriate treatment for their dry eye 
condition. The tests normally performed in practice include the non-invasive tear break 
up time (NIBUT), invasive or fluorescein break up time (NaFL TBUT), conjunctival and 
corneal staining, tear meniscus height measurement (TMH), phenol red test (PRT) and 
numerous questionnaires (Marci et al., 2000; Doughty et al., 2002,2005,2007; 
Santodomingo-Rubido, 2006). In recent years the diagnostic ability of metrics such as 
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lid parallel conjunctival folds (LIPCOF) has been endorsed (Höh et al., 1995, Pult et al., 
2000). 
A survey conducted by Korb et al., (2000) determined the preferred tests for dry eye 
diagnosis of a number of eye care practitioners with an interest in the tear film. If given 
only one test, 28% chose a dry eye questionnaire, followed by fluorescein break up 
time (19%), then fluorescein staining (13%) and lastly rose bengal (10%). On the other 
hand, a study by Smith et al., (2008) found that symptom assessment with 
questionnaires was preferred alongside tear break up time, corneal staining, tear film 
assessment, conjunctival staining and Schirmer test. The majority of practitioners used 
multiple tests (mean number 6). Doughty (2010) recommended just a logical approach 
as to what tests might be used, suggesting it makes sense to be selective and 
consistent in the tests undertaken. 
 
 
1.2 The Tear Film 
 
1.2.1 The tear apparatus  
The tear system consists of various components; these are the secretory, distribution 
and excretory components. 
 
1.2.1.1 The Secretory component includes the conjunctival goblet cells, and lacrimal 
epithelial cells which are responsible for secreting mucin. The glands of Krause present 
in the fornices and the glands of Wolfring present in the upper and lower tarsal boarder; 
these glands are responsible for secreting aqueous. The thin superficial lipid layer is 
produced by secreting meibomian glands and glands of Zeiss and Moll. All of these 
make up the secretory component of the tear apparatus (Snell and Lemp, 1998). 
1.2.1.2 The Distributary component consists of the lids that mix the tear components 
in order to provide one of the main functions of the tear film by providing a smooth 
optical surface over the cornea. These tears reform after every blink action. There are 
small accumulations of the tears at the lid margins forming the tear ‘lake’ (Saude, 
1993). 
1.2.1.3 The Excretory component comprises of the superior and inferior lacrimal 
canaliculi, their puncta, the lacrimal sac and the naso lacrimal duct. In 60% of eyes the 
puncta are found to be round, however they tend to gradually get more oval in shape 
and more slit like with age (Patel et al., 2006). 
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The tears help protect the corneal surface by maintaining epithelial hydration and act 
as a lubricant to prevent the eyelids from rubbing against the cornea on blinking 
(Saude, 1993). 
1.2.2 Tear film structure 
The classic composition of the tear layer is made of three distinct layers: 
 
1.2.2.1  Lipid Layer is produced by the meibomian glands (or tarsal glands) and is 
responsible for coating the aqueous layer and provides a hydrophobic layer that 
evaporates and prevents tears from dropping on to the cheek (Greiner et. al., 1996). 
These glands are found among the tarsal plates. Therefore the tear fluid deposits 
between the eye ball and oil barriers of the lids (Mishima et al., 1961). Rapid and 
forceful blinking has been shown to increase the thickness of the lipid layer (Korb et al., 
1994). 
1.2.2.2 Aqueous Layer water produced by the lacrimal gland acini and the soluble 
mucins secreted by the goblet cells which promotes spreading of the tear film (Walcott 
et al., 1994), the control of infectious agents (Lal and Khurana, 1994, Flanagan and 
Wilcox, 2009), providing a smooth refracting surface to the cornea (Montes-Mico, 2007) 
and osmotic regulation. The sebum consisting of polar lipids spread over the aqueous 
surface and apolar lipids spread over the polar lipids (Holly, 1980). 
1.2.2.3 Mucus Layer comprises of immunoglobulins, salts, urea, glucose, leukocytes, 
tissue debris, and enzymes such as betalysin, peroxidase and lysozyme (Holly and 
Lemp, 1977). Mucins are produced in the goblet cells of the conjunctiva and secreted 
from them to become the gel forming component in the mucus layer of the tear film 
(Nichols et al., 1985). Mucins from various sources have similar structures (Silberberg 
et al., 1982; Allan, 1983).They are Glycoproteins containing 50 to 80 % carbohydrate. 
They are large, elongated molecules (2-15 X10 6 Daltons) with a protein back bone to 
which oligosaccharides are fixed in a bottle-brush configuration. Cross linking of these 
molecules through disulphide bridges forms polymers of high molecular weight, which 
bind to similar polymers by weak, interactions of their carbohydrate chains to form a 
gel. 
 
Mucin produced by the conjunctival goblet cells and coats the cornea providing a 
hydrophilic layer allowing even distribution of the tear film covering the cornea. It helps 
it adhere to the epithelium and the lipid layer on the top and protects it from rapid 
evaporation. This layer is the innermost layer and is in contact with the microvilli of the 
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corneal epithelium in order to aid wetting of the epithelium and spread the tears over 
the hydrophobic corneal tissue (Hirji and Patel, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Composition of the tear layer. The outer lipid layer protects the tear film 
from evaporation. The middle aqueous layer of the tear film is produced 
by the lacrimal glands. The inner mucin layer underneath helps it to 
adhere to the corneal epithelium. 
 
However, a revised view of the tear layer is that it is an aqueous-mucin gel with 
sulphated glycoaminoglycanson the microvilli of the corneal epithelium. The gel forming 
mucins and the soluble mucins are distributed in a concentration gradient that reduces 
towards the surface lipid (Pflugfelder et al., 2000), see figure 1.2. 
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Figure 1.2: A schematic representation of the tears. The aqueous-mucin gel with 
glycocalyx (sulphated glycoaminoglycans) on the microvilli of the 
corneal epithelium, whilst the gel-forming mucins and soluble mucins 
are distributed in a concentration gradient that decreases towards the 
surface lipid layer. (Adapted from Hirji and Patel, 2010) 
 
1.2.3 Properties of the tear layer 
The tear layer is by most techniques is 7-10μm thick (DEWS, 2007), and secretes at a 
rate of 1-2μl/min (Ehlers, 1965) an undisturbed resident volume of approximately 6-8 
ml (Mishima et al., 1966) and a surface tension of 42-46 dyn/cm (Nagyova et al., 1999). 
The pH of the tears is 7.5 ± 0.1 (Fischer et al., 1982) and osmolarity of 310-334 
mOsms/kg (Benjamin et al., 1983). 
 
The normal estimated tear volume tear volume is 6-10µl, (Mishima et al., 1966; 
Franklin et al., 1973; Port et al., 1990). There are two types of aqueous production: 
basic rate production and reflex production (Jones, 1966). Therefore tear volume 
assessment should ideally be carried out without stimulating reflex tears in order to 
assess tear volume in its most natural state. 
The tears are important in providing protection and nourishment for the cornea and 
conjunctiva. The tears also play an important role in transporting the atmospheric 
oxygen in to the avascular cornea; it also supplies the cornea with glucose, salts, and 
minerals and removes cellular debris and metabolic waste. The tears maintain a 
constant pH whilst maintaining a smooth and transparent optical surface for the best 
refraction through the cornea. The tears also lubricate the cornea and the eyelids 
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preventing dehydration and enabling smooth movement of the eyelids over the cornea 
thus maintaining ocular comfort. In addition the tears trap foreign particles and flush 
them from the eye. They also defend against microbial attack through action of anti-
bacterial enzymes such as lysozyme (DEWS, 2007). 
An instable tear film can cause patients to have dry eye syndrome. These patients 
would complain of irritation, burning, grittiness, foreign body sensation, blurred vision, 
photophobia or discomfort. There are two main types of dry eyes. Secretive dry eye 
where there is inadequate tear production. Many of these patients have inflammation in 
the tear gland together with the presence of inflammatory mediators in the tears and 
within the conjunctiva (Jones et al., 1994) and inflammation elsewhere in the body like 
Rheumatoid arthritis or Sjögren's syndrome. 
Evaporative dry eye is where there is adequate tear production but excess evaporation. 
The commonest causes of increased evaporation of the tears are due to meibomian 
gland disease in which the oil glands of the eyelids fail to coat the surface of the tears 
with a healthy layer of oil (DEWS, 2007). An abnormal tear film lipid layer can be 
caused by various forms of blepharitis which affect the changes in the meibomian 
gland secretions (McCulley et.al., 1982). There are generally lower levels of 
phosphatidyl ethanolamine and sphingomyelin in meibum of patients with blepharitis 
who suffer from dry eye symptoms (Shine et al., 1998). 
Therefore, when evaluating the tears, it is important to note that an alteration or 
anything that affects the secretary, distributary or excretory components of the lacrimal 
system will have an effect on the effectiveness of the quantity and quality of the tears 
on the eye.  
 
 
1.3 Dry Eye Disease 
Dry eye has been recognised as an inefficiency of the lacrimal glands, ocular surface 
including the cornea conjunctiva and meibomian glands and the lids, including the 
sensory and motor nerves that connect them (Stern et al., 1998). Dry eye is a disorder 
of the tear film due to deficiency or excessive evaporation which causes damage to the 
interpalpepebral ocular surface and is associated with symptoms of ocular discomfort 
(Lemp, 1995). Dry eye disease is a common yet under recognised clinical condition 
whose management challenges optometrists and other medical professionals alike. 
There have been great advances in the understanding of dry eye disease in the last 
decade with regards to epidemiology, pathogenesis, clinical representation and 
potential treatment.  
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The Dry Eye Work Shop (DEWS) report developed a new definition of dry eye based 
on current understanding of the disease and recommended a three part classification 
system. The first part is etiopathogenic and illustrates the numerous causes of dry eye. 
The second is mechanistic and shows each cause of dry eye may act through a 
frequent pathway. The third and final part is based on the severity of the dry eye 
disease which is expected to provide a rational basis for treatment. The DEWS 
definition of dry eye was enhanced from previous definitions in the light of new 
information gathered with regards to the roles of tear hyperosmolarity and ocular 
surface inflammation in dry eyes as well as the effects on visual function.  
 
The DEWS definition is – ‘Dry eye is a multifactorial disease of the tears and ocular 
surface that results in symptoms of discomfort, (Begley et al., 2003; Adatia et al., 2004; 
Vitale et al, 2004) visual disturbance, (Rieger 1992; Liu et al., 1999; Goto et al., 2002) 
and tear film instability (Holly et al., 1973; Bron, 2001; Goto et al., 2003) with potential 
damage to the ocular surface. It is accompanied by increased osmolarity of the tear 
film (Farris et al., 1986; Gilbard, 1994; Murube, 2006; Tomlinson et al., 2006) and 
inflammation of the ocular surface’ (Pflugfelder et al., 1999; Tsubota et al., 1998). 
Figure 1.3 Summarises the DEWS definitions and classification of Dry eye. Dry eye is 
classified in to two major groups:  the aqueous deficient dry eye and the evaporative 
dry eye. Aqueous-deficient dry eye has two major divisions, Sjögren syndrome dry eye 
and non-Sjögren syndrome dry eye. Evaporative dry eye is either intrinsic, where the 
regulation of evaporative loss from the tear film is directly affected, e.g., by meibomian 
lipid deficiency, poor lid congruity and lid dynamics, low blink rate, and the effects of 
drug action. In contrast, extrinsic evaporative dry eye occurs where there is an increase 
in evaporation by their pathological effects on the ocular surface. The causes of this 
include: vitamin A deficiency, the action of toxic topical agents such as preservatives, 
contact lens wear and a range of ocular surface diseases, including allergic eye 
disease.  
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Figure 1.3: Illustrating the Major etiological causes of dry eye disease. 
(Adapted from DEWS report 2007) 
 
 
Evidence supports a role of sex hormones in the aetiology of dry eye (Sullivan, 2004) 
with a consensus that low levels of androgens and high oestrogen levels are risk 
factors for dry eye. Lacrimal and meibomian gland function is promoted by androgens 
and a deficiency is associated with dry eye (Sullivan, 2004). 
Physiological changes associated with aging are pre disposed to dry eye including 
reduced tear volume and flow, an increase in osmolarity, (Mathers et al., 1996) 
reduced tear film stability, (Patel et al., 1989) and alterations in the composition of the 
meibomian lipids (Sullivan et al., 2006). 
The 1995 National Eye Institute (NEI) / Industry Dry Eye Workshop classifications of 
dry eye are still held. Firstly there is aqueous tear deficient dry eye which refers mainly 
to a failure of lacrimal secretion and a failure of water secretion by the conjunctiva may 
also contribute to this. Secondly, evaporative dry eye which is dependent on intrinsic 
conditions of the lids and ocular surface.  
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The major classes and sub classes of dry eye are described below: 
1.3.1 Aqueous tear deficient dry eye (ADDE) 
ADDE is due to a failure of lacrimal tear secretion. Dryness results from a reduced 
lacrimal secretion as well as volume (Mishima et al 1966.; Scherz et al., 1975). A 
dysfunction in the lacrimal tear secretion causes tear hyperosmolarity due to a reduced 
aqueous tear pool. The tear film hyperosmolarity causes hyperosmolarity of the ocular 
surface epithelial cells which stimulate a series of inflammatory events (Li et al., 2004; 
Luo et al., 2005). There is an uncertainty in ADDE whether evaporation is increased 
(Tsubota et al.; 1992, Mathers, 1996) or if evaporation is reduced. Studies have 
suggested that the reservoir of lid oil is greater in non-Sjögren syndrome dry eye (Yokoi 
et al., 1999) and the tear film lipid layer is thicker (Yokoi et al., 1996). However, studies 
of the tear film lipid layer in ADDE have shown that spreading of the lipid layer is 
delayed in the inter blink interval (Owens et al., 2002, Goto et al., 2003) 
 
ADDE has two classes’ Sjögren syndrome dry eye (SSDE) and non-Sjögren syndrome                
eye (NSSDE). 
 
1.3.1.1 Sjögren syndrome dry eye (SSDE)  
SSDE is when the lacrimal and salivary glands are targeted by an autoimmune process 
and other organs are also affected. The lacrimal glands are penetrated by activated T-
cells, which results in acinar and ductular cell death and hypo secretion of the tears. 
The dryness of the ocular surface is due to this hypo secretion and inflammation of the 
lacrimal gland, in conjunction with the existence of inflammatory mediators in the tears 
and within the conjunctival tissue (Jones et al., 1994). 
 
1.3.1.2 Non-Sjögren syndrome (NSSDE) 
NSSDE is due to lacrimal dysfunction where the systemic auto immune features which 
are characteristic of the SSDE have been excluded. Age related dry eye is the most 
common form of NSSDE. Different forms of NSSDE are listed in table 1.1. 
 
Primary Lacrimal Gland Deficiencies  Age Related Dry Eye 
Congenital Alacrima 
Familial Dysautonomia  
Secondary lacrimal gland deficiencies Lacrimal Gland infiltration 
Sarcoidosis 
Lymphoma 
Aids 
Graft Vs Host disease 
Lacrimal gland ablation 
Lacrimal gland denervation 
Obstruction of the lacrimal gland ducts Trachoma 
Cicatricial pemphigoid and mucous 
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membrane pemphigoid 
Erythema multiforme 
Chemical and thermal burns.  
Reflex Hypo secretion Reflex sensory block – contact lens wear, 
diabetes, neurotrophic keratitis 
Reflex motor block – VII cranial nerve 
damage, Multiple neuromatosis, Exposure to 
systemic drugs.  
Table 1.1: Conditions associated with non-Sjögren syndrome dry eye. (Adapted 
from DEWS, 2007) 
 
1.3.1.2.1 Age related dry eye (ARDE) - is a primary disease and there is some 
uncertainties as to whether tear dynamics are affected by age in the normal population 
(Tomlinson et al., 2005). A significant age related correlation for tear evaporation flow 
osmolarity and volume has been shown (Mathers, 1996). However, studies conducted 
by Craig and Tomlinson (Craig et al., 1998) have shown that there is no such 
relationship. Likewise for tear turnover (Sahlin et al., 1996) tear evaporation (Rolando 
et al., 1983, Tomlinson et al., 1993) and the lipid layer (Norn et al., 1979) no age 
relationship has been found. 
 
 
1.4 Evaporative dry eye (EDE)  
EDE is due to excessive water loss from the ocular surface in the presence of normal 
lacrimal secretion. Evaporative dry eye causes have been described as intrinsic 
disease affecting structures or the dynamics of the eye, or extrinsic where the ocular 
surface disease to some external exposure (DEWS, 2007). 
1.4.1 Intrinsic causes of EDE  
1.4.1.1 Meibomian Gland Dysfunction (MGD) - is the most common cause of EDE 
(Bron, 2004). If present to a sufficient extent it is associated with a reduced tear lipid 
layer, an increase in tear evaporation and evaporative dry eye (Knope et al., 2011). 
1.4.1.2 Disorders of lid aperture or lid globe congruity- proptosed eyes will 
encounter an increased evaporation of the tear film (Gilbard et al., 1983). An increased 
palpebral fissure is associated with tear hyperosmolarity and ocular surface drying 
(Gilbard et al., 1983). Having an upward gaze position is also known to affect ocular 
surface drying as it causes an increased ocular surface exposure (Tsubota et al., 
1995). An increased palpebral fissure correlates well with an increase in tear film 
evaporation (Rolando et al., 1985). 
1.4.1.3 Low blink rate - drying of the ocular surface will be affected when the period 
between blinks increases (Abelson et al., 2002). This can occur as a physiological 
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phenomenon through particular visual tasks e.g. working at a display screen (Nakamori 
et al., 1997). It is also known to be a characteristic of Parkinson’s disease (Lawrence et 
al., 1991). 
1.4.2 Extrinsic causes of EDE  
1.4.2.1 Ocular surface disorders– a condition affecting the ocular surface will lead to 
poor surface wettability thus causing a short tear break up time of the tear film and 
hyperosmolarity which leads to a dry eye. The main causes of ocular surface disorder 
include a deficiency in Vitamin A and the effects of topical anaesthetics and 
preservatives.  
 
1.4.2.1.1 Vitamin A- is crucial for goblet cell production and glycocalyx formation (Tei 
et al., 2000). Vitamin A deficiency causes lacrimal acinar damage as well; hence 
patients with xeropthalmia will result in having aqueous tear deficient dry eye (Sommer 
et al., 1982). 
 
1.4.2.1.2 Topical drugs and preservatives- preservatives such as benzalkonium 
chloride (BAK) can cause a toxic response of the epithelium of the cornea causing 
reduced surface wettability. Hence non-preserved tear preparations are preferable to 
preserved ones (Pisella et al., 2002). Topical anaesthesia reduces lacrimal secretion 
by inhibiting the sensory innervation to the lacrimal gland and reduces the blink rate. 
The chronic use of anaesthesia causes a neurotrophic keratitis which can lead to 
corneal perforation (Pharmakakis et al., 2001, Chen et al., 2004). 
 
1.4.2.2 Contact lens wearers– are 12 times more likely than an emmetrope and 5 
times more likely than spectacle wearers to state dry eye symptoms (Nichols et al., 
2004). Females report more dry eye symptoms than males, with 40% of males and 
62% of females classified as having dry eye in one study in the USA (p<0.0001; 
Nichols et al., 2006). 
 
1.4.3 Ocular Surface Disease   
Evidence suggests that various forms of chronic ocular surface disease result in 
disruption of the tear film and add a dry eye component to the ocular surface disease. 
A well-studied example is allergic eye disease (Abelson et al., 2003). Similarly any form 
of dry eye, whatever its origins, may cause at least a loss of goblet cell numbers, so 
that an ocular surface element is added (Ralph, 1975). 
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1.4.4 Allergic Conjunctivitis 
Allergic conjunctivitis includes seasonal allergic conjunctivitis, vernal 
keratoconjunctivitis, and atopic keratoconjunctivitis. There is stimulation of goblet cell 
secretion and loss of surface membrane mucins (Kunert et al., 2001). Surface epithelial 
cell death occurs, affecting conjunctival and corneal epithelium (punctate 
keratoconjunctivitis). Surface damage and the release of inflammatory mediators’ leads 
to allergic symptoms and to reflex stimulation of the normal lacrimal gland. 
 
The Beaver Dam study, noted that ocular allergy was a risk factor for dry eye, although 
the concomitant use of systemic medications, such as antihistamines, was recognized 
as a potential contributor (Moss et al., 2004). 
 
1.5 The core mechanisms of Dry Eye 
The tear hyperosmolarity and tear film instability can change dry eye over time. The 
interactions of various aetiologies with these fundamental processes are summarised 
in figure 1.3. 
 
1.5.1 Tear Hyperosmolarity 
In the early stages of dry eye, it is considered that ocular surface damage is caused by 
osmotic, inflammatory or mechanical pressure, resulting in reflex stimulation of the 
lacrimal gland. Trigeminal nerve activity is responsible for an increase in blink rate and 
increased lacrimal secretion. This may help to reduce the degree of tear 
hyperosmolarity. However, tear flow in these patients may be greater than average, 
which show reduced tear breakup time and increased ocular surface staining 
(Shimazaki et al., 1998).  
 
Tear hyperosmolarity is deemed as the fundamental mechanism causing ocular 
surface inflammation, damage and symptoms in dry eye. It arises as a result of water 
evaporation from the exposed ocular surface. It occurs in circumstances of a low 
aqueous tear flow, or a consequence of excessive evaporation, or a mixture of these 
events (DEWS, 2007). There appears to be wide variation of tear film thinning rates in 
normal subjects, and therefore, it is reasonable to conclude that, for a given initial film 
thickness, subjects with the fastest thinning rates would experience a greater tear film 
osmolarity than those with the slowest rates as demonstrated by Nichols et al., (2004). 
 
Osmolarity is higher in the tear film itself than in the adjacent menisci. This is due to the 
ratio of area to volume which is higher in the film than the menisci (Bron et al., 2002). 
Hyperosmolarity stimulates a series of inflammatory events in the epithelial surface 
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cells, involving MAP kinases and NFkB pathways (Li et al., 2004) and the group of 
inflammatory cytokines (IL-1α; -1β; TNF-α) and MMPs (principally MMP9), (De Paiva et 
al., 2006), which stimulate inflammatory cells  at the ocular surface (Baudouin, 2007). 
Hyperosmolarity stimulates inflammatory events in epithelial surface cells and the 
production of inflammatory cytokines and matrix metallo-proteinases (Li et al., 2004; 
Tsubota and Yamada, 1992). These inflammatory events lead to the death of surface 
epithelial cells, including goblet cells (Yeh et al., 2003). A trait of every form of a dry 
eye is a loss of goblet cells (Zhao et al., 2001). A decline in goblet cells will result in 
reduced mucin production (Argüeso et al., 2002) and therefore a reduction in tear film 
stability (DEWS Report 2007). A diminished goblet cell density has been shown to 
correlate with decreased levels of MUC 5AC in dry eye patients by Argüeso and 
colleagues (2002). The effects of chronic inflammation may be directly associated with 
goblet cell loss (Brignole et al., 2000; Kunert et al., 2002). 
Inflammatory mediators such as tumour necrosis factor A and interleukin-1 result from 
a hyperosmolar state and severely affects the nerve supply to the cornea (Acosta et al., 
2007) causing a  reduction in tear flow (Figure 1.4). This will support the pre-existing 
reduced tear flow in ADDE and may well reduce tear volume in a previous high volume 
EDE. Hence patients with ADDE and hyperosmolar tears may have a reduction in 
goblet cell density and secondary increased tear film evaporation - EDE. On the other 
hand a patient with primary EDE, e.g. secondary to MGD, will encounter reduced 
corneal sensitivity and a consequently a reduction in tear production resulting in a form 
of ADE (Mathers et al., 1996; Tomlinson et al., 2005). Therefore, for this reason 
differentiating between ADDE and EDE in a clinical setting is challenging. 
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Figure 1.4: Aetiology of dry eye disease (Taken from DEWS 2007).The core 
mechanisms of dry eye are driven by tear hyperosmolarity and tear film 
instability. The cycle of events is shown on the right of the figure. Tear 
hyperosmolarity causes damage to the surface epithelium by activating 
a cascade of inflammatory events at the ocular surface and a release of 
inflammatory mediators into the tears. Epithelial damage involves cell 
death by apoptosis, a loss of goblet cells and disturbance of mucin 
expression, leading to tear film instability. This instability exacerbates 
ocular surface hyperosmolarity and completes the vicious circle. Tear 
film instability can be initiated, without the prior occurrence of tear 
hyperosmolarity, by several aetiologies, including xerophthalmia, ocular 
allergy, topical preservative use, and contact lens wear (DEWS, 2007). 
 
The epithelial injury caused by dry eye stimulates corneal nerve endings, leading to 
symptoms of discomfort, increased blinking and, potentially compensatory reflex 
lacrimal tear secretion. Loss of normal mucins at the ocular surface contributes to 
symptoms by increasing frictional resistance between the lids and globe. During this 
period, the high reflex input has been suggested as the basis of a neurogenic 
inflammation within the gland (DEWS, 2007). 
1.5.2 Tear Film Instability 
Tear film instability may be the initiating factor in some categories of dry eye. It is 
generally accepted that a TBUT < 10 seconds is abnormal (Lemp, 1995). Once break-
up occurs within the blink interval, hyperosmolarity of the tears will result with all of the 
sequelae discussed in the previous sections (Figure 1.4) and further disrupt the tear 
film. 
 
Tear film variability is increased with a low TBUT due to local drying and 
hyperosmolarity, surface epithelial damage, and disturbance of glycocalyx and goblet 
cell mucins. The tear film instability is thought to be due to a disturbance of ocular 
surface mucins (Sommer et al., 1982). The early loss of tear stability in vitamin A 
deficiency results from a decreased amount of mucins at the ocular surface and a loss 
of goblet cells (Sommer et al., 1982). Other examples include the actions of topical 
agents, in particular, preservatives such as BAK. These excite the expression of 
inflammatory cell markers at the ocular surface, causing epithelial cell damage, cell 
death by apoptosis, and a decrease in goblet cell density (Ronaldo et al., 1991). Tear 
film evaporation is inhibited by the presence of the tear film lipid layer (Mishima et al., 
1961). The lipid layer comprises of an inner polar layer, interfacing with the aqueous 
phase, and a thicker outer non-polar layer (Bron et al., 2004). The tear film lipid layer 
stabilises the tear film by reducing the surface tension by 25% and aqueous 
evaporation by 90-95% (Lozato et al., 2001). 
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1.6 Clinical Tear Film Tests  
There are multiple clinical tests to evaluate the tear film:  
 
1.6.1 Non Invasive Break up Time (NIBUT) 
NIBUT is a means of measuring the stability of the tear film without a staining agent. 
NIBUT is typically measured by observing a grid pattern, Purkinje image I or 
keratometer mires projected onto the corneal surface. This can be achieved by using a 
slit lamp, Tearscope (Keeler Inc., Windsor, Berkshire, UK), (Guillon et al., 1994, 1997, 
1998a) or a keratometer, (Patel et al., 1985). Although the tearscope is no longer 
available there is a new product named Polaris on the market (www.bon.de). 
 
Various  acronyms have been used to define these non-invasive measurements of tear 
stability-tear thinning time (TTT), measured using the Bausch & Lomb keratometer 
(Patel et al., 1985); tear film pre-rupture phase time (TP-RPT), measured using a 
modified grid on a Bausch & Lomb keratometer (Hirji et al., 1989); and NIBUT using 
instruments that project a grid pattern image that covers about 70 to 80% of the corneal 
surface (Mengher et al., 1985; Young et al., 1991; Cho et al., 1993). 
 
1.6.2 Tear Meniscus Height (TMH) and Regularity 
The volume of aqueous tears contained within the upper and lower tear meniscus is 
approximately 75-90 per cent of the total volume of the aqueous component 
(Mainstone et al., 1996). Therefore a reasonable assessment for the tear volume can 
be made by observing the height and width of this tear meniscus. 
 
The height of the tear meniscus can be measured with a slit lamp graticule, directly 
below the pupil centre, adjusting the beam height or by capturing an image and 
quantifying with digital callipers. The TMH can be observed with or without fluorescein. 
An increased height indicates poor tear drainage due to an obstructed punctum or an 
excessive aqueous layer giving a watery tear film. On the other hand a reduced tear 
meniscus height suggests a reduced tear volume. The TMH is classified as follows:  
 
 Good: >0.2mm 
 Normal: =0.2mm  
 Poor <0.2mm (Kawai et al., 2007). 
 
If the prism height is regular along the lid margins it indicates the potential for the tears 
to wet the eye consistently. This is said to reduce with age (Gasson & Morris, 1998). 
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Numerous studies demonstrate a good correlation between TMH and symptoms of 
dryness (Mainstone et al., 1996; Golding et al., 1997; Glasson et al., 2003). 
 
A normal TMH has been stated to be between 0.2 and 0.3 mm (Kulkarni et al., 1997) or 
0.5 mm (Marquardt, 1986), therefore suggesting that  any value of <0.2 mm could be 
indicative of lacrimal deficiency. The TMH values of <0.1 mm (Herreras et al., 1992), 
0.1–0.2 mm (Basinger et al., 1994) are suggestive of a marginal dry eye, and TMH of 
≤0.3 mm is abnormal (Lithgow, 1996; Kinney, 1998), or that <0.3 mm was diagnostic 
for dry eye (Terry, 1984). Liao et al., (2000), suggested that a TMH of ≥0.2 mm as a 
high value and indicative of ocular irritation, possibly applying to the elderly patients. 
 
1.6.3 The Schirmer Test 
The Schirmer test was introduced at the turn of the last century for assessing aqueous 
production/volume (Schirmer, 1903). The Schirmer strip is a filter paper, measuring 
5mm in width and 35mm in length and is folded 5mm from one end. The folded end is 
inserted nearly one third from the temporal canthus amid the lower eyelid and the 
ocular surface (Farrell, 2010). 
 
The Schirmer test (I), is performed without anaesthesia, and perhaps the most 
frequently used of the Schirmer tests in clinical practice (Farrell, 2010). The strip is left 
in position for 5 minutes while the patient is instructed to keep their eyes open and blink 
normally. In normals the average result is approximately 17mm wetting in five minutes 
(Wright et al., 1962; Loran et al., 1987). A wetting value of 5mm or less in five minutes 
is considered abnormal (severe deficiency), while 5-10mm in five minutes is 
moderately deficient (Farrell, 2010). However, when the test is performed without 
anaesthetic, the invasive nature of the test may stimulate reflex lacrimation, therefore, 
under these conditions tears quantified may combine both basal and reflex production 
(Doughman, 1973). Hence, the use of anaesthetic is aimed at preventing reflex 
secretion to allow for isolated basal measurement (Jones, 1966). The difference 
between the result with and without anaesthetic has been suggested as a measure of 
reflex production (Kanski, 1989). 
 
There is wide intra subject, day-to-day, and visit-to-visit variation, but the variation and 
the absolute value decrease in aqueous-deficient dry eye, probably because of the 
decreased reflex response with lacrimal failure (DEWS, 2007).The diagnostic cut off 
used in the past was ≤5.5 mm in 5 minutes, (Van Bijsterveld, 1969; Mackie et al., 
1981). Pflugfelder et al., (1997 and 1998) and Vitali et al., (2002) have made a case for 
using ≤5 mm. By lowering the cut-off will decrease the sensitivity (i.e. the detection 
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rate), but will increase the specificity of the test. DEWS (2007) have recommended 
conducting the Schirmer test using a cut-off of ≤ 5 mm in 5 minutes. 
 
1.6.4 Phenol Red Thread (PRT) (ZONE QUICK) 
The Phenol Red Test (PRT) consists of cotton, treated with a pH indicator phenol red 
(phenolsilfonphthalein) (Contact lens manual). The thread is pH sensitive and changes 
from yellow to a light red colour as it comes in to contact with the tears (Hamano et al., 
1987). The PRT measures the tear volume. 
 
The PRTs characteristics is that it is easy to handle, has a rapid testing time of only 15 
seconds for each eye and the discomfort associated with the Schirmer tear test is 
minimised. As the Schirmer test may stimulate reflex lacrimation may combine both 
basal and reflex tear production, the PRT measures the tears in the lower tear 
meniscus without causing this stimulating reflex. The advantages of the PRT test, is 
that it does not require any anaesthesia and it may also be performed whilst patients 
are wearing contact lenses. However, it is very difficult to purchase PRT in the UK, and 
the PRT used for this study were purchased from the Netherlands. 
 
 
Figure 1.5: Picture showing the PRT. 
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Fig 1.6: Photograph showing the PRT in situ. 
 
 
The PRT test has been shown to be repeatable and the interpretation of the results 
are: (Little and Bruce, 1994a) 
 
 < 11 mm wet suggests low tear secretion 
 11-16 mm wet suggests borderline secretion 
 >21 mm wet suggests normal tear flow 
 
1.6.5 Sodium Fluorescein Tear Break up Time (NaFL TBUT) 
The application of a standard volume of fluorescein, illuminated by a blue light source 
and the use of a yellow barrier filter can enhance the visibility of the breakup of the tear 
film. The established NaFL TBUT cut-off for dry eye diagnosis, as with NIBUT, has 
been < 10 seconds (Lemp and Hamill, 1973). Abelson et al., (2002), suggested that the 
diagnostic cut-off falls to < 5 seconds when small volumes of fluorescein are instilled. 
At present, sensitivity and specificity data to support this choice have not been 
provided, and the population in that study was not defined. Selecting a cut off below 
<10 seconds will tend to decrease the sensitivity of the test and increase its specificity. 
It has been suggested by various authors that the introduction of fluorescein may affect 
the TBUT by disrupting the stability of the aqueous layer of the tear film, increasing the 
volume of the tear film, and affecting the surface tension of the tear film (Holly, 1978; 
Mengher et al., 1985; Norn, 1986). Some researchers have stressed that the volume 
and concentration of fluorescein could disrupt the tear film (Norn, 1969; 1974; Lemp, 
1973; Mengher et al., 1985; Patel et al., 1985; Guillon et al., 1988; Sorbara et al., 1988;  
Jaanus, 1990) and is therefore been criticised if these are not controlled (Johnson et 
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al., 2005; Peterson et al., 2006). Therefore many researches use a micropipette in 
order to control the volume of fluorescein however; this is not practical in clinical 
practice. Korb et al., (2001) developed the Dry Eye Test (DET) which is a 5 times 
smaller fluorescein strip, in order to enable a controlled amount of fluorescein. The 
DET (Amcon Laboratories, Inc., USA) is not CE labelled and unfortunately cannot be 
used in Europe. Therefore Pult et al., (2012) modified a standard fluorescein strip, by 
folding over the top 1mm of the strip in order to define a standard area for fluorescein 
instillation, and concluded that the modified fluorescein strip was better in the 
repeatability of fluorescein instillation than the use of a standard fluorescein strip. 
 
1.6.6 Corneal Staining 
The corneal or conjunctival surfaces and/or the intracellular surfaces become 
compromised (Korb, 2002) in dry eye patients and staining agents allow these changes 
to be observed. Sodium Fluorescein is the most frequently utilised stain in optometric 
practice.  
 
Sodium fluorescein is a pH-dependent indicator dye which derives its functionality from 
its fluorescent properties (Morgan and Moldonado-Codina, 2009). At the normal ocular 
surface pH (6.5-8.0), the colour of fluorescence remains a constant green (Wang et al., 
2002), and once exposed to light of a wavelength of 495nm, maximum excitation of 
fluorescein is achieved. A blue filter is placed in the illumination system; which blocks 
the wavelengths that don’t stimulate fluorescein molecules, allowing only beneficial 
light to be shone on to the eye. A yellow filter, such as a Kodak Wratten 12, in the 
viewing system will absorb the unwanted reflected light and transmit only the longer 
wavelengths emitted by the fluorescein, when stimulated by the blue light. A moistened 
fluoret shaken to remove excess saline provides a peak intensity of fluorescence after 
about 1 minute (Peterson et al., 2006). An increase in corneal staining has been shown 
to occur with successive doses of fluorescein, however the reasons why are poorly 
understood (Korb and Herman, 1979).  
 
Corneal staining is observed when fluorescein enters damaged epithelial cells (Wilson 
et al., 1995); however, evidence also suggests that fluorescein can diffuse into 
adjoining cells (Kanno and Loewenstein, 1964). McNamara and colleagues (1998) 
demonstrated that low levels of fluorescein can enter healthy corneal epithelium 
through tight cell junctions, but at insufficient levels to be detected with a slit lamp. 
Dundas and colleagues (2001) found up to 79% of healthy corneas have some degree 
of staining. 
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Figure 1.7: Flouret of 1mg fluorescein sodium. 
 
A drop of sodium fluorescein is instilled in to the eye and a blue light is used to observe 
the pre corneal tear film after a few blinks. This is to ensure that the fluorescein is 
completely mixed in to the tear film. The patient is asked to stare ahead whilst the blue 
beam of light is focused on to the cornea. Observation is made as to any damage that 
may appear on the corneal surface. Various grading scales to score fluorescein 
staining have been devised, such as: 
 
 Van Bijsterveld system, (Van Bijsterveld, 1969) 
 Oxford system, (Bron et al., 2003) 
 Standardized version of the  NEI/Industry Workshop system, (Lemp, 1995) 
 Efron (Efron, 1999) 
 CCLRU (CCLRU, 1997) 
 
The Oxford system uses a wider range of scores than the Van Bijsterveld system, 
allowing for the detection of smaller steps of change in a clinical trial. A study 
conducted by Efron et al., (2000), evaluated the validation of grading scales for contact 
lens complications comparing two artist-rendered scales `Efron’ (Efron, 1999), 
`Annunziato' (Annunziato et al., circa 1992), and two photographic grading scales 
‘CCLRU' (CCLRU, 1997) and `Vistakon' (Andersen et al., 1996). It was concluded from 
their study all four grading systems are valid for clinical use and practitioners can 
expect to use these systems with average 95% confidence limits of +1.2 grading scale 
units (observer range +0.7 to + 2.5 grading scale units). However, in view of the 
significant differences revealed in this study in both precision and reliability between 
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systems, observers and conditions, their advice was to consistently use the same 
grading system. 
 
1.6.7 Lissamine Green Conjunctival Staining 
Lissamine green (LG) is a vital stain which is primarily a conjunctival dye which stains 
membrane dead and degenerate cells (Feenstra et al.,1992) and areas of the 
conjunctiva not protected by mucus. It is now replacing the use of rose bengal as the 
preferred dye for conjunctival staining due to better availability and causing less 
discomfort (Machado et al., 2009).  
 
It is instilled using impregnated paper strips containing 1.5mg of the dye. A drop of 
sterile saline is added to the strip before it is placed into the lower fornix of the eye. 
When lissamine green is used it is important to instil a relatively large volume (10-20µl) 
in order to allow adequate staining (Matheson, 2007). At least a minute and no more 
than four minutes, shows optimum staining (Foulks et al., 2003). 
 
A Wratten 25 filter (or equivalent red filter) has been advocated by some to enhance 
the staining contrast against the sclera. Conjunctival staining with LG could show up 
prior to corneal staining with fluorescein in patients with early dry eye (Uchiyama et al., 
2007). 
 
 
Figure 1.8: Lissamine Green Strips. 
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1.6.8 Lid Parallel Conjunctival Folds (LIPCOF) 
LIPCOF are subclinical folds in the lower conjunctiva parallel to the lower lid margin 
(Höh et al., 1995; Pult et al., 2000; Schirra et al., 1998), which have been shown to be 
predictive of dry eye symptoms in contact lens wearers (Pult et al., 2000). 
 
There are several hypothesised causes of bulbar conjunctival folds. The conjunctiva 
‘looseness’ as a result of inflammatory processes, (Meller et al., 1998; Zhang et al., 
2004; Di Pascuale et. al., 2004), aging (Meller et al., 1998; Hirotani et. al., 2003), a 
reduction of elastic fibres (Meller et al., 1998; Zhang et al., 2004), or lymphatic dilation 
by mechanical forces between the lower lid and conjunctiva that progressively 
interferes with lymphatic flow (Watanabe et al., 2004). An increase in friction in blinking 
may follow from insufficient mucins, or transformed composition of the mucins at the 
ocular surface (Pult, 2008; Berry et al., 2008; Pult et al., 2008). 
 
They are typically evaluated, without the instillation of fluorescein, using a 2-3 mm wide 
vertical slit located along the temporal limbus at an angle between the observation and 
illumination system of 20-30 degrees, viewed at 25 times magnification. The slit lamp 
beam ought to run from the temporal limbus to the inferior bulbar conjunctiva just 
above the lower lid margin. Höh et al., (1995) examined the relationship between the 
degree of severity of the dry eye disease (DED) and the presence of the LIPCOF. They 
classification LIPCOF developing a grading scale based on the height of the normal 
tear meniscus and the number of individual folds contained in the LIPCOF (Table 1.2). 
The ‘normal’ TMH for this study was set at 0.15mm.  
 
Degree of intensity of 
LIPCOF 
Description of the finding of the 
conjunctival fold in primary 
position. 
 
Interpretation/intensity 
of the dry eye 
syndrome. 
Degree 0 No permanently present fold. No dry eye. 
Degree 1 Single small fold; smaller than the 
normal tear meniscus. 
Mild intensity of dry eye. 
Degree 2 Fold of up to the height of the 
normal tear meniscus multiple 
folds. 
Moderate intensity of dry 
eye. 
Degree 3 Fold being higher than the normal 
tear meniscus multiple folds. 
Severe intensity of dry 
eye. 
Table 1.2: LIPCOF grading scale (Höh et al., 1995). The different degrees of 
LIPCOF, description of the finding of the conjunctival fold in primary 
position and Interpretation / intensity of the dry eye syndrome are noted. 
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LIPCOF Degree 3 
Fold being higher than the normal tear 
meniscus, multiple folds 
Figure 1.9: Schematic diagram of LIPCOF degrees (from Höh et al., 1995). These 
small folds are illustrated at the temporal lid margin. 
 
LIPCOF can also be graded by ‘optimized LIPCOF grading scale’ where by the 
conjunctival folds are just counted. The four point scale is represented in table 1.3. Pult 
et al., (2008), provided evidence that LIPCOF graded ≥grade 2 is likely to be 
associated with dry eye symptoms. 
Table 1.3: Optimised LIPCOF grading scale (Pult and Sickenberger, 2000). 
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Fig 1.10: LIPCOF grade 3. It can be observed that there are several folds. (The 
image was kindly provided by Dr Heiko Pult). 
 
 
1.6.9 Lipid Analysis 
The lipid layer of the tears is created by the meibomian glands located in the tarsal 
plates of the eyelids. The function of the lipid layer is to reduce tear film evaporation 
and enhance tear film stability (Mishima et al., 1961). The secretion from the 
meibomian glands is known as meibum and consists of polar and non-polar lipids. The 
polar component of the meibomian layer is comprised mainly of phospholipids, hence 
acting like a surfactant allowing spreading over the aqueous layer. The non-polar 
component of the meibomian layer lies at the air-lipid interface (Greiner et al., 1996; 
Figure 1.11). Mishima et al., (1961) showed that the absence of a lipid layer in rabbits 
increased tear film evaporation by a factor of 10; therefore an increase in tear film 
evaporation will result in tear film hyperosmolarity. A rapid and forceful blinking has 
been shown to increase the thickness of the lipid layer (Korb et al., 1994).  
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Composition of the Lipid Layer                          
HC: Hydrocarbon             CE: Cholesterol Ester 
WE: Wax Ester                  TG: Triglyceride (Mono & Doimsaturated) 
F: Fatty Acid                                                        Corboxyl or Ester Group 
C: Cerebroside                                            ~~~  Unsaturated 
P: Phospholipid                                           ___  Saturated 
Fig 1.11: Composition of the lipid layer (Adapted from McCulley and Shine, 1997). 
 
The varied lipid layer thickness has been estimated by observation of interference 
patterns, to measure between 0.06-0.18 microns in the open human eye (Korb, 1998) 
and it spreads from the opening of the meibomian glands to cover the tear film (Table 
1.4). The lipid layer can be considered independent from other features of the tear film 
as it does not flow from lateral to medial canthi; neither does it enter the conjunctival 
sac (Ruskell and Bergmanson, 2007). 
 
The observation of the pre-ocular tear film can be observed by using the Keeler 
Tearscope Plus. The Tearscope (Keeler) developed by Guillon in 1986, comprises a 
90mm hemispherical cup and handle with a central 15mm diameter observation hole 
(Figure 1. 12). The inner cup surface is illuminated by a cold cathode ring light source, 
which was specifically designed to prevent any artificial drying of the tear film during an 
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examination. The light emitted is diffuse, therefore, does not need to be in focus to 
observe the tear film. It is designed to be used in conjunction with various inserts 
(Guillon, 1997).  
 
The advantage of the Tearscope Plus is that the illuminated source consisting of a 
double concentric cold cathode light is positioned away from the corneal surface, 
avoiding increased tear film evaporation. 
 
 
Figure 1.12: Tearscope Plus by Keeler. (Keeler Inc., Windsor, Berkshire, UK). 
(Permission granted by Keeler to reproduce the image). 
 
  
 
Fig: 1.13: Fine grid patterns as used with the Tearscope. (Permission granted by 
Keeler to reproduce the image). 
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The lipid layer is visible by specular reflection. As the lipid layer becomes thicker, a 
pattern of flowing lipids appears. With an increase in thickness of the lipid layer, an 
amorphous pattern becomes apparent. The ideal observation appears when no 
coloured patterns are seen, which are due to interference and relate to abnormal 
clumps and irregularity in the thickness of the tear lipid layer. Figure 1.14 displays the 
patterns typically seen in the normal population. 
 
Figure 1.14: Pre Ocular Tear Film Lipid Patterns. (Permission granted by Keeler to 
reproduce the image). The various lipid layer thickness, incidence (%) 
and lipid layer pattern are illustrated. 
 
Patients with lipid observation of closed meshwork marmoreal, flow and normal 
coloured fringes are all possible candidates for contact lens wear; however they may 
experience having some lipid deposits on their contact lenses. Contact lens wear is 
contraindicated for patients with lipid observation of abnormal coloured fringes and 
open meshwork marmoreal observation would cause some drying problems. Patients 
with an amorphous lipid layer observation are excellent candidates for contact lenses.  
Table 1.4 below, highlights the description and approximate thickness of the tear lipid 
layer. 
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Lipid Layer 
Pattern 
Appearance Clinical Estimated 
Thickness 
(nm) 
Incidence 
(%) 
Code Grade 
Used 
For 
This 
Study 
Absent No lipid layer 
visible 
 <10  Abs 0 
Open 
Meshwork 
marmoreal 
Indistinct, 
grey, marble-
like pattern, 
frequently 
visible, only 
by post blink 
movement 
Contact lens 
drying problems 
10-20 21 M(o) 
 
1 
Closed 
Meshwork 
marmoreal 
Well defined 
grey, marble 
like pattern 
with a tight 
meshwork 
Stable tear film. 
Possible contact 
lens candidate. 
Possible excess 
lipid deposition 
 
20-40 10 M(c) 2 
Flow Constantly 
changing, 
wavelike 
pattern 
Generally stable 
tear film. 
Possible contact 
lens candidate.  
Possible excess 
lipid deposition 
 
30-90 23 F 3 
Amorphous Blue-whitish 
appearance 
with no 
discernible 
features 
Highly stable 
tear film. 
Excellent contact 
lens candidate. 
Occasional  
greasing 
problems 
 
80-90 24 A 4 
Normal 
coloured 
fringes 
Appearance 
of coloured 
interference 
fringes 
Contact lens 
wear possible 
but excessive 
lipid deposition 
likely 
 
>100 15 CF(n) 5 
Abnormal 
coloured 
fringes 
Discrete 
areas of 
highly 
variable 
coloured 
fringes. 
These 
change 
rapidly in 
colour over a 
small area. 
Contact lens 
wear  
contraindicated 
 
variable 7 CF(ab) 6 
Table 1.4: The appearance and approximate thickness of the lipid layer patterns, 
observed by specular reflection with the Tearscope (Adapted from 
Craig, 1997 and Guillon, 1986). The grade used for this study can be 
seen in the far right column. 
 
The Keeler Tearscope plus has been used traditionally to measure and observe the 
lipid layer of the tears, there are currently new more objective devices available to 
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observe and measure the lipid layer of the tears, namely the  Keratograph 5M and 
LipiView®. 
 
The LipiView® Ocular Surface Interferometer (Tear Science, Inc., Morrisville, NC) is 
device that illuminates the tear film and is capable of delivering quantitative values of 
the tear-film lipid layer thickness (LLT) (Finis et al., 2013; 2014). The assessment of the 
LLT may possibly be a suitable screening test for identifying meibomian gland 
dysfunction (Finis et al., 2013). The LipiView® Ocular Surface Interferometer measures 
the tear film objectively. It records and measures the interference pattern of the 
reflected light. This “interferogram” is captured and analysed by software included with 
the device, allowing lipid layer thickness to be determined with nanometre accuracy. If 
the lipid layer is too thin or the tear film composition abnormal, then the associated 
LipiFlow® Thermal Pulsation System treatment may be advised, provided the 
meibomian glands remain expressible (McDonald, 2012). 
 
The Keratograph 5M (OCULUS Optikgeräte GmbH, Wetzlar, Germany) combines a 
placido disc topographer with objective NITBUT, lipid layer observation, infrared 
meibography, blue light fluorescein viewing, bulbar hyperaemia grading and tear film 
particle tracking (Figure 1.14). The tear layer with the Keratograph 5M is observed 
subjectively by the examiner. While earlier versions have shown promise although the 
average objective NITBUT is much lower than subjective observation (Best et al. 2012; 
Hong et al., 2013; 2014), the 5M version is yet to be evaluated in the academic 
literature.   
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Figure 1.15: Keratograph 5M. (Photograph kindly provided by OCULUS Optikgeräte 
GmbH). 
 
1.6.10 Tear Osmolarity 
An increase in osmolarity occurs when water is lost from the aqueous phase of the tear 
film, thus leaving behind the metal ions. These left over solutes then draws the 
moisture out of the cornea in an effort to re-establish stability, causing dryness. This 
event causes a reduction in mucous production, steering in to further tear loss. 
Therefore a greater tear osmolarity has been shown to cause ocular surface 
inflammation (Gilbard, 2005; Luo et al., 2005) which results in signs and symptoms of 
ocular discomfort. Patients with dry eyes generally have a higher tear osmolarity than 
normal patients (Gilbard, 1986). This hyperosmolarity is said to be a primary reason 
causing inflammation seen in dry eye patients resulting in ocular discomfort and 
surface damage (Farris et al., 1983; Gilbard et al., 1978). Hyperosmolarity can trigger 
an inflammatory response, resulting in the production of inflammatory cytokines (Li et 
al., 2004) which can lead to increased apoptosis of corneal and conjunctival epithelial 
cells and conjunctival goblet cells. A decrease in goblet cells would result in reduced 
mucin production (Argueso et al., 2002) and increase in tear film instability (DEWS, 
2007). The tear osmolarity has great value as it assesses a parameter that is directly 
involved in the mechanism of dry eye. Tear hyperosmolarity may reasonably be 
regarded as the signature feature that characterizes the condition of “ocular surface 
dryness” (DEWS, 2007). Tear osmolarity is said to be a single biophysical 
measurement that can provide significant information about the balance between tear 
46 
 
production, retention and elimination (Tomlinson et al., 2006). Tear osmolarity has 
been offered as a “gold standard” in dry eye diagnosis in the past (Farris et al., 1981).  
Traditionally Tear osmolarity has been measured by researchers based in laboratories. 
Collecting these tear samples were a very complicated and longwinded process due to 
the calibration of the device. Tear Osmolarity has been traditionally measured by 
observing the alteration in the freezing point of tear samples (Gilbard and Farris, 1979; 
Farris et al., 1983). These traditional methods required approximately 0.2 microliters of 
tears, a high level of user training, continuous maintenance of the equipment and 
errors may well occur owing to tear sample evaporation (Nelson and Wright, 1986; 
Tomlinson et al., 2006). Tear osmolarity can also be measured by method of electrical 
conductivity of the tear film by placing a sensor on the ocular surface (Ogasawara et 
al., 1996), unfortunately may well trigger reflex tearing. 
 
The feasibility of this objective test is greatly enhanced by the availability of the 
TearLab (Sullivan, 2004; Buchholz et al., 2006). The TearLab (TearLab Ltd, San Diego, 
CA, USA) is a relatively new device available for practitioners to determine the tear 
osmolarity (i.e. the amount of total solute concentrate in patients' tears). The 
advantages of the TearLab Osmolarity System are fast and accurate results are 
collected in seconds using 50 nanoliters (nL) of tear film to diagnose dry eye disease 
(Sullivan et al., 2010), with a recommended cut-off value of 316 mOsms/L (Tomlinson 
et al.,2006). 
 
A. TearLab Osmolarity System Reader 
 
B. TearLab Osmolarity System Pen 
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C. TearLab Osmolarity Test Cards 
              
D. TearLab Electronic Check Cards 
 
 
E. TearLab Control Solutions 
 
Figure 1.16: TearLab System. (TearLab Ltd, San Diego, CA, USA). (Permission 
granted by TearLab to use the images). 
 
1.6.11 Symptomology 
Numerous questionnaires have been developed for use in dry eye diagnosis, over time. 
These questionnaires explore different aspects of dry eye disease in changing 
complexity, ranging from diagnosis alone, to the identification of triggering factors and 
impact on quality of life. The time taken to administer a questionnaire may affect the 
choice of questionnaire for general clinical use. The number of questions administered 
in various questionnaires is listed in Table 1.5.  
 
Authors/Report Instrument 
Title/Description/Reference 
Questionnaire 
Summary 
 
Description/Use 
McMonnies,1986 McMonnies 
Key questions in a dry eye 
history (McMonnies) 
15 Questions Screening 
questionnaire-used 
in a clinic population 
Nichols et al., 
2004 
McMonnies 
Reliability and validity of 
McMonnies Dry Eye Index 
(Nicholos et al.,) 
Previously 
Described 
Screening 
questionnaire Dry 
eye clinic population 
Doughty et 
al.,1997 
*CANDEES 
A patient questionnaire 
approach to estimating the 
prevalence of dry eye 
symptoms in patients 
presenting to optometric 
practices across Canada 
13 questions Epidemiology of dry 
eye symptoms in a 
large random 
sample 
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(CANDEES) 
Schiffman et al., 
2000 
OSDI 
The Ocular Surface Disease 
Index 
12 item 
questionnaire 
Measures the 
severity of dry eye 
disease; end points 
in clinical trials, 
symptoms, 
functional problems 
and environmental 
triggers queried for 
the past week 
Vitale et al., 2004 OSDI and NEW-VFQ 
comparison. 
Comparison of 
existing 
questionnaires 
Tested in Sjögren 
Syndrome 
population 
Rajagopalan et al., 
2005 
IDEEL Comparing the 
discriminative validity of two 
generic and one disease-
specific health-related quality 
of life measures in a sample 
of patients with dry eye 
3 modules (57 
questions): 
1.Daily Activities 
2.Treatment 
satisfaction 
3.Sympton 
bother 
Epidemiologic and 
clinical studies 
Schein et al., 1997 Salisbury Eye Evaluation 
Relation between signs and 
symptoms of dry eye in the 
elderly 
Standardized 6-
question 
Questionnaires* 
Population – based 
prevalence survey 
for clinical and 
subjective evidence 
of dry eye 
Bandeen-Roche et 
al., 1997 
Salisbury Eye Evaluation 
Self-reported assessment of 
dry eye in a population-
based setting 
Standardized 6-
question 
Questionnaires* 
Population-based 
prevalence survey 
for clinical and 
subjective evidence 
of dry eye 
Oden et al., 1998 Dry Eye Epidemiology 
Projects (DEEP) 
Sensitivity and specificity of a 
screening questionnaire for 
dry eye 
19 questions Screening 
Schaumberg et al., 
2003  
Women’s Health Study 
Questionnaire 
Prevalence of dry eye 
syndrome among US women 
3 items from 14 
item original 
questionnaire 
Women’s Health 
Study/Epidemiologic 
studies 
Mangione et al., 
1998 
National Eye Institute Visual 
Function Questionnaire (NEI-
VFQ) 
25 item 
questionnaire; 2 
ocular pain 
subscale 
questions 
Useful tool for 
group-level 
comparisons of 
vision-targeted, 
health-related QOL 
in clinical research; 
not influenced by 
severity of 
underlying eye 
disease, suggesting 
use for multiple eye 
conditions 
Begley et al., 2003 Dry Eye Questionnaire 
(DEQ) 
Habitual patient-reported 
symptoms and clinical signs 
among patients with dry eye 
of varying severity 
21 items on 
prevalence, 
frequency, 
diurnal severity 
and 
intrusiveness of 
sx 
Epidemiologic and 
clinical studies 
Begley et al., 2000 Dry Eye Questionnaire 
(DEQ) 
Use of the dry eye 
questionnaire to measure 
As Above As Above 
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symptoms of ocular irritation 
in patients with aqueous tear 
deficient dry eye 
Begley et al., 2000 Contact Lens DEQ  
Responses of contact lens 
wearers to a dry eye survey 
13 Questions Screening 
questionnaire for 
dry eye symptoms 
in contact lens wear 
McCarty et 
al.,1998 
Melbourne Visual Impairment 
Project  
The epidemiology of dry in 
Melbourne, Australia 
Self-reported 
symptoms 
elicited by 
interviewer-
administered 
questionnaire 
Epidemiologic 
studies 
Hays et al., 2003 National Eye Institute 42-
Item refractive Error 
Questionnaire 
42-Item 
questionnaire: 4 
related 
questions: 
ocular pain or 
discomfort, 
dryness, 
tearing, 
soreness or 
tiredness 
QoL due to 
refractive error 
Bowman et al., 
2003 
Sicca/SS questionnaire 
Validation of the Sicca 
symptoms inventory for 
clinical studies of Sjögrens 
Syndrome 
Inventory of 
both symptoms 
and signs of 
Sjögren 
Syndrome 
Epidemiologic 
studies for Sjögren 
syndrome 
Bjerrum, 2000 Bjerrum questionnaire 
Study Design and Study 
Populations 
3-part 
questionnaire 
which includes 
an ocular part 
with 14 
questions 
QOL due to SS dry 
eye, diagnosis of 
dry eye, 
epidemiology of SS 
 
Bjerrum, 2000 Bjerrum questionnaire 
Dry eye symptoms in 
patients and normal 
As Above Screening 
questions 
Bjerrum, 1996 Bjerrum questionnaire 
Test and symptoms in 
keratoconjunctivitis sicca and 
their correlation 
Dry eye tests 
Ocular 
symptoms 
questionnaire 
(14 questions) 
Examine correlation 
between dry eye 
test and ocular 
symptoms 
questionnaire 
responses 
Schiffman et al.,  
2003 
Utility assessment 
questionnaire 
Utility assessment among pts 
with dry eye disease 
Utility 
assessment 
Utility assessment 
Shimmura et al., 
1999 
Japanese dry eye awareness 
study 
Results of a population-
based questionnaire on the 
symptoms and lifestyles 
associated with dry eyes 
30 questions 
relating to 
symptoms and 
knowledge of 
dry eye 
Population-based, 
self-diagnosis study 
to asses public 
awareness and 
symptoms of dry 
eye 
Jensen et al., 
1999 
Sicca/SLE questionnaire 
Oral and ocular sicca 
symptoms and findings are 
prevalent in systemic lupus 
erythematosus 
6 question 
symptom 
questionnaire 
Screening for dry 
eye symptoms in 
SLE patients 
Vitali et al., 2002 American-European 
Consensus Group 
Classification criteria for 
Sjörgen’s syndrome: a 
6 areas of 
questions: 
Ocular 
symptoms; oral 
Clarification of 
classification of 
primary and 
secondary Sjögren 
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revised version of the 
European criteria proposed 
by the American-European 
Consensus Group 
symptoms; 
ocular signs; 
histopathology; 
oral signs; auto-
antibodies 
syndrome, and of 
exclusion criteria. 
Ellwein, 1994 The Eye Care Technology 
Forum Impacting Eye Care 
Issues: 
Standardizing 
clinical 
evaluation  
Decree for change 
Table 1.5: Symptom questionnaires in current use (Adapted from DEWS 2007).The 
instrument title / description, questionnaire summary and the use of 
these tests are summarised. 
 
These questionnaires have been validated to differing extents, and they differ in the 
degree to which the dry eye symptoms assessed correlate with dry eye signs. The 
Diagnostic Methodology Subcommittee concluded that the administration of a 
structured questionnaire to patients presenting to a clinic provides a great opportunity 
for screening patients with potential dry eye disease (DEWS, 2007). Clinic time can be 
used most efficiently by utilizing trained support staff to administer the questionnaires.  
Symptomatology questionnaires should be used in combination with objective clinical 
measures of dry eye status. Questionnaires are employed in clinical practice in order to 
screen for the diagnosis of dry eye disease, the effects of the treatment and to grade 
the severity of the disease. Begley et al., (2002) and Nichols et al., (2004) advocate 
that the use of dry eye questionnaires is valuable in evaluating the following with 
regards to DED: for determining the severity of the condition; evaluating the success of 
the treatment or otherwise; identifying the environmental triggers; and assessing the 
end points in clinical trials. 
 
1.7 Treatment of Dry Eyes 
Currently treatment goals for dry eye disease are directed towards either ‘tear 
replacement’ or ‘tear retention’, and are aimed primarily at relieving the subjective 
symptoms associated with this condition (Farrell, 2010). The treatment of dry eyes by 
means of artificial tears have been labelled and marketed over the years, those 
responsible for labelling and marketing simple tear replacement therapy or ocular 
lubricants (Doughty, 2010). Artificial tears can be considered as ‘simple’ or ‘complex’, in 
order to re wet a ‘dry’ ocular surface (Doughty, 2010). 
 
Simple artificial tears are mostly to be created on saline (0.9% sodium chloride) with a 
single polymer in order to assist ocular surface lubrication. Whilst complex artificial 
tears contain two or more polymers and true ocular lubricants contain the highest 
concentration of polymers or special polymers or an ointment vehicle base rather than 
saline (Doughty, 2010). 
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A cure for dry eye disease has still to be found. The aims of treating dry eye can be 
broken down to improving the patient symptoms and improve the ocular surface health. 
There are multiple treatments available which include artificial tears to improve tear 
volume and the quantity of the mucus layer; lid hygiene and hot compresses to improve 
the tear lipid layer; punctal plugs to reduce tear drainage; ointments to reduce tear 
evaporation; anti histamines or steroids to reduce inflammation. The main route for 
treating dry eye are tear supplements with little evidence as to their effectiveness and 
whether some work better for some patients than others.  
 
Numerous formulations have been introduced over the years. These formulations with 
and active ingredients can be classified as aqueous artificial tears, ocular lubricants 
and viscoelastics (Farrell, 2010). These will be discussed later on in this chapter in 
detail. 
 
Unfortunately, it is very apparent that dry eye suffers self-prescribe artificial 
supplements in order to alleviate their symptoms and is usually based on trial and 
error. However, the treatment goals for dry eye will always be aimed at appropriate 
ocular healing, and the re-establishment of a normal ocular surface (Göbbels et al., 
1992). In order to choose the most suitable treatment option the cause and severity of 
the dry eye should be established, and the management strategy selected to 
successfully target the nature of the condition.  
 
The ultimate tear supplement requires the following fundamental features: 
 
 Provide immediate discomfort relief 
 Give prolonged residency of the tear film, for long lasting relief 
 Is non-toxic to the ocular surface 
 Is simple to instil 
 Does not blur vision after instillation (Atkins, 2008). 
 
The model delivery system for these tear supplements requires the following important 
features: 
 
 Easy/simple to use/instil 
 Small (measured) droplet size to avoid blurring/washing away the tear film 
 Helps maintain solution sterility between usage (with or without preservatives) 
 Should be affordable (Atkins, 2008). 
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Regrettably, all of these requirements cannot be met in a single preparation, and at 
best a single product is a compromise. The pharmaceutical industry is constantly 
developing new products and many artificial tears can be purchased in pharmacies and 
opticians. Several over-the-counter topical lubricants are available based on two 
treatment methods, which are: 
 
 Designed to lubricate the ocular surface allowing uninhibited movement of the 
lids   without causing epithelial damage;  
 Designed to mimic the natural tear fluid as closely as possible, with properties 
similar to its natural counterpart pH, tonicity and electrolyte balance (Nichols et 
al., 2004). 
 
The perfect tear substitute should be comfortable on instillation and last for a long 
period.  As a result, there are several artificial tears that vary in property which explains 
why a number of patients benefit from a particular type while others benefit from 
another. 
 
Artificial lubricants contain buffers, sodium salts, preservatives, electrolytes and a 
viscosity enhancing agent. The importance of electrolytes is to maintain corneal 
thickness, increasing goblet cell density and corneal glycogen contents. The electrolyte 
bicarbonate is used in artificial eye drops as it preserves the mucin layer as well as 
promotes the regeneration of an impaired corneal epithelium. Table 1.6 summarises 
the various artificial tear supplements that are available. 
 
 Active Ingredient 
 
Product brand name 
Aqueous artificial tears Hypromellose Tears Naturale 
Isopto Plain 
Artelac SDU 
 Carboxymethycellulose Optive 
Theratears 
 Polyvinyl alcohol Sno Tears 
Liquifilm Tears 
Hypotears 
Liquifilm 
 Polyvinyl alcohol with povidone Refresh 
Clinitas Ultra 
Ocutect (povidone) 
Liposomes Liposome Spray Tears Again 
Optrex Actimist Eye 
Spray 
Dry Eye Mist  
Tear Mist 
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Viscoelastics Sodium hyaluronate Optrex Dry Eye Drops 
Blink Revitalising Drops 
Sainsbury’s Dry Eye 
Drops 
Clinitas Soothe 
Hyabak 
 Carbomer 940 Geltears* 
 Carbomer 980 Viscotears* 
Liposic* 
Clinitas Hydrate 
Viscotears 
 Hydroxypropyl guar Systane 
 Tamarind seed polysaccharide 
and hyaluronic acid 
Rohto Dry Eye Relief  
Rohto daily dose 
Ocular lubricants Liquid paraffin Lacri-Lube 
 White soft paraffin Lubri-Tears 
 Yellow soft paraffin Simple Eye Ointment 
Lubrifilm 
Lipid Emulsion   Refresh Dry Eye 
Therapy 
Soothe 
Sodium Chloride 0.9% 
(Similar to that of natural 
tears) 
  
Table1.6: Artificial Tears available in the UK (2013) (Adapted from McGinnigle et. 
al., 2011). All the solutions listed are preserved with Benzalkonium 
chloride with the exception of those highlighted with an asterisk (*), 
which use Certrimide. Italics indicate single unpreserved preparations. 
 
The pH of tears is comparable to that of blood plasma at approximately 7.4-7.5; 
therefore a pH value of 7.4 is typically elected for artificial tear supplements (Farrell, 
2010). It is very important to adjust the pH of artificial tears in order to reduce ocular 
irritation; as the tears would be have to neutralise the pH of the solution on contact with 
the ocular surface. The appropriate isotonic solution helps maintain a normal corneal 
thickness and reduce visual disturbance. The use of a hypotonic solution aids the 
cornea to successfully transport essential nutrients into the corneal stroma, in severe 
dry eye.  
 
In order to provide the suitable conditions for lubricating the ocular surface and 
retaining the artificial tear drops the viscosity of the solution is extremely important. 
Therefore an artificial tear supplement with low viscosity would decrease the surface 
tension and increase spreading across the cornea, increase the aqueous evaporation 
rate and reduce the retention time. On the other hand, a high viscosity lubricant would 
significantly decrease evaporation and increase the retention time, but may increase 
the surface tension and cause reduced vision (Farrell, 2010). 
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Numerous artificial eye drops have been introduced over the years with varying active 
ingredients and formulations with varying success; these can be classified as aqueous 
artificial tears, ocular lubricants and viscoelastics (Table 1.7). 
 
Tear replacement – Classification Active ingredient (polymer) 
Aqueous artificial tears (low viscosity) 
 
Flowing liquid that replaces/ replenishes 
the tear aqueous element. 
Cellulose derivatives: 
-methylcellulose (MC) 
-hydroxymethylcellulose (HEC) 
-carboxymethycellulose (CMC) 
-hydroxypropylmethylcellulose (HPMC) 
Polyvinyl alcohol (PVA) 
Polyvinylpyrrolidone (PVP) 
 
Ocular Lubricants (high viscosity) 
 
Ointments – resistant to flowing and 
reduce 
 
Friction between palpebral and ocular 
surface 
White soft paraffin 
Liquid paraffin 
Lanolin alcohol 
Viscoelastics (thixotropic) 
 
Exhibit both liquid and gel properties 
Polyacrylic acid (Carbomer 940) 
Sodium hyaluronate 
Table 1.7: Common polymers in use in tear replacement classification (Adapted 
from Farrell, 2010). 
 
1.7.1 Aqueous artificial tears 
The natural aqueous tear film in tear-deficient dry eyes has been treated typically by 
varying formularies by means of topical ‘artificial tears’ (Holly, 1991; Bernal et al., 
1993). These include cellulose derivatives, mucomimetics, polyvinyl alcohol and 
providone.  
 
Cellulose derivatives can be prepared in a variety of viscosities and are water-soluble 
polymers. Various cellulose organic compounds have been used to enhance the 
viscosity of artificial eye drops; these include the following: carboxymethylcellulose 
(CMC or carmellose sodium), hydroxyethylcellulose (HEC), hydroxy-
propylmethylcellulose (HPMC) and methylcellulose (MC). The advantage of these 
chemically inert polymers enables them to be suitable for the use as artificial tear 
drops,  is that they have a similar refractive index to that of natural tears (n=1.336) and 
have a stable pH. A disadvantage of these cellulose derivatives is that they are watery 
in substance requiring frequent instillation of the artificial tear drops (Gilbard et al., 
1979). Due to their low molecular weight, these cellulose derivatives are absorbed 
easily by the corneal epithelium, therefore reducing the retention time of the drops 
being used and ideally for use in mild cases of aqueous deficiency. Marquardt (1986), 
recommended that artificial tears ‘must have a long retention time', which is not the 
case for these cellulose derivatives especially MC. They are used in combination with 
tear gels in moderate aqueous deficiency due to their low surface tension which 
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increases in distribution which helps maintain a moist corneal epithelium and therefore 
reduce further tissue damage.  
 
Mucomimetics contain the cellulose derivatives in a greater viscous preparation and 
molecular structure. The cellulose derivatives used in mucomimetics are HPMC CMC. 
An advantage of mucomimetics are that they improve retention time on the ocular 
surface, as they act as muco adhesives (mimicking the action of tear mucus 
glycoprotein) in order to improve tear stability. As the preparation is more viscous tear 
evaporation reduces as the surface tension of the tears increases. The viscous nature 
may increase surface tension to the point where the surface activity of the preparation 
is reduced in severe dry eye cases (Lemp, 1972). An increase in viscosity may also 
result in matting of eyelashes and temporary blurring of vision, which should be 
considered cautiously for patients who may be driving or operating machinery.  
 
Polyvinyl alcohol (PVA) is a hydrophilic polymer which reduces surface tension. It is 
used as a viscosity enhancer and chiefly as a wetting agent, due to its outstanding 
lubricating function, in artificial tears. PVA is less viscous than mucomimetics and 
offers better aqueous lubrication to the epithelial tissues, in moderate and severe 
aqueous deficiency, particularly in patients where the natural mucin is diminished 
(Farrell, 2010).  
 
PVA has been shown to extend tear break-up time as a measure of tear stability 
(Nelson et al., 1988). In aqueous deficiency the tear film is frequently in a condition of 
hyperosmolarity (Edwards et al., 1993; Smith, 2002), hence the hydrophilic properties 
of PVA, in conjunction with decreased osmolarity, may help to re-establish tonicity. 
PVA has the property to decrease surface tension without affecting the vision 
(Marquardt, 1986). PVA has a considerably greater retention period than a viscosity-
increasing agent acting on its own and continues to maintain its moistening properties 
in low concentrations (Hardberger et al., 1975). PVA is very unstable in alkaline 
solutions and has an ideal effective pH value of between 5 and 6 (Gilbard et al., 1979; 
Lenton et al., 1998). Therefore the tear film is required to neutralise the slightly acidic 
pH following instillation which may cause the dry eye patient minor discomfort for 
several minutes. 
 
Polyvinylpyrrolidone (PVP) is a hydrophilic polymer with a related structure and 
lubricating properties to PVA. The molecular weight of the polymer can be varied for 
several uses; such as dispersing and suspending agents as well as a vehicle for 
pharmaceuticals. PVP is ideal as a lubricating agent for artificial tears due to its 
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consistent rate of dissolution. PVP also helps to improve the solubility of artificial tear 
preparations, as it increases their retention rate and be able to sweep across the ocular 
surface. Unfortunately, the preservation of artificial tear drops on the eye is poor and 
there is no improvement with frequent usage and may increase patient symptoms 
(Farris, 1991). The natural tears would dilute and wash away essential antibodies and 
anti-bacterial agents, by frequent use of eye drops. Benzalkonium chloride (0.01%) 
which is frequently used in artificial tears is toxic to ocular tissues and the adverse 
effects are increased with frequent use of preserved eye drops (Holly, 1978; Bernal et 
al., 1991). Benzalkonium chloride is known to reduce the corneal epithelial barrier, 
disrupt the tear film and decrease the tear break-up time. Unpreserved saline or 
hydroxyethylcellulose are available in single dose Minims form for the patients who 
develop solution toxicity. The pharmaceutical industry has increasingly introducing 
various formulations in single-dose preservative-free options.  
 
1.7.2 Ocular lubricants  
For patients suffering from severe lacrimal deficiency, ocular lubricants containing 
various concentrations of white soft paraffin, liquid paraffin and/or lanolin alcohol as a 
base, have been developed, in order to increase the retention time on the ocular 
surface (Farrell, 2010). Ocular lubricants are high viscosity ointments, with a similar 
formulation to E45 cream, which help to reduce the friction created between the 
palpebral conjunctiva and ocular surface during blinking (Farrell, 2010).They have a 
high molecular structure, which aids an increase in the retention time of the lubricant on 
the ocular surface and is unable to penetrate the tear-cornea barrier with a decreased 
evaporation rate compared with conventional aqueous solutions. It is traditionally 
promoted in cases of sever aqueous disorders for overnight (Farrell, 2010). 
Unfortunately, these ointments cause blurring of vision (Rieger, 1990), therefore, 
limiting their daytime use, especially for driving. Ointments can also disrupt the tear film 
to a condition that increased evaporation of the depleted underlying aqueous may 
follow (Holly, 1978). Some patients may also have a hypersensitive response to lanolin 
(Farrell, 2010). 
 
1.7.3 Viscoelastics   
Viscoelastics predominantly gel polymers that display thixotropic properties (they have 
the ability to become fluid when agitated and set again when left at rest). These gel 
polymers are referred to as 'non-Newtonian' (pseudoplastic) by demonstrating an 
increased viscosity when stationary and during blinking their viscosity decreases 
considerably to that similar of water which is believed to simulate the function of the 
tear glycoprotein. Therefore, this characteristic permits the combined gel-fluid and 
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natural tear film to distribute more successfully during blinking, aiding the formation of a 
more stable tear film between blinks. When compared with aqueous tear supplements 
the retention time of vicoelastics is significantly increased. The main viscoelastics used 
by the pharmaceutical industry in artificial tears are carbomer and sodium hyaluronate 
(Farrell, 2010). 
 
Carbomers are high molecular weight polymers of polyacrylic acid, which linger in the 
conjunctival sac for numerous hours and dissolve gradually. Carbomers have an 
increased retention time of approximately sixteen minutes, in comparison to PVA which 
is two minutes (Brodwall et al., 1997). This increase in retention time offers a more 
sustained symptomatic relief as well as reduced frequency of application for patients 
suffering from moderate and severe aqueous deficiency. Gambaro and colleagues 
(1990) noted that carbomer gel increased the stability of the tear film as well as 
improvement in the corneal and conjunctival epithelium in patients with KCS. An 
increase in the occurrence of ‘sticky eyelids’ has been reported (Brodwall et al., 1997), 
due to the high viscosity and increased ocular retention time of carbomers. If 
carbomers are administered in large doses or too frequently, ocular irritation and 
blurred vision have been reported (Lebowitz et al., 1984). Therefore, on these grounds, 
the use of carbomers overnight is preferred and the use of a less viscous drop used 
during the daytime to treat dry eye patients.  
 
The viscoelastic Sodium Hyaluronate is a biologically occurring polymer, responsible 
for the jelly-like consistency of the vitreous humour. Sodium hyaluronate is a 
pharmacologically inert polymer making it non-toxic. It protects the eye due to its 
physicochemical and rheological properties and has an effective water binding property 
which decreases evaporation and assists retention. The spreading of Sodium 
hyaluronate during blinking is enhanced as it increases its elasticity (Farrell, 2010), 
which enhances the aqueous lubrication of the epithelial tissues on the ocular surface. 
Sand et al., (1989), reported reduced rose Bengal staining after KCS patients used 
sodium hyaluronate. Sodium hyaluronate increases in viscosity aiding to stabilise the 
tear film hence increasing the measured tear break-up time (Mengher et al 1986, 
Limbreg et al., 1987). Sodium hyaluronate has also been shown to act as a muco-
adhesive (Saettone et al., 1989) and may therefore mimic the action of tear mucus 
glycoprotein to further enhance tear film stability. When Sodium hyaluronate is applied 
instead of hypromellose, patient symptoms of 'burning' and 'grittiness', are considerably 
relieved (Bron et al., 1991).There are no reports available in literature of any significant 
drawbacks of the use of sodium hyaluronate in KCS patients apart from minor initial 
blurring following instillation.   
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1.7.4 Lipid Emulsion 
It has been reported by researchers that there is a significant decrease in tear 
evaporation and improvement in lipid layer thickness with the use of topical lipid 
emulsion eye drops containing neutral oils and castor oil (Scaffadi et al., 2007; Di 
Pascuale et al., 2004; Goto et al., 2002; Khanal et al., 2007). 
 
An emulsion-based lubricant eye drop has been conducted in normal subjects and 
patients with aqueous-deficient dry eye, with or without MGD (Di Pascuale et al., 2004; 
Solomon et al., 2005) and the results showed that the eyes treated with the emulsion 
showed a swift rearrangement of the tear film lipid layer in comparison to the control 
eyes.  
 
A study conducted by Scaffadi et al., (2007) concluded that the use of lipid emulsion 
eye drops would increase the tear film lipid layer thickness and therefore benefit 
patients with deficient lipid layers who suffer from dry eye symptoms. They used two 
different products and concluded from their study that the lipid based eye drop Soothe 
effectively doubled the lipid layer thickness with a mean increase in the lipid layer 2.5 
times greater than the Refresh Dry Eye Therapy. Emulsion eye drops also produces 
significant changes in the tear film of normal and dry eye patients (Di Pascuale et al., 
2004). 
 
A small double-masked, placebo-controlled crossover clinical study conducted by Goto 
et al., (2002); in patients with non-inflamed obstructive MGD, with and without aqueous 
deficient dry eye. The patients used homogenised 2% castor oil eye drops, six times 
per day. The results showed that patients’ subjective symptoms tear interference image 
grade, tear evaporation rates, rose bengal staining scores, tear film breakup time and 
meibomian gland expressibility grades after using these eye drops showed significant 
improvement compared with the results after the placebo period. It was concluded that 
castor oil eye drops are safe and effective in the treatment of MGD. The advantage of 
this kind of treatment would improve tear stability as a result of lipid spreading, prevent 
tear evaporation and ease meibum expression. Castor oil emulsion (1.25%) has been 
proven to be more effective than hypromellose in reducing tear evaporation than 
hypromellose, which signifies the potential of castor oil emulsion being used in the 
management of evaporative dry eye (Khanal et al., 2007). 
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1.7.5 Liposomal Sprays 
The lipid layer of the tears plays an important role in reducing tear film evaporation 
(Craig et al., 2010). Meibomian gland dysfunction results in an abnormal tear lipid layer 
and has been identified as one of the main causes of ocular discomfort and ocular 
surface damage (Paulsen et al., 2010; Bischoff et al., 2011; Singh et al., 2011). 
 
Phospholipids have been identified to  be  significant components  within  the  natural 
tear  film and are imperative to the surface  mono-layer  formation as well as  surfactant  
properties. The polar lipids of the tear lipid layer consist of 70% phospholipids, with 
phosphatidylcholine being the most prevalent (38%).  A deficit of these phospholipids 
prevents  formation  of  a  stable,  uninterrupted  lipid  layer,  which, causes  an 
increased evaporation rate (Craig et al., 1997; McCulley et al., 2003). 
 
Liposomes are minute spherical vesicles, which form when hydrated phospholipids 
become organised with harmonious head-tail formation into circular sheets (Ebrahim et 
al., 2005). These sheets unite to form a phospholipid bi-layer membrane, which 
captures the aqueous-soluble material within aqueous to produce a phospholipid 
sphere. Liposomes remain stable in aqueous solvents so long as the liposomes are 
held together by hydrophobic connections (Lee et al., 2004). Phospholipid based 
sprays aim to improve the tear lipid polar layer by improving lipid dispersion over the 
tear film. The  spray  is  applied  to  the  closed  eyelids  and  supplements 
phospholipid liposomes  to  the  eye lid  margins where they blend  the lipid  reservoir 
at the lid margin  from. The lipid  reservoir  disperses  over  the  tear  film and  reforms  
the  tear  film  lipid  layer. Various authors have reported improvements  in  
symptomatology,  visual  acuity,  lipid  layer  thickness,  tear  film  stability,  eyelid 
margin  inflammation,  tear  production  and  lid  parallel  conjunctival  folds  with  use 
of  liposomal sprays in  dry  eye  patients (Lee et al., 2004; Dausch et al., 2006; Craig 
et al., 2010; Khaireddin et al., 2010; Bischoff et al., 2011) in contact lens wear (Künzel, 
2008); and following cataract surgery (Reich et al., 2008). 
 
Various studies have been conducted over recent years with phospholipid liposomal 
sprays as a potential therapy for evaporative dry eye. Dausch et al., (2006) concluded 
that liposomal eye spray (Tears Again) shows statistically significant clinical 
advantages over triglyceride-containing eye gel. The patients’ subjective direct 
comparisons of the two preparations revealed a clear preference for the liposomal eye 
spray regarding its application onto the closed eye as well as for its effectiveness and 
tolerability. A direct comparison disclosed that the phospholipid-liposome therapy is 
advantageous and distinctly superior to conventional standard therapy. A significant 
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improvement in tear film stability and lipid layer thickness can be achieved in normal 
eyes between 60 and 90 minutes following a single application of a phospholipid 
liposomal spray (Tears Again) (Craig et. al. 2010). However, a limitation of this study 
was the absence of significant dry eye signs and symptoms in the subject group. Pult 
et al., (2012), concluded that the liposomal spray ActiMist (Tears Again; liposome 
phosphatidylcholine) significantly enhanced ocular comfort and tear film stability while 
TearMist and DryEyesMist worsened these metrics. It was concluded that TearMist and 
DryEyesMist may not be effective clinically in dry eye treatment due to either too little 
or inappropriate type of liposomal ingredients (liposomate isoflavonoids). 
 
1.8 Defining Dry Eye Treatment Success  
While the primary principle of successful dry eye treatment is to improve the ocular 
surface and prevent damage to the cornea, it is also important to try to provide relief of 
symptoms and so offer the patient some degree of satisfaction (Asbell et al., 2010). 
The final point for relief and/or provision of satisfaction is, however, likely to vary 
between patients and the practitioners managing the patient. A patient with a dry eye is 
likely to suffer from some symptoms, and successful treatment may just be that the 
frequency of symptoms has subsided. Patient satisfaction with treatment may also be 
linked to the cost, i.e. relief from use of an inexpensive product may be considered 
adequate in comparison to gaining slightly more relief from use of a more expensive 
product. Most tear supplements act as lubricants; other actions may include 
replacement of deficient tear constituents, dilution of pro inflammatory substances, 
reduction of tear osmolarity (Asbell, 2006; DEWS, 2007), and protection against 
osmotic strain (DEWS, 2007; McDonald, 2007). 
 
A wide variety of over-the-counter (OTC) artificial tear products are available. These 
products differ with respect to a number of variables which include electrolyte 
composition, osmolarity, viscosity, the presence or absence of preservatives, (Asbell, 
2006) and the presence or absence of compatible solutes (McDonald, 2007). 
 
 Electrolyte composition - Products that mimic the electrolyte composition of 
natural tears are available. Potassium and bicarbonate appear to be the most 
important, of the electrolytes (Asbell, 2006). 
 
 Osmolarity - DED patients have greater than normal tear film osmolarity. 
Although some studies suggest that artificial tears ideally should mimic the 
osmolarity of normal tears, others suggest that hypo-osmolar artificial tears are 
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optimal (DEWS, 2007). Products with varying degrees of hypo-osmolarity have 
been developed (DEWS, 2007). 
 
If the use of a dry eye product produces even mild undesirable sensations or adverse 
effects, then a patient is less likely to be compliant. As the primary goal of dry eye 
treatment is to improve the ocular surface, then this provides the only real means of 
assessing product efficacy and so also allowing for comparison between products or 
different product types (Doughty, 2010). This contrasts to what is being termed a 
surrogate marker, i.e. changes in tear film osmolarity (Lemp, 2008). 
 
Rose Bengal has been used traditionally in order to assess the ocular surface in order 
to diagnose for dry eye disease as well as to provide follow-up on treatment efficacy 
(Doughty et al., 2009). The severity of rose bengal staining was introduced in the 
1960s by Van Bijsterveld (Van Bijsterveld, 1969). A score of between 0 and 3 is 
delegated for the nasal, temporal conjunctiva and corneal surface.  
 
Therefore, the worse the rose bengal staining, the worse the condition and the more 
intensive the treatment that is required. At the follow up appointment by assessing the 
staining, a change in the rose bengal score can be evaluated in absolute terms (e.g. 
the Van Bijsterveld score go down from 7 to 5) or in relative terms (e.g. if the score 
changed from 7 to 5, could be regarded as a 29% reduction or a 40% improvement in 
ocular surface staining). It is also worth noting whether the patient’s symptoms have 
reduced with treatment. 
 
Hence from this viewpoint, it is suitable to consider whether dry eye treatments have 
improved over the past twenty five years, where the percentage improvement in rose 
bengal staining is given as the treatment efficacy as represented in figure 1.17. The 
upward trend shown in fig 1.17 shows that over the last twenty five year period, the 
efficacy of dry eye treatments has improved. Equally, it could also suggest that 
practitioners are getting better at managing dry eye, especially in terms of maintaining 
compliance with treatments (Doughty, 2010).  
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Figure 1.17: Assessment of the overall efficacy of dry eye treatments over a 25-year 
period as assessed by improvement in rose bengal staining of the ocular 
surface following one-month tear of replacement therapy. The line is that 
generated by a step-wise Lowess regression (Taken from Doughty, 
2010). 
 
Even the best treatments only produce less than 100% effect, with very few published 
data available on whether there is much further improvement. There is a high likelihood 
that moderate dry eye patients will often swap treatments, probably because of a 
perceived lack of efficacy of the product type or regimen. Asbell et al., (2010) indicated 
that almost half (47.4%) of those with mild dry eye used two products over a year and a 
similar proportion of those with moderate dry eye used three different treatments.  
 
Published articles over a twenty five year period have also been used to try to assess 
the average improvement after one month of treatment (Doughty et al., 2009). The 
treatments included traditional artificial tears versus the viscous eye drops or HA based 
eye drops. The viscous eye drops were likely to be multi-dose, while the HA products 
preservative-free preparations. The frequency of use with the gels was usually twice a 
day, and those for preservative-free product use at least four times per day if not more 
frequent. The overall outcome of any of these treatments, over one month, is shown in 
Figure 1.18. There appears to be an improved change of most rose bengal scores after 
one month of treatment. There is approximately 25% improvement overall indicating 
that suitable artificial tear drops can maintain and protect the ocular surface (Doughty, 
2010). 
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Figure 1.18: Responses of dry eyes to one month of tear replacement therapies, as 
assessed by rose bengal staining. The data is from 30 different 
published studies with the red bars showing the rose bengal scores prior 
to treatment (baseline) and the grey hatched bars the scores after being 
treated. (Taken from Doughty, 2010). 
 
The effects of treatment with different types of tear replacement therapy can also be 
analysed, however the apparent outcome depends on the calculations used (Doughty 
et al., 2009). 
 
Unfortunately, there is no published data for equivalent rose bengal staining data does 
for the efficacy of ointments. Carbomer-based products show an equivalent effect to 
traditional artificial tears when assessing the absolute reduction in rose bengal scores 
after one month of treatment (Doughty and Galvin, 2009). There was a greater 
reduction in rose bengal scores with HA-based products and when the rose bengal 
score is analysed in terms of the percentage improvement, the use of carbomer 
products appears to provide a superior outcome to traditional artificial tears, and the 
HA-based products provide a similar efficacy to the gels (Doughty and Galvin, 2009). 
 
1.9 Relative effectiveness of dry eye treatments  
Dry eye remains the commonest complaint encountered in clinical practice. The 
constant discomfort leads to a high level of nuisance that only the patients can fully 
appreciate and unfortunately, many practitioners continue to rely on ad hoc use of eye 
drops as a solution, thus this strategy usually provides little more than temporary relief. 
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There are various papers showing how well each individual drops and eye sprays 
perform (Lee et al., 2004; Matheson, 2006; Rahman et al., 2012). However, very few 
seem to compare various drops and sprays perform against each other (Table 1.8) 
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Authors Type of study Tests Used Drops Used How many 
subjects 
 
Results/Conclusions 
Forest-
Larsen et al., 
1978. 
 
Randomised, 
double blind 
crossover trial 
Schrimer Test, BUT Bromhexine 24 mg and 48 mg 
Vs Placebo 
29 In the Sjögren’s patients BUT increased after 
bromhexine with a dose effect. 
 
Meghner et 
al., 1986. 
 
 NIBUT Sodium Hyaluronate (0.1%) 10 Tear film stability was significantly increased, 
and symptoms of grittiness and burning were 
also significantly alleviated in eyes treated with 
sodium hyaluronate. 
Tsubota et 
al., 1999. 
Controlled 
double-masked 
 Calcium Carbonate (10%) Vs 
Control 
18 Subjective symptoms significantly improved, as 
well as fluorescein, rose bengal scores, and 
blink rate. Tear evaporation also significantly 
decreased. BUT did not improve. 
Stevenson et 
al., 2000. 
Multi-centre, 
randomised, 
double-masked, 
parallel-group, 6 
month, vehicle 
controlled. 
Corneal and inter palpebral 
staining, Schrimer test, 
TBUT, OSDI, facial 
expression, patients 
subjective rating scale, 
symptoms of dry eye, 
investigators evaluation of 
global response to treatment, 
treatment success and daily 
use of artificial tears 
Cyclosporine A (CsA 0.05% 
and 0.1% ophthalmic 
emulsions) 
 
877 Improvement in corneal staining and Schrimer 
values, blurred vision, need to concomitant 
artificial tears, and the physicians’ evaluation of 
global response treatment. 
Nepp et al., 
2001. 
Randomised, 
double-blind 
study 
TBUT, Schrimer test, lipid-
layer thickness and 
fluorescein staining. 
Sodium hyaluronate 
(0.4% and 0.25%) 
Chondroitin sulphate. 
28 Sodium chloride solutions may be a useful 
short term alternative to other tear 
formulations. 
Albietz et al., 
2001. 
 McMonnies survey TBUT, 
nucleo-cytoplasmic (N/C), 
goblet cell density (GCD) and 
expression of monoclonal 
antibodies HLA DR and 
CD23 
Preserved and Non-preserved 
dry eye treatments 
134 No significant differences were found between 
the group perceiving non-preserved dry eye 
treatments and untreated dry eye group. The 
group receiving the preserved treatments had 
a reduced GCD and an increased expression 
of HLA DR and CD23 compared to the group 
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receiving non-preserved treatments. 
Dogru et al., 
2002. 
Single – centre, 
3-visit, 
prospective, 
open-label study 
Measurements of corneal 
sensitivity, Schrimer test, 
TBUT fluorescein staining. 
Oloptadine hydrochloride 
0.1% 
58 Patients mean corneal sensitivity improved, 
BUT values improved, goblet cell density 
improved 
Aragona et 
al., 2002. 
 
Blind Study Subjective symptoms, TBUT, 
fluorescein, rose bengal 
staining, Schrimer I test, 
conjunctival impression 
cytology 
Hypotonic (150 mOsm/l) 0.4% 
hyaluronate eye drops, 
isotonic 0.4% hyaluronate eye 
drops. 
40 Symptoms significantly improved. An 
improvement of BUT, fluorescein, and rose 
bengal score. Improved conjunctival 
impression cytology Hyaluronate eye drops are 
useful for treating severe dry eye in Sjögren’s 
syndrome patients. 
Aragona et 
al., 2002. 
Randomised 
double blind 
study 
Rose bengal, fluorescein 
staining, TBUT, Schrimer test 
Preservative free sodium 
hyaluronate or saline 
86 Sodium Hyaluronate improved impression of 
cytology score Sodium hyaluronate may 
effectively improve ocular surface damage 
associated with dry eye syndrome. 
Shimmura et 
al., 2003. 
 The effects of albumin on the 
viability of serum deprived 
conjunctival cell were 
observed in vitro. Rose 
Bengal, fluorescein, TBUT, 
subjective symptoms. 
5% or 10% solutions of human 
albumin. 0.3% sodium 
hyaluronate. 
40 Japanese 
white rabbits. 
9 human 
subjects 
Corneal erosions in rabbits healed significantly 
faster in eyes treated with albumin compared 
with control and sodium hyaluronate. Patients 
with Sjögrens syndrome used albumin drops 
showed improvement in fluorescein and rose 
bengal scores, but not in TBUT and subjective 
symptoms. The use of albumin as a protein 
supplement in artificial tear solutions is a viable 
approach in the treatment of ocular surface 
disorders associated with tear deficiency. 
Di Pascuale 
et al., 2004. 
 
Design 
comparative, 
non-randomised 
interventional 
study 
Symptom score, TBUT, dye 
staining and fluorescein 
clearance test. 
Single dose of emulsion eye 
drop (EED) and non-
preserved saline. 
15 Emulsion eye drops produces significant 
changes in the tear film or normal and dry eye 
patients. 
Nakamura et 
al., 2004. 
 
 Non-invasive specular 
reflection video recording 
system, appearance of a tear 
break up area and tears film 
images. 
1ppm hypochloric acid 
(HOCL) sodium hyaluronate 
(SH), 
hydropropylmethycellulose 
(HPMC), hydroxyethylcelluose 
(HEC) or chondroitin sulphate 
 Ocular surface bathing with artificial tear 
preparations composed of suitable viscosity 
agents could be useful in managing tear film 
instability. 
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(CS) 
Chag et al., 
2005. 
Randomly 
divided into two 
groups. 
Schrimer Test, Rose bengal 
fluorescein test, TBUT, 
questionnaires 
Chi-Ju-Di-Huang-Wan 80 Chi-Ju-Di-Huang-Wan is an effective stabiliser 
of tear film and decrease the abnormality of 
corneal epithelium. It provides an alternative 
choice for dry eye treatment. 
Johnson et 
al., 2006. 
Randomised, 
double-masked. 
Symptom intensity and 
NIBUT 
Sodium hyaluronate 0.1% and 
0.3% (SH) 
13 Sodium hyaluronate of 0.1% and 0.3% reduces 
symptoms of ocular irritation and lengthens 
NIBUT in subjects with moderate dry eye more 
effectively than saline, in terms of peak effect 
and duration of action. 
Moon et al., 
2007. 
 
 Schrimer Test, TBUT, 
conjunctival impression 
cytology 
Topical 0.05% cyclosporine, 
0.08% chondroitin, 0.06% 
sodium hyaluronate 
36 While both CS-HA and 0.05% CsA eye drops 
improve ocular surfaces, topical CsA may have 
a better effect on enhancing tear film stability 
and goblet cell density. 
Prabhasawat 
et al., 2007. 
Randomised, 
double blind, 
controlled, 
exploratory 
study 
NIBUT 
 
Isotonic 0.3% hydropropyl-
methycelluose (HPMC) 0.1% 
dextran 
10 Treatment with sodium hyaluronate and 
HPMC/dextran eye drops is useful for treating 
patients with dry eye. Sodium hyaluronate 
caused a significantly greater increase in 
NIBUT values than HPMC/dextran. 
Durrie et al., 
2008. 
Randomised, 
double-masked, 
single centre, 
placebo 
controlled 
contralateral 
study 
TBUT, visual acuity, corneal 
and conjunctival staining and 
treatment related adverse 
events 
Systane Lubricant eye drops 30 Systane Lubricant Eye Drops are safe for use 
following LASIK surgery to relieve the 
discomfort symptoms of dry eye associated 
with the procedure. 
Kim et al., 
2009. 
Randomised, 
controlled, 
parallel group 
study. 
Fluorescein staining, 
Schrimer tear test, TBUT, dry 
eye symptoms, and 
impression cytological 
analysis 
Vitamin A (retinul palmitate) 
and cyclosporine A 0.05% eye 
drops. 
150 Both vitamin A eye drops and topical 
cyclosporine A treatments are effective for the 
treatment of dry eye disorder. 
Gupta et al., 
2009. 
Retrospective 
observational 
case series 
Fluorescein staining, TBUT, 
Schrimer test 
Cyclosporine 0.05% 539 Majority of patients has improvement in their 
symptoms. 
Benelli et al., 
2010. 
Randomised, 
investigator –
Schrimer test, TBUT, visual 
acuity, fluorescein staining, 
Carboxymethylcellulose 
sodium (CMC) 0.5%, 
60 The results found that polyethylene glycol 400, 
0.25% and sodium hyaluronate significantly 
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masked 
evaluation. 
tear osmolarity and wave 
front aberrometry. 
polyethylene glycol 400 2.5%, 
sodium hyaluronate and HP 
Guar 18% 
improved tear osmolarity compared with 
carboxymethylcellulose sodium (CMC), 0.5% 
and HP Guar 0.18% after instillation. 
Sanchez et 
al., 2010. 
 
Prospective, 
interventional, 
single-centre 
study 
Corneal and conjunctival 
staining with fluorescein and 
lissamine green, TBUT, 
Schrimer test with 
anaesthesia, tear clearance 
and OSDI 
Hydroxyprpyl HP-Guar 48 The addition of HP-Guar to regular treatment 
after cataract surgery reduces ocular surface 
inflammation and dry eye signs and symptoms. 
Zhivov et al., 
2010. 
Randomised 
double-blind 
clinical trial 
Subjective discomfort, slit-
lamp biomicroscopy, TBUT 
and Schrimer test. 
0.01% Benzalkonium Chloride 
(BAC) solution and a placebo. 
20 The return of Langerhans Cells (LC) counts 
toward (or even below) baseline levels just four 
weeks after the end of BAK administration 
demonstrates the rapid normalization of the 
inflammatory environment. 
Rodriguez-
Torres et al., 
2010. 
 Height of lacrimal meniscus, 
Schrimer II test (with 
anaesthetic), break up time 
BUT, and liassamine green 
staining. 
Carboxymethylcellullose, 
hydroxypropylmethylcellulose, 
polyethyleneglycol, 
cyclosporine A 0.05% 
56 Conjunctival lissamine green staining is a 
useful guideline that could be routinely used to 
confirm diagnosis in subjective evaluations and 
patient follow-up. Patients with dry eye show a 
decrease in OSDI after being treated with the 
appropriate medication prescribed for each 
particular group, depending on severity. 
Shafaa et al., 
2011. 
 
 Schrimer test and TBUT. Atropine sulphate eye drops 
1%, tetracycline 
24 albino 
rabbits 
There was a significant improvement in the 
group treated with tetracycline alone and 
empty liposome. The use of liposome 
encapsulated tetracycline significantly 
improved Schirmer test results and TBUT 
values as well as reverse surface ocular 
pathology. 
Evangelista 
et al., 2011. 
Randomised NIBUT and Ocular Protection 
Index (OPI) 
Benzalkonium chloride-
containing lubricant – 
Carnidrop, Optive and Blu Sal 
 The instillation of compounds that improve the 
quality and stability of the tear film, which are 
impaired in dry eye syndrome, could be 
effective in the treatment of this condition. 
Opitz et al., 
2011. 
Open Label 
study. 
TBUT, corneal and 
conjunctival staining, 
Schrimer test scores with 
anaesthetic, meibomian 
Azithromycin 1.0% 33 Azithromycin 1% ophthalmic solutions offer 
viable option for the treatment of posterior 
blepharitis. 
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gland score, patients 
symptom scores and OSDI 
score 
Lemp et al., 
2011. 
 
Prospective, 
observational 
case. 
Bilateral tear osmolarity, 
TBUT, corneal and 
conjunctival staining, 
Schrimer test and meibomian 
gland grading. 
 314 Tear osmolarity is the best single metric both to 
diagnose and classify dry eye disease. Inter 
eye variability is a characteristic of dry eye not 
seen in normal subjects. 
Byun et al., 
2012. 
 Symptom scores, TBUT, 
Schrimer test, corneal and 
conjunctival staining. 
Cyclosporine 0.05% (tCsA) 
and 1% Methylprednisolone 
21 Treatment with tCsA appears to be safe and 
effective in moderate-to-severe chronic dry 
eye. Additional short-tern use of a topical 
steroid had the benefit of providing faster 
symptom relief and improvement of ocular sign 
without serious complications. 
Kinoshita et 
al., 2012. 
Randomised, 
double-masked, 
multicentre, 
placebo, 
controlled phase 
II study 
Fluorescein corneal staining, 
lissamine green conjunctival 
staining, TBUT and Schrimer 
test 
1% & 2% Rebamipide 308 The incidence of ocular abnormalities was 
similar across the rebamipide and placebo 
groups. Rebamipide was effective in treating 
both objective signs and subjective symptoms 
of dry eye and were well tolerated in this 4-
week study. Although 1% and 2% rebamipide 
were both efficacious, 2% Rebamipide may be 
more effective than 1% Rebamipide in some 
measures. 
Stanković-
Babić et al., 
2012. 
 Ocular discomfort, Schrimer 
test, TBUT and Rose Bengal 
staining. 
 50 The use of autologous serum in dry eye 
therapy should provide benefit to the patients, 
relieve symptoms and improve objective 
parameters for the evaluation of dry eye. 
Kamiya et al 
2012. 
A prospective, 
randomised, 
multicentre 
study 
Tear volume, TBUT, 
fluorescein and rose Bengal 
staining, subjective 
symptoms and adverse 
events 
Diquafosol tetrasodium and 
sodium hyaluronate 0.1% 
32 In dry eyes where sodium hyaluronate 
monotherapy was insufficient, diquafosol 
tetrasodium was effective in improving 
objective and subjective symptoms, suggesting 
its viability as an option for the additive 
treatment of such eyes. 
Liu et al., 
2012. 
 OSDI, TBUT, Schrimer test, 
ocular surface staining (OSS) 
and conjunctival HLA-DR 
Pranoprofen 0.1% 
sodium hyaluronate 0.1% 
60 Topical pranoprofen 0.1% has a beneficial 
effect in reducing the ocular signs and 
symptoms of dry eyes and decreasing 
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expression. inflammatory marks on conjunctival epithelial 
cells. 
Matsumoto et 
al., 2012. 
Randomised, 
double masked, 
multicentre, 
parallel-group, 
placebo 
controlled trial. 
Fluorescein corneal staining, 
rose bengal corneal and 
conjunctival staining scores, 
tear break up time (BUT) and 
subjective symptom 
assessment. 
1% or 3% diquafosol 286 Both 1% and 3% diquafosol ophthalmic 
solutions are considered effective and safe for 
the treatment of dry eye syndrome. 
Çömez et al., 
2013. 
Single-
institution, single 
masked, 
randomised, 
pilot study 
OSDI Systane, Eyestil, Tears 
Naturale II and Refresh tears. 
43 All four artificial tear formulations were effective 
in reliving dry eye signs and symptoms. 
Although the greatest improvement in two of 
the objective tests was achieved by Eyestil, the 
drug with the lowest osmolarity, differences 
among the four artificial tear eye drops were 
not statistically significant. 
Chung et al., 
2013. 
 Schrimer test I, TBUT, 
corneal temperature and dry 
eye symptom questionnaire. 
Cyclosporine 0.05% and 
saline 0.9% 
32 The dry eye symptom score was significantly 
reduced in the cyclosporine 0.05% group. 
Cyclosporine 0.05% can also be an effective 
treatment for dry eye after cataract surgery. 
Saeed et al., 
2013. 
Multi-centre, 
open label, 
uncontrolled 
study 
TBUT, Schrimer test, corneal 
staining 
Sodium hyaluronate eye gel 250 Sodium Hyaluronate can provide a suitable 
alternate in the treatment of dry eye disease 
due to its reported efficacy on foreign body 
sensation, itching, burning, watering, 
photophobia and feeling of dryness. 
Tomić et al., 
2013. 
 
 Intraocular pressure (IOP), 
TBUT and OSDI 
BAK-preserved travoprost 
0.004% 
40 This study showed that BAK-preserved 
travoprost 0.004% is an effective medication in 
newly diagnosed POAG patients, but its long-
term use may negatively influence ocular 
surface health by disrupting the tear film 
stability. 
Guo et al., 
2013. 
Randomised 
controlled study. 
Eye symptom score, 
Schrimer I test, TBUT, 
corneal fluorescein staining 
(CFS) and visual analogue 
scale (VAS) 
 47 Both electro acupuncture and ordinary 
acupuncture in improving eye symptom and 
Schirmer score. 
Koh et al.,  Subjective dry eye Diquafosol  Prolonged use of diquafosol ophthalmic 
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2013. symptoms, corneal and 
conjunctival staining with 
fluorescein, TBUT, lower 
TMH, optical coherence 
tomography, Schrimer testing 
and adverse reactions. 
solution for 6 months produced significant 
improvement both subjectively (dry eye 
symptom score) and objectively (ocular 
staining score and tear function tests) for 
aqueous-deficient dry eye. 
Celebi et al., 
2014. . 
Prospective 
double-blind 
randomised 
crossover study 
OSDI, TBUT, Schrimer test 
and oxford scale. 
20% diluted Autologous serum 
(AS) eye drops vs 
Preservative free artificial 
tears (PFAT) 
20 AS eye drops were more effective than 
conventional eye drops for improving tear film 
stability and subjective comfort in patients with 
severe DES. 
Zhang et al., 
2014. 
Single factor 
experiments 
TBUT and fluorescein 
staining 
Nanoscale-dispersed eye 
ointment (NDEO), petrolatum, 
lanoline and triglycerides 
(MCT) 
 Histological evaluation demonstrated that the 
NDEO restored the normal corneal and 
conjunctival morphology and is safe for 
ophthalmic application. 
Ueta et al., 
2014. 
 TBUT Rebamipide 4 Rebamipide eye drops might attenuate giant 
papillae in patients with allergic conjunctival 
diseases and that these eye drops may be 
useful for the treatment of not only dry eye but 
also of allergic conjunctival diseases. 
Kaercher et 
al., 2014. 
A prospective, 
multi-centre, 
non-
interventional 
study. 
Dry eye severity, TBUT, 
Schrimer test, OSDI and 
patient assessment of 
symptoms. 
Optive Plus  Optive plus was well tolerated and effective in 
reducing the signs and symptoms of all types 
of dry eye but is recommended for lipid-
deficient dry eye patients. 
Lee et al., 
2013. 
Randomised 
controlled trial. 
OSDI, TBUT), Schrimer test 
fluorescein staining, tear 
osmolarity and adverse 
events. 
0.1% sodium hyaluronate 95 No differences were found between the two 
groups in measures other than the OSDI. 
Adverse events were mild and transient. 
Thermal massage was effective in improving 
dry eye syndrome both subjectively and 
objectively. 
Kinoshita et 
al., 2014. 
Multi centre, 
open-label study 
Fluorescein corneal staining, 
lissamine green conjunctival 
staining, TBUT and 
subjective symptoms 
2% rebamipide ophthalmic 
suspension 
154 2% rebamipide is effective in improving both 
the objective signs and subjective symptoms of 
dry eye patients for at least 52 weeks. In 
addition, 2% rebamipide treatment was 
generally well tolerated. 
Toda et al., Prospective Subjective dry eye Diquafosol tetrasodium and 105 Hyaluronate and diquafosol combination 
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2014. randomised 
comparative 
trial. 
symptoms, uncorrected and 
corrected visual acuity, 
functional visual acuity, 
manifest refraction, TBUT, 
fluorescein corneal staining, 
Schrimer test and corneal 
sensitivity 
Sodium Hyaluronate therapy is beneficial for early stabilization of 
visual performance and improvement of 
subjective dry eye symptoms in patients after 
LASIK. 
Table 1.8: A summary of numerous studies investigating the effectiveness of various artificial eye drops. The studies represented in the table 
have been conducted from 1978 to 2014; the type of study conducted; tests and drops used; the number of subjects in each study and 
the results and conclusion of the studies. 
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1.9.1 Predictability 
At present there is a plethora of literature which evaluates individual artificial eyes 
drops or compares various different artificial eye drops in order to assess the effective 
treatment of dry eye. However, there is a lack of evidence on the actual predictability of 
which artificial eye drops will work best on the signs and symptoms of individual dry 
eye patients. 
 
A review on the outcomes-based on treatment options for patients with dry eye 
secondary to Sjögren’s syndrome was (SS) conducted by Akpek et al., (2011). They 
used a search strategy to identify prospective, interventional studies of treatments for 
SS-associated dry eye from electronic databases. Eligible references were restricted to 
English-language articles published after 1975. These sources were augmented by 
hand searches of reference lists from accessed articles. Study selection, data 
extraction, and grading of evidence were completed independently by 4 review authors. 
They assessed 245 full-text papers, 62 of which were relevant for inclusion in the 
review. Akpek et al., (2011) concluded that current literature on SS-associated dry eye, 
there is a lack of rigorous clinical trials to support therapy recommendations. However, 
the recommended treatments including topical lubricants, topical anti-inflammatory 
therapy, and tear-conserving strategies appear to improve symptoms. The efficacy of 
oral secretagogues seems greater in the treatment of oral dryness than ocular dryness. 
Although oral hydroxychloroquine is commonly prescribed to patients with SS to 
alleviate fatigue and arthralgia, the literature lacks strong evidence for the efficacy of 
this treatment for dry eye. No peer reviewed publications have attempted to determine 
which artificial tear formulation will work best for a patient based on baseline 
parameters. 
 
Demonstrating clinical efficacy of therapeutic agents for dry eye has proven to be 
challenging because therapeutic effects must overcome environmentally induced day-
to-day and seasonal fluctuations of eye discomfort symptoms and ocular surface signs. 
Alex et al., (2013), conducted a study to identify factors predicting the ocular surface 
response to experimental desiccating stress. The results of their study showed that 
corneal and conjunctival staining significantly increased in all subjects following 90-
minute exposure to an adverse environment and the degree of change was similar in 
normal and dry eye subjects, except superior cornea which stained more in dry eye 
patients. Irritation severity in the desiccating environment was associated with baseline 
dye staining, baseline tear meniscus height and blink rate after 45 minutes.  
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1.10 Correlation of tests 
The goals of the Diagnostic Methodology Subcommittee (DEWS, 2007) were to identify 
tests used to screen, diagnose, and monitor dry eye disease, as well as establish 
criteria of test efficacy and to consider their practical use in a clinical setting. They 
reviewed a number of tests used to diagnose and monitor dry eye disease. 
 
Dry eye tests are used for a variety of reasons, as listed below: 
 
1. To diagnose dry eye in everyday clinical practice. 
2. To assess eligibility in a clinical trial. These tests used in recruitment, could also 
be used as primary, secondary, or tertiary end points in a trial. 
3. To follow quantitative changes over the period of a clinical trial. These tests 
may differ from those employed in recruitment.  
4. To characterize dry eye as part of a clinical syndrome, e.g., as in the 
regularised classification criteria of Sjögren syndrome (Vitali et al., 2002). 
5. To follow the natural history of the disorder. However this opportunity is limited 
for dry eye, because treatment is so widespread in the population.  
 
There are a few shortcomings of tests for dry eye which include selection and spectrum 
bias. 
 
1.10.1 Selection Bias  
Unfortunately, there is no “gold standard” for the diagnosis of dry eye. Thus, when a 
test, is being evaluated for effectiveness, the test population may have been classified 
as affected or non-affected based on those identical tests. Likewise, the 
implementation of any “new” test may be compromised when the test is evaluated in a 
population of dry eye patients who have been diagnosed using un-established criteria.  
 
Furthermore, because of the multi-factorial nature of dry eye, inconsistent test efficacy 
is likely to occur from study to study. 
 
1.10.2 Spectrum Bias 
Spectrum bias is when the study sample consists of subjects with either very mild or 
very severe disease. The results are therefore compromised because the severity of 
the disease in the sample studied has been highly selected. The bias is due to 
differences in the features of different populations e.g., sex ratios, age, severity of 
disease, which influences the sensitivity and/or specificity of a test. 
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Certain ground rules were proposed for appraising the performance of tests for dry eye 
diagnosis reported in the literature (Table 1.9). 
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Table 1.9: Characteristics and current tests for dye eye. The table shows the 
effectiveness of a range of tests, used singly or in combination, for the 
diagnosis of dry eye. The tests included in the table are those for which 
values of sensitivity and specificity are available in the literature. The 
predictive values of these tests (positive, negative and overall accuracy) 
are calculated for a 15% prevalence of dry eye in the study population. 
The data shown here is susceptible to bias; selection bias applies to 
those studies shown in bold, in these, the test measure was part of the 
original criteria defining the dry eye sample group and spectrum bias 
applied to those studies (shown in light shading) where the study 
population contained a large proportion of severe cases. Both of these 
forms of bias can lead to an artificially increased test sensitivity and 
specificity. In most of the studies listed above the efficacy of the test was 
shown for the data from the sample on which the cut off or referent 
value for diagnosis was derived (indicated by a *), again this can lead to 
increased sensitivity and specificity in diagnosis. Ideally test 
effectiveness should be obtained on an independent sample of patients, 
such date is shown in studies indicate by the symbol ** (Taken from 
DEWS, 2007). 
 
1.10.3 Appraisal of tests used for screening for dry eye 
A screening test should be simple, effective, appropriate to a specific population, and 
economical. However, diagnosis is of little interest without a targeted treatment. 
 
1.10.3.1 Recommended screening and diagnostic tests for dry eye 
The recommended diagnostic and screening tests by the diagnostic methodology 
subcommittee (DEWS, 2007) are listed below. It was advised that when a sequence of 
tests is performed, they should be performed in the sequence that best preserves their 
integrity (Table 1.10). However, these tests would take too long to conduct on each 
patient in everyday clinical practice, so information on their relative usefulness is much 
needed. 
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Table 1.10: A sequence of tests used in dry eye assessment (DEWS, 2007). Test 
invasiveness increases from A to L. Intervals should be left between 
tests. Tests selected depend on facilities, feasibility and operational 
factors (Foulks et al., 2003). 
 
1.11 Literature review summary 
Irrespective of all the research performed to aid in the screening for dry eye and 
understanding the mechanism for developing dry eye, none or very little work has been 
done on determining the most effective treatment for an individual at diagnosis. There 
appears to be some overlap in determining the clinical tests that provide useful 
independent information on the ocular surface (chapter 2). However, there is a need for 
randomised controlled trials of artificial tear treatments on a relevant population to see 
how the treatments perform relevant to each other (chapter 3), and whether the 
preferred treatment could have been predicted (chapter 4). If the preferred treatment 
could not have been predicted, then is the preferred treatment subjectively related to 
the greatest improvement in ocular physiology and tear film performance (chapter 4). 
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CHAPTER 2 
 
150 Subjects:  Correlation of Dry Eye Tests in Optometric Practice 
 
2.0 Introduction 
Dry eye disease is typified by patient symptoms, ocular surface damage, diminished 
tear film stability, tear hyperosmolarity as well as inflammatory components (Bron, 
2001). This condition can be classified as evaporative dry eye; in which the cause is 
excessive evaporation, or tear deficient, in which there is a deficiency of aqueous tear 
secretion (Lemp, 1995). The inflammatory factor has become increasingly apparent, 
which causes patient symptoms, and the disease process itself. Symptoms are the 
most important characteristic of their dry eye condition. However in order to diagnose 
dry eye disease, it is important for the practitioner to assess for tear film instability and 
ocular surface damage, as well as the patient symptoms (Bron, 2001). Tear film 
instability appears to be an important element of all forms of dry eye disease, where, 
tear hyperosmolarity is an important mechanism for causing ocular surface damage 
(Gilbard and Farris, 1979). Each form of dry eye has some universal characteristics in 
common, which include the following: 
 
 A set of characteristic patient symptoms 
 Ocular surface damage 
 Reduced tear film stability 
 Tear hyperosmolarity (Bron, 2001). 
 
The prevalence of dry eye has been reported as 9% of patients over 40 years of age, 
increasing to 15% of those over 65 years (Schein et al., 1997; McCarty et al., 1998). A 
large survey (n = 893), conducted by Nichols et al., (2005), reported that on average 
52.3% of contact lens wearers, 23.9% of spectacle wearers and 7.1% of clinical 
emmetropes self-report dry eye in optometric practice. In optometric practice, dry eye 
remains the primary reason for reduced wearing times and for contact lens failure with 
studies reporting approximately 50% prevalence of self-reported dry eye in contact lens 
wearers compared with 20% in non-contact lens wearers (Nichols et al., 2005). 
 
An increase in age, female gender, medication, connective tissue disease, radiation 
therapy and refractive excimer laser surgery are proven factors for causing dry eye 
(Lemp et al., 2007). It has also been reported that environmental stresses at the 
workplace such as prolonged VDU use or during recreational activities can also initiate 
or exacerbate dry eye (Miljanovic et al., 2007). Allergic and inflammatory ocular surface 
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conditions disrupt the tear film (Fujishima et al., 1996) and smoking interferes with the 
lipid layer (Altinors et al., 2006). 
 
Dry eye signs and symptoms often do not correlate well (Nelson, 1988; Nelson et al., 
1992; Schein et al., 1997); however, both these factors are believed to be important in 
the diagnosis and management of dry eye, with the patient’s history and symptoms 
playing a significant role (Smith et al., 2008). Patients attending optometric practice 
may report ocular irritation, grittiness, burning, foreign body sensation, blurred vision, 
photophobia or possibly overall discomfort, predominantly in the evening (Begley et al., 
2003). Doughty (2010) has suggested that it can be useful, especially for borderline 
cases, to confirm the patient’s perception of their condition, i.e. do they think they have 
‘dry eye’ or not, or maybe they are not sure. Therefore the nature of a patient’s 
symptoms i.e. how do they describe them and how frequent these symptoms bother a 
patient should be made e.g. sometimes, often, always (Doughty, 2002). The symptoms 
that patients present with can be ocular or visual or both and they can also experience 
a transient degradation of vision associated with their symptoms (Doughty, 2010). 
However, clinical assessment of the patient’s ocular surface and tear integrity is 
important too. 
 
Experience over many years from a collection of practitioners, has taught that clinicians 
cannot expect a logical agreement between the external eye appearance and the 
symptoms that a dry eye patient is reporting (Nichols et al., 2004; Johnson, 2009). 
Hence, a logical approach is needed as to what tests might be used in order to 
diagnose dry eye and clinicians should be selective and consistent in the tests that 
have been selected in order to do so (Doughty, 2010).  
 
The overall features of dry eye disease can be identified by the following types of 
diagnostic tests: 
 
1. Symptom questionnaires,  
2. Tear break up time to assess tear instability or quality  
3. Staining to identify ocular surface damage,  
4. Osmolarity, (Bron, 2001). 
 
The two most popular validated questionnaires dry eye questionnaires are the 
McMonnies Dry eye Questionnaire (McMonnies, 1986; McMonnies et al., 1998) and 
the Ocular Surface Disease Index (OSDI) ©Allergan Inc. (Schiffman et al., 2000).  
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In order to assess the tear film quality, non-invasive stability tests can be conducted 
without touching either the tear film or ocular surface. This is because they are more 
validated than ‘traditional’ tests, since fluorescein has the potential to disrupt the tear 
film and reduce the measured tear break up time (Patel et al., 1985). In non-invasive 
tear tests the mires are reflected from the tear film (Hirji et al., 1989). The Bausch & 
Lomb keratometer and Tearscope Plus™ with grid insert can be used to measure non-
invasive break up tear time. The tear film stability measurements are variable therefore 
an average of at least three values was recorded for each eye. Overall, non-invasive 
stability values are longer than those measured with fluorescein. The cut-off for a 
healthy vs. dry eye is usually considered to be >20 seconds with non-invasive tear test, 
compared with >10 seconds with the fluorescein tear break-up test (Guillon et al., 
2004).  
 
Invasive tear break up time measured with fluorescein disrupts the tear film and 
shortens the normal tear break up time (Mengher et al., 1985). It has been suggested 
that in order to reduce its provocative nature, the instillation of fluorescein sodium must 
be minimised and volumes of 1µl does not cause the same destabilisation of the tear 
film that occurs with larger volumes (Craig et al., 2002). 
 
The tear lipid quality can be assessed with the aid of a wide-angle lighting system with 
a cold-cathode light source. The Tearscope Plus™ was used in conjunction with non-
illuminated slit lamp bio microscope in order to assess the tear lipid layer thickness and 
quality.  
 
The tear volume can be assessed by simply observing the heights of the lower tear 
menisci with the slit-lamp bio microscope. Heights of less than 0.2mm (which can be 
estimated using the calibrated slit beam height adjuster on the slit lamp) indicate 
reduced tear volume. The Phenol Red Thread (PRT) tear can also be used in order to 
assess the tear volume. The use of the PRT test is where thin cotton thread, 
impregnated with phenol red dye is hooked over the lateral third of the lower eyelid. 
The wetted length is measured after 15 seconds, where values less than 10mm thread 
wetting are indicative of aqueous insufficiency. Even though this is an invasive test, an 
advantage is that most patients are ever aware of the thread be in in situ.  
 
In order to assess the health of the ocular surface, Lid parallel conjunctival folds 
(LIPCOF), bordering the posterior lid margin in the primary direction of gaze, can be 
observed in dry eye patients. Lissamine green observed in white light, produces a 
staining pattern similar to rose bengal, (i.e. staining is best seen over the white of the 
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sclera and on the cornea, over a dark iris) (Norn, 1973). Lissamine green highlights 
epithelial surfaces that have been deprived of mucin protection or which have exposed 
epithelial cell membranes. 
 
There is significant evidence suggesting that tear hyper osmolarity is a principle 
mechanism for ocular surface damage in all forms of dry eye (Gilbard and Farris, 1979; 
1983). In the rabbit, deficiency of the aqueous or lipid layer of the tear film, in rabbit 
studies showed a rise in tear osmolarity and associated squamous metaplasia and loss 
of goblet cells (Gilbard et al., 1988; 1989). In clinical practice the Tear film osmolarity 
can be measured with the TearLab. The disposable probe was touched onto the lower 
tear meniscus at the lid margin, where a nanolitre sample of tears was collected, 
analysed within seconds and provided a reading.  
 
The diagnosis and management of dry eye patients greatly depends on the results of a 
number of the above tests, which ideally could be performed at a single clinic visit. It is 
therefore very important to perform these dry eye tests in an appropriate sequence, in 
order to avoid one test interfering with another. Bron, (2001), suggested a suitable 
order of diagnostic tests. It is advisable that after all non-invasive and minimally 
invasive tests have been performed, should staining agents be utilised as there is no 
formal data to validate a particular sequence of tests or the intervals between them 
(Table 2.1) suggests a suitable order of diagnostic tests. 
 
Symptomology OSDI Questionnaire 
Non-invasive tests Non-invasive tear break-up test (to assess tear stability) 
Tear Volume test (TMH)  
Tear Lipid Observation 
Minimally invasive tests Tear break-up test (to assess tear stability) 
Staining of the bulbar conjunctiva and cornea (to assess 
ocular surface damage) 
A 5-minute gap is recommended before the next test 
Tests of tear volume or secretion Phenol red thread test (to assess tear volume) 
A 5-minute gap is recommended before the next test 
Tear Osmolarity  TearLab 
Additional dye tests Lissamine green staining (to assess ocular surface 
damage) 
Table 2.1: Suggested sequence of tests for the diagnosis of dry eye disease. 
(Adapted from Bron, 2001). 
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Although numerous studies have investigated the correlations between dry eye tests in 
different populations, no one study has used a comprehensive suite of currently 
recognised clinical dry eye tests, and in general the population sizes examined in these 
past studies have been limited. Some studies concluded that there was no correlation 
between the dry eye tests and patient symptoms (Fuentes-Paez et al., 2011; De AF 
Gomes et al., 2012); on the other hand, some studies concluded that there was a 
correlation between symptoms and the dry eye tests (Pult et al., 2011; Cuevas et al., 
2012). Studies investigating these correlations have been summarised in table 2.2. 
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Korb et 
al., 
2005 
100 
patients 
divided into 
those 
with and 
those 
without dry 
eye 
symptoms 
N=100 mean age 44.3 
(symptomatic), 
42.8 
(asymptomatic) 
              76% of 
symptomatic 
patients had lid 
wiper 
staining, 12% of 
the asymptomatic 
patients 
had staining of the 
lid wiper 
Pult et 
al., 
2009 
New 
contact 
lens wearer 
N=33 median age 
30.5 (range 19 
to 44) 
                     LIPCOF, NIBUT 
and OSDI are 
significant 
discriminators of 
contact lens 
induced dry eye 
Fuentes-
Paez 
et al., 
2011 
Patients > 
50 years 
N=270 average age 
64.5 
                 No correlation 
between screening 
questionnaire 
and objective tests 
Pult et 
al., 
2011 
Non-
contact 
lens 
wearers 
N=47 median age 45 
(range 19-70) 
                      NIBUT, TMH, 
Phenol red, 
LIPCOF and LWE 
We’re related to 
ODSI scores. 
The strongest 
relationship 
appeared by 
combining NIBUT 
with LIPCOF 
Cuevas Subjects N=21                    Correlation 
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et al., 
2012 
with 
evaporative 
dry eye 
secondary 
to 
meibomian 
gland 
disease 
between 
symptoms and 
some clinical 
tests (TBUT, conj 
hyperaemia, TMH, 
conj stain) 
De AF 
Gomes 
et al., 
2012 
Patients 
with 
systemic 
sclerosis 
n=45, 
N=45                  No statistically 
significant 
correlations 
Table 2.2: A summary of several studies investigating the correlation between several of dry eye tests in different populations. The study 
population, number of subjects in an individual study and the age range are noted. The ‘ticks’ indicate the dry eye tests that were 
performed in each individual study with any comments related to the correlation of the tests performed. 
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Based on their uses over the years, the commonest clinical tests include the Schirmer 
test, the phenol red thread test (PRT), tear meniscus height (TMH), and fluorescein-
based tear break up time (NaFL TBUT) (Doughty et al., 2002; 2005; 2007; Miller et al., 
2004; Macri et al., 2000; Santodomingo et al., 2006). Dry eye induced damage of the 
ocular surface has been observed with staining induced by fluorescein, rose bengal or 
lissamine green dyes (Bron et al., 2003). 
A combination of two or three objective tests have been suggested in order to obtain 
reasonable correlations between symptoms and signs (Klaassen-Broekema et al., 
1992; Bron et al., 2001; Viso et al., 2006). It is has been suggested by Doughty (2010), 
that it is very difficult to differentiate between a preference for a test based on 
convenience or practitioners chair time against a choice made because the outcome of 
the tests might provide definitive answers.  
Therefore, the practitioner is justified on relying on their own experience in the 
diagnostic tests that they choose to perform on a routine basis, as it is difficult to 
differentiate between a patient having dry eye disease (DED) or not (Doughty, 2010). 
Hence, from this point of view, the practitioner might choose to adopt certain cut-off 
values to assist them in coming to a diagnosis for a dry eye condition (Table 2.3). 
However, this approach lacks evidence basis and researchers must support clinicians 
by identifying a group of dry eye tests that are most informative of patient outcomes, 
but can be rapidly conducted within everyday clinical practice. It should be noted that 
some tests are prone to reflex tearing and/or the impact of use of any recent 
treatments, which may hinder the interpretation of results and impact on the order in 
which a group of tests should be performed (Doughty, 2010). 
Table 2.3: Some typical outcomes for dry eye tests (Taken from DEWS, 2007). The 
dry eye tests included are Schirmer test (without anaesthesia, Phenol 
Red Thread test (PRT), Tear meniscus height (TMH),  Tear break up 
time with fluorescein (NaFl TBUT), Fluorescein staining, Rose Bengal 
87 
 
staining and Lissamine green staining, with values for  normal eyes and 
the outcome for true dry eye patients. 
 
Therefore, the purpose of this study is to utilise a wide range of clinical tests and a 
large patient cohort to better understand the independent contribution of each of these 
clinical dry eye tests prior to later chapters which will examine how well they predict dry 
eye management. 
 
2.1 Methods 
One hundred and fifty subjects (average age 56.33 years, range 19 to 91 years; 96 
females and 54 males) were recruited from the patients of a community optometric 
practice in the North West of England, over a four month period. To be eligible, patients 
reported a ‘dry eye’ and were then asked to complete the OSDI questionnaire in routine 
practice (no cut of value was set for the OSDI questionnaire). A convenient 
appointment was offered to the patients between 9am to 5pm from Monday through to 
Saturday. Unfortunately the TearLab ‘chips’ did not arrive into the practice in time for 
when the study commenced, so a further convenient appointment was offered to the 
patients between 9am to 5pm from Monday through to Saturday. Patients were advised 
of this minor setback at the initial appointment and were advised that they would have 
to return for the TearLab test. The patients were happy to return to the practice in order 
to have their tear osmolarity tested. Ethics approval was granted by the Aston 
University Ethics Committee and the research conformed to the tenets of the 
Declaration of Helsinki. Subjects gave their written consent following an explanation of 
the study procedures and potential risks. A copy of the ethics application form can be 
seen in Appendix A.  The approval letter from the ethics committee can be seen in 
Appendix B. 
 
2.1.1 Clinical Evaluation  
Given the complex nature of the tear film and the existence of several different types of 
dry eye, it is apparent that a single clinical method will not detect all tear abnormalities 
resulting from lacrimal, meibomian, or conjunctival disturbances.  
 
Essentially, the hallmark of dry eye damage to the corneal and conjunctival surfaces, 
associated with an array of symptoms of varying severity that include, photophobia, 
foreign body sensation, ocular discomfort and itching (Foulks, 2003; Nichols et al., 
1999). Therefore an assessment of the tear film must include a plethora of tests for 
assessing tear volume, stability and quality, in order to differentiate the normal from the 
dry eye (Farrell, 2010). Although none of these tests used to diagnose dry eye are 
highly sensitive or specific (Heath, 2004), and tests for one category of dry eye may be 
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positive and yet yield a negative result for another category of dry eye, despite the fact 
that both may lead to ocular surface disease (Heath, 2004). Most forms of dry eye have 
symptoms associated with the condition and some form of symptom screening will offer 
valuable information for diagnosis (McMonnies et al., 1987). 
 
Tear film ‘stability’ was assessed by Non-invasive mire break-up time (NIBUT), Non-
invasive Tearscope break up time (NITBUT) and Fluorescein break up time (NaFL 
BUT). Tear film ‘volume’ tests were measured by means of Tear meniscus height 
(TMH) and Phenol red thread (PRT). The relationship to ocular surface damage was 
assessed by observing the corneal and conjunctival staining, lid-parallel conjunctival 
folds (LIPCOF) and lipid interference pattern. Patient symptoms were measured by 
using the Ocular Surface Disease Index (OSDI). The tear film osmolarity was also 
measured.  
 
It has been recommended, that when a battery of tests is performed, they should be 
performed in an arrangement that best preserves their reliability (DEWS, 2007), and 
intervals should be left between the tests (Bron, 2001; Foulks and Bron, 2003). The 
tear film metrics were assessed in the following order due to the invasive nature of 
some tests. The right eye was observed followed by the left eye for every patient. 
These dry eye metrics: 
 
 Symptoms – were assessed using the OSDI questionnaire (Appendix C). The 
OSDI was selected from the range of possible questionnaires for assessing dry 
eye symptoms (see Table 1.5 for a summary) due to its validity in the chosen 
population and extensive use in the academic literature. The OSDI consists of 
12 questions arranged on a scale of 0-4 designed to assess the level of 
discomfort as well as how dry eye interferes with daily living activities. The 
questions are broken down further in to: 
 
1. Three of the twelve questions relate to ocular symptoms 
2. Six of the twelve to visual function 
3. Three of the twelve to environmental triggers  
 
The frequency is with 1 week recall period. The answers to the questions are:  
 None of the time,  
 Some of the time,  
 Half of the time,  
 Most of the time,  
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 All of the time [0-4] 
 
The scoring algorithm published:  
 100 = complete disability;  
 0 = no disability. 
 
The OSDI score was calculated by multiplying the total score by 25 and dividing 
by the total number of questions answered generating a result between 0 and 
100.  
 
 Non-invasive break-up time (NIBUT) – was measured by observing a 
keratometer mire projected onto the front of the corneal surface achieved by 
using a keratometer (Patel et al., 1985). The one position Bausch and Lomb 
keratometer with circular mires was used to measure the NIBUT in this study. 
Subjects were instructed to blink normally and then keep their eyes open for as 
long as possible. The NIBUT was recorded with a stop watch, when distortion is 
first seen in any part of the mire pattern. This was repeated 3 times in total and 
was averaged to give a mean NIBUT value. 
 
 Tear meniscus height (TMH) - was measured using a slit lamp bio-microscope 
(25 times magnification). The slit beam was rotated to align parallel to the lower 
eyelid margin, and the height of the slit beam was adjusted to correspond to the 
tear meniscus located directly below the pupil while the patient was looking in 
primary gaze. The TMH was expressed as the gap between the lower eyelid 
margin and the upper limit of the reflected zone of the tear meniscus (Farrell et 
al., 2003). The TMH was recorded from the built in, calibrated, slit beam width 
scale. This process was repeated 3 times in total and was averaged to give a 
mean TMH value. 
 
 Lid Parallel Conjunctival Folds (LIPCOF) - are folds in the lower conjunctiva, 
parallel to the lower lid margin (Pult and Sickenberger, 2000). They were 
observed using a 2-3 mm wide vertical slit beam located along the temporal 
limbus, to the inferior bulbar conjunctiva just above the lower lid margin. The 
angle between the observation and illumination system was between 20-30 
degrees and the LIPCOF viewed at 25 times magnification. The number of folds 
were counted and graded. This table can be seen in table1.2 (Höh et al., 1995). 
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 Non-invasive Tearscope break up time (NITBUT) - was measured using the 
Tearscope Plus (Keeler Ltd, Windsor, UK) in conjunction with a fine grid pattern 
insert mounted on a slit lamp bio-microscope to produce an image of the fine 
grid pattern over the entire cornea via specular reflection. Subjects were 
instructed to blink normally and then keep their eyes open for as long as 
possible. The NITBUT was defined as the time period between the last 
complete blink and the appearance of a break or distortion in the fine grid 
pattern (Guillon, 1998), measured using a digital stop-clock. This was repeated 
3 times in total and was averaged to give a mean NITBUT value. 
 
 Lipid pattern as observed by the Tearscope - was measured using the 
Tearscope Plus (Keeler Ltd, Windsor, UK) on a slit lamp bio-microscope. With 
the patient’s head positioned on the slit-lamp chin rest, the slit-lamp source was 
positioned nasally and switched off, as alternative illumination is provided by the 
Tearscope itself. The Tearscope was held as close to the eye as possible and 
positioned to allow observation through the sight hole via one of the bio 
microscope objectives. The light reflected from the tear film was observed as a 
white circular area, 10-12mm in diameter. Magnification was set at 10 times to 
examine the interference patterns after blinking, via specular reflection. 
Subjects were instructed to blink normally and then keep their eyes open for as 
long as possible. The observation patterns were compared with the pictures as 
provided by Keeler, as shown in figure 1.14. Tear lipid observation was graded 
from zero to 6, according to the lipid observation; where absent lipid layer 
pattern =0, open meshwork marmoreal =1, closed meshwork marmoreal =2, 
wave flow =3, amorphous =4, normal coloured fringes =5 and abnormal 
coloured fringes =6 (table 1.4). This is a categorisation scale related to 
thickness rather than a range from good to bad; hence correlation is against 
apparent thickness rather than severity of a sign. 
 
 Fluorescein break up time (NaFL TBUT) - was measured with the slit lamp 
bio-microscope (magnification 10 times) with a diffuse cobalt blue light at 
maximum brightness. A single drop of sterile saline was applied to a fluorescein 
sodium impregnated paper strip (Fluorets, 1mg fluorescein sodium, Chauvin 
Pharmaceuticals, Essex, UK) and the excess shaken off before applying it to 
the patients’ eye. The lower lid of both eyes was lowered and the moistened 
strip was swiftly, but gently applied to the lower tarsal conjunctiva. The subject 
was then instructed to blink normally after application to circulate the 
fluorescein. Subjects were then asked to look in primary gaze without blinking. 
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NaFL TBUT was defined as the interval of time between the last complete blink 
and the first appearance of a dry spot or disruption (black/dark blue area) in the 
tear film (Lemp et al., 1995) measured with a digital stop clock. A yellow filter 
(Kodak Wratten 12) was used to enhance contrast and improve visibility of 
breaks in the tear film (Bron et al., 2003). This was repeated 3 times in total and 
was averaged to give a mean NaFL TBUT value. 
 
 Corneal staining - corneal staining was assessed using fluorescein sodium 
(Fluorets) impregnated paper strips. A single drop of sterile saline was applied 
to a fluorescein sodium impregnated paper strip and the excess shaken off 
before applying it to the patients’ eye. The lower lid of both eyes was lowered 
and the moistened strip was swiftly and gently applied to the lower tarsal 
conjunctiva. The cornea of each eye was examined using a cobalt blue light 
source (10 times magnification), with contrast enhanced using a yellow filter. 
The presence of staining on the cornea of both eyes was recorded. The Efron 
grading scale used to denote the corneal staining (Efron, 2000). The Efron 
grading scale provides practitioners with a simple method of grading the ocular 
condition, enabling assessment of any ocular changes in the future. There are 
16 sets of grading images which cover the key anterior ocular complications of 
contact lens wear. The conditions are illustrated in five stages of increasing 
severity from 0 to 4, with 'traffic light' colour banding from green (normal) to red 
(severe) (Efron, 2000). Once the corneal staining was noted via the Efron 
grading scale; for statistical analysis, no corneal staining was graded =0, the 
presence of corneal staining in one quadrant was graded =1, and if there was 
corneal staining in more than one quadrant was graded =2.  
 
After a 5 minute break the following tests were performed as recommended by 
Bron, (2001). 
 
 Phenol red thread (PRT) - was used to measure tear volume. A yellow phenol 
(phenolsulfonphthalein) impregnated thread with the top 3mm folded over, was 
inserted along the lower temporal eyelid margin of both eyes approximately 1/3 
of the distance from the lateral canthus. The subject was instructed to blink 
normally while looking in primary gaze for 15 seconds, immediately after 
insertion (timed with a digital stop-clock). Following the 15 seconds, the thread 
was removed and the section of the thread transformed to a red colour from 
yellow was measured using a ruler to the nearest 0.5mm (Little & Bruce, 1994). 
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 Conjunctival staining – Lissamine Green (Green Glo, 1.5mg Lissamine 
Green, HUB Pharmaceuticals, USA) strips were used to evaluate the 
conjunctival integrity, where a single drop of sterile saline was applied to the 
strip. The wetted strip was quickly but gently applied to the lower tarsal 
conjunctiva after lowering the lower lid. The subject was then instructed to blink 
normally after application to distribute the lissamine green, before the 
conjunctiva of each eye was studied using a slit lamp bio-microscope (white 
light, 10 times magnification) (Feenstra et al.,1992). The presence of staining 
on the bulbar conjunctiva in both eyes was recorded (i.e. nasal, temporal, 
superior or inferior bulbar conjunctiva) and then graded by numbers with no 
staining =0, staining in one quadrant =1, and staining in more than 1 quadrant 
=2. 
 
 Osmolarity – was measured by The TearLab (TearLab Ltd, San Diego, CA, 
USA). It requires only a very small volume of tears, therefore can be used in 
subjects with relatively dry ocular surfaces. The TearLab osmolarity test utilizes 
a temperature-corrected impedance measurement to provide an indirect 
assessment of osmolarity. After applying a lot-specific calibration curve, 
osmolarity is calculated and displayed as a quantitative numerical value. It was 
ensured that patients had not use medicinal eye drops at least 2 hours prior to 
testing. Tears were collected from the outer margin of the eye lid lacrimal lake 
without lid manipulation as pulling the lower lid away from the globe may reduce 
the tear meniscus height, affecting tear collection. The patient was seated with 
their head tilted back looking upwards. The tear collection pen was positioned 
parallel over the inner margin of the lower eye lid and moved downwards on the 
lid until an audible sound indicated that sufficient tears had been gathered. Both 
eyes were tested and the higher of the two numbers was taken as 
recommended by the manufacturer 
(http://www.tearlab.com/products/doctors/productinfo.htm; Tomlinson et al, 
2006).  The patients returned a couple of weeks after their first visit to have their 
tear osmolarity measured, this is due to the chips for the TearLab system not 
arriving in to the practice on time.  Patients were happy returning to the store to 
have their tear osmolarity measured. 
 
Further details on all of the above tests can be found in section 1.6. A summary of the 
tear film metrics assessed are represented in figure 2.1. 
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Figure 2.1: Summary of the tear film metrics, in the order represented due to the 
invasive nature of certain tests. 
 
2.1.2 Data Analysis 
The data of the three repeats of NIBUT, NITBUT, NaFL TBUT and TMH were averaged 
for analysis. Corneal and conjunctival staining were graded as 0 if none was observed, 
1 if punctate staining occurred in one quadrant only and graded as 2 if punctate 
staining was evident in more than one quadrant. Tear lipid observation was graded 
from zero to 6, according to the lipid observation; where absent lipid layer pattern =0, 
open meshwork marmoreal =1, closed meshwork marmoreal =2, wave flow =3, 
amorphous =4, normal coloured fringes =5 and abnormal coloured fringes =6. One-
Sample Kolmogorov-Smirnov Tests were used to test for a normal distribution, and 
where there was a deviation from this with a particular metric, non-parametric statistics 
were applied. 
 
A cluster analysis technique was conducted in order to appreciate if there were groups 
with similar tear film metric results (SPSS v 20 software, IBM Corporation, New York, 
USA). A k-means cluster algorithm was utilised (where k is the number of clusters). 
The primary phase locates the k cluster centres by identifying cases that are well 
separated and treating these as initial cluster centres. The software then assigns cases 
to the cluster closest to them based on the distance from the cluster centre. After the 
•Ocular Surface Disease Index (OSDI)  
•Non Invasive break up time (NIBUT) 
•Tear Meniscus Height (TMH) 
•Lid Parrallel Conjunctival Folds (LIPCOF) 
•Non Invasive Teascope break up time (NITBUT) 
•Lipid Pattern as observed by Tearscope 
•Fluorescein break up time (NaFL TBUT) 
•Corneal Staining 
•Five minute break 
•Phenol red thread test (PRT)  
•Lissamine Green Staining  
•Tear Osmolarity (Measured at a later date due to 'chips' not arriving on time). 
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cases have been assigned, the cluster centres are recalculated and cases are 
reassigned using the new cluster centres. This procedure is repeated until no cluster 
centre changes significant in the number of iterations assigned. The number of clusters 
was selected based on whether the analysis failed to converge within 10 iterations or 
less than a certain percentage of these cases were within each cluster. The clusters 
were chosen to maximise the differences among cases between the clusters, hence, 
analysis of variance (ANOVA) statistical significance levels were used for the 
descriptive purposes only, (an increase in levels of significance indicate that it is more 
likely that a variable contributes to cluster separation). 
 
 
2.2 Results 
 
2.2.1 Comparison of the Eyes  
Analysis using the one-Sample Kolmogorov-Smirnov Tests showed that only NITBUT 
(p = 0.085) and osmolarity (p = 0.672) were normally distributed whereas the OSDI (p 
<0.001), NaFL TBUT (p = 0.008), TMH (p = 0.002), PRT (p = 0.009) and lipid pattern 
grade (p = 0.001) were not normally distributed and non-parametric statistics were 
applied. The average results of the 150 subjects are presented in table 2.4. As 
expected the results from the two eyes were similar for all the tear film metrics except 
NaFL TBUT (where the difference of 0.0 ± 1.2sec could be considered clinically 
insignificant) – note for osmolarity, the manufacturer recommends measuring both eyes 
and selecting the higher value, hence although a comparison is made, the highest 
value was used for subsequent evaluation. As this was the case, all further analysis 
was conducted on the right eye data only (highest eye value for osmolarity), to prevent 
statistical bias.  
 
 OSDI 
(%) 
NITBU
T 
(sec) 
NIBUT 
(sec) 
NaFL 
TBUT 
(sec) 
TMH 
(mm) 
PRT 
(mm) 
Osmolari
ty 
(mOsms/
L) 
Lipid 
Patter
n 
Grade 
Right Eye 22.7± 
0.2 
7.41± 
2.32 
13.04± 
2.07 
13.23± 
2.28 
0.12± 
0.02 
12.72± 
3.58 
306.7± 
13.3 
2.62± 
1.10 
Left Eye 7.31± 
2.23 
13.08± 
2.50 
13.28± 
2.69 
0.12± 
0.02 
12.77± 
3.48 
302.5± 
11.3 
2.62± 
1.09 
Significan
ce 
 0.737 0.777 0.023 0.677 0.221 0.001 <0.00
1 
Table 2.4: Comparison of the two eyes of each subject (average + S.D) for non-
invasive break-up time (NIBUT / NITBUT), fluorescein tear break-up 
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time (NaFL TBUT), tear meniscus height (TMH), phenol red test (PRT), 
osmolarity and lipid pattern grade (all analysed by related-samples 
Wilcoxon Signed Rank except NITBUT and osmolarity, evaluated with a 
t-test) tear film metrics of the right and left eyes. For completeness the 
Ocular Surface Disease Index (OSDI) data is also presented. N=150.
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  OSDI NIBUT 
NaFL 
TBUT 
NI 
TBUT TMH PRT 
Corneal 
Staining 
Conjunctival 
Staining LIPCOF Lipid Osmolarity 
 Age r=.284** r=-.222** r=-.217** r=-.047 r=-.387** r=-.236** r=.161* r=.264** r=.276** r=-.251 r=-.071 
 p<.001 p=.006 p=.008 p=.748 p<.001 p=.004 p=.049 p=.001 p=.001 p=.079 p=.624 
 OSDI  r=-.331** r=-.293** r=.111 r=-.463** r=-.317** r=.234** r=.493** r=.597** r=-.041 r=-.075 
  p<.001 p<.001 p=.443 p<.001 p<.001 p=.004 p<.001 p<.001 p=.777 p=.603 
 NIBUT   r=.916** r=.120 r=.466** r=.531** r=-.428** r=-.331** r=-.182* r=-.018 r=.096 
   p<.001 p=.405 p<.001 p<.001 p<.001 p<.001 p=.026 p=.093 p=.508 
 NaFLTBUT    r=.206 r=.457** r=.497** r=-.417** r=-.316** r=-.208* r=.018 r=.034 
    p=.151 p<.001 p<.001 p<.001 p<.001 p=.011 p=.901 p=.815 
 NITBUT     r=.301* r=.218 r=-.171 r=-.145 r=-.104 r=.149 r=-.053 
     p=.033 p=.128 p=.235 p=.315 p=.473 p=.303 p=.714 
 TMH      r=.576** r=-.349** r=-.445** r=-.407** r=-.089 r=-.117 
      p<.001 p<.001 p<.001 p<.001 p=.540 p=.419 
 PRT       r=-.377** r=-.223** r=-.187* r=-.090 r=.012 
       p<.001 p=.006 p=.002 p=.535 p=.931 
 Corneal Staining        r=.358** r=.254** r=-.238 r=-.450** 
        p<.001 p=.002 p=.097 p=.001 
 Conjunctival 
Staining 
        r=.601
**
 r=-.008 r=-.109 
         p<.001 p=.958 p=.452 
 LIPCOF          r=-.106 r=-.072 
          p=.464 p=.620 
 Lipid           r=.214 
           p=.136 
 **. Correlation is significant at the 0.01 level (2-tailed).*. Correlation is significant at the 0.05 level (2-tailed). 
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Table 2.5: The average + S.D. for 150 patients for the right eye only, for tear film 
metrics. Non-invasive break-up time (NITBUT) and osmolarity (analysed 
by t-test) and fluorescein tear break-up time (NaFL TBUT), non-invasive 
break-up time (NIBUT), tear meniscus height (TMH), phenol red test 
(PRT), corneal and conjunctival staining grade, lid-parallel conjunctival 
folds (LIPCOF) and lipid pattern grade (all analysed by related-samples 
Wilcoxon Signed Rank) tear film metrics of the right eye. For 
completeness the Ocular Surface Disease Index (OSDI) data is also 
presented. **. Correlation is significant at the 0.01 level (2-tailed) and *. 
Correlation is significant at the 0.05 level (2-tailed).N=150, right eye 
only. 
  
2.2.2 Comparison of Tear Film Tests 
As only two of the tear film metrics was found to be normally distributed (NITBUT and 
osmolarity), and ocular surface tear film and damage metrics of lipid layer pattern, 
LIPCOF, corneal and conjunctival staining were graded, non-parametric correlations 
(Spearman’s Rank) were performed on the 150 subjects for the following tests and 
demographics: age, OSDI score, NIBUT, NaFL TBUT, TMH, PRT, osmolarity, lipid 
pattern, LIPCOF, and corneal and conjunctival staining (Table 2.5). The link between 
the tests is presented visually in figure 2.2. 
 
The correlation ‘r’ is mostly weak between the dry eye tests with some of the tests 
performing better in relation to symptomology (OSDI) than others. The following tests 
performed better in relation to the OSDI, LIPCOF; conjunctival staining; TMH; NIBUT; 
PRT; NaFL TBUT, with the least correlated  being corneal staining. The tear stability 
tests (NIBUT and NaFL TBUT), were correlated to the tear volume tests (PRT and 
TMH), corneal and conjunctival staining and to a lesser extent LIPCOF. The TMH was 
correlated with PRT; conjunctival staining; LIPCOF and corneal staining. The dry eye 
tests correlated with LIPCOF were conjunctival staining; TMH and to a lesser extent 
NaFL TBUT followed by NIBUT and PRT. The only test correlating to the tear 
osmolarity was corneal staining. 
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Conjunctival 
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                  PRT 
 
 
 
Lipid Observation 
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OSDI 
 
LIPCOF 
Osmolarity 
Figure 2.2: A representation of the various tests which correlate with each other. 
Age correlates with Non Invasive Tearscope Break Up Time (NITBUT), 
Fluorescein break up time (NaFL TBUT), Tear meniscus height (TMH), 
Phenol red thread (PRT), Lid parallel conjunctival folds (LIPCOF), 
Ocular Surface Disease Index (OSDI) and Conjunctival staining. TMH is 
correlated with PRT, LIPCOF, Corneal staining and Conjunctival 
staining. PRT is correlated to conjunctival and corneal staining. Corneal 
staining is correlated to Conjunctival staining, LIPCOF and Osmolarity. 
OSDI is correlated to NITBUT, NaFL TBUT, TMH, PRT, LIPCOF, 
Corneal and Conjunctival staining. 
 
Ocular Surface Disease Index (OSDI), non-invasive break-up time (NITBUT), 
fluorescein tear break-up time (NaFL TBUT), tear meniscus height (TMH), phenol red 
test (PRT), osmolarity and lipid pattern values were compared for patients with an 
absence or presence of lid-parallel conjunctival folds (LIPCOF), corneal staining and 
conjunctival staining ocular surface ‘damage’ for the right eye (Table 2.6). For corneal 
staining there were only two subjects with corneal staining and the rest with no 
staining; for conjunctival staining, nine subjects did not have staining and the rest did - 
hence no statistical comparison with lipid grade was possible. 
 
 
 
99 
 
 OSDI NITBUT 
(sec) 
NaFL 
TBUT 
(sec) 
TMH 
(mm) 
PRT 
(mm) 
Osmolarity 
(mOsms/L) 
Lipid 
Pattern 
Grade 
LIPCOF 
Absent 11.47±9.
34 
13.65±1.5
8 
13.69±1.5
9 
0.12±0.0
2 
13.33±2
.63 
314.0±15.2 2.67+1.3
7 
Presen
t 
30.14±18
.33 
12.60±2.2
5 
12.60±2.4
7 
0.10±0.0
2 
12.30±4
.06 
310.3±18.0 2.61+1.0
8 
P <0.001 <0.001 <0.001 0.002 <0.001 0.606 0.037 
Corneal Staining (Fluorescein) 
Absent 21.03±17
.77 
13.42±1.7
7 
13.43±1.9
7 
0.12±0.0
2 
13.14±3
.59 
316.1±17.3 2.65+1.1
2 
Presen
t 
31.41±15
.90 
10.64±2.9
7 
10.60±2.1
2 
0.12±0.0
2 
10.27±2
.29 
291.3±3.5 2.00+0.0
0 
P 0.962 <0.001 <0.001 0.258 <0.001 <0.001 N/A 
Conjunctival Staining (Lissamine Green) 
Absent 14.20±12
.95 
13.79±1.5
9 
13.83±1.6
8 
0.12±0.0
2 
13.38±3
.13 
315.8±19.4 2.62+1.0
0 
Presen
t 
29.76±18
.31 
12.78±1.8
9 
12.87±2.1
6 
0.11±0.0
2 
11.88±3
.58 
309.8±17.3 2.54+1.1
2 
P <0.001 <0.001 <0.001 0.017 0.029 0.441 N/A 
Table 2.6: Findings and significance for dry eye tests; (p value for parametric or 
non-parametric test as appropriate) for Ocular Surface Disease Index 
(OSDI), non-invasive break-up time (NITBUT), fluorescein tear break-up 
time (NaFL TBUT), tear meniscus height (TMH), phenol red test (PRT), 
osmolarity and lipid pattern for the absence or presence of lid-parallel 
conjunctival folds (LIPCOF), corneal staining and conjunctival staining 
ocular surface ‘damage’ for the right eye. N=150. NA = not applicable. 
 
2.2.3 Cluster analysis 
Cluster analysis was carried out for 7, 6, 5, 4, 3 and 2 groups with the number of 
subjects in each cluster identified shown below in table 2.7. 
 
Cluster 
Number 
Number of clusters and resulting subject split between these 
2 3 4 5 6 7 
1 53 33 37 25 26 27 
2 97 77 31 28 21 14 
3  40 33 21 20 20 
4   49 39 25 24 
5    37 26 23 
6     32 24 
7      18 
Table 2.7: The number of subjects in each cluster, when 2 to 7 way cluster analysis 
was completed. N=150. 
 
Convergence was achieved when there was no significant change in cluster centres 
between iterations. Table 2.8 below shows the number of iterations performed for each 
cluster and the minimum distance between the initial cluster centres.  
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Cluster Iteration Minimum distance between initial 
clusters 
7 5 24.44 
6 6 24.76 
5 4 30.26 
4 7 38.90 
3 4 60.78 
2 5 75.03 
Table 2.8: The distance between the initial cluster centres and iterations for the 
clusters. 
 
None of the cluster analyses failed to converge. Once more than 3 clusters were 
established, the size of at least one of the clusters identified had less than 20% (n= 30) 
of the subjects (Table 2.9). To increase the number of clusters to consider, the 
percentage (in 5% steps) required for a cluster would have to be lowered to 10% (n = 
15) of the subjects, in which case 5 clusters were identified (Table 2.10).  
 
A) Final Cluster Centres 
 Cluster 
1 2 3 
Age 49.55 70.83 33.08 
OSDI .20 .27 .17 
NIBUT 12.80 12.72 13.83 
NaFLTBUT 12.77 12.66 13.91 
NITBUT 6.28 7.34 8.12 
TMH .12 .11 .13 
PRT 12.85 12.47 13.05 
Corneal Staining .36 .34 .13 
Conjunctival Staining .73 1.30 .73 
LIPCOF .45 1.14 .68 
Lipid 3.25 2.42 3.10 
Osmolarity 334.75 307.03 305.60 
 
B) ANOVA 
 Cluster Error F Sig. 
Mean Square Df Mean Square Df 
Age 19666.639 2 62.434 147 315.000 .000 
OSDI .142 2 .031 147 4.654 .011 
NIBUT 17.367 2 4.105 147 4.231 .016 
NaFLTBUT 21.908 2 4.701 147 4.660 .011 
NITBUT 5.174 2 5.410 47 .956 .392 
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TMH .003 2 .000 147 8.584 .000 
PRT 4.891 2 12.880 147 .380 .685 
Corneal Staining .721 2 .444 147 1.624 .201 
Conjunctival Staining 6.145 2 .902 147 6.810 .001 
LIPCOF 6.474 2 .628 147 10.301 .000 
Lipid 2.690 2 1.157 47 2.324 .109 
Osmolarity 1453.899 2 111.832 47 13.001 .000 
The F tests should be used only for descriptive purposes because the clusters have been chosen to 
maximize the differences among cases in different clusters. The observed significance levels are not 
corrected for this and thus cannot be interpreted as tests of the hypothesis that the cluster means are 
equal. 
Table 2.9: A) Final Cluster centres and B) Analysis of Variance (ANOVA) between 
cluster centres for Ocular Surface Disease Index (OSDI), non-invasive 
break-up time (NITBUT), fluorescein tear break-up time (NaFL TBUT), 
tear meniscus height (TMH), phenol red test (PRT), osmolarity and lipid 
pattern, lid-parallel conjunctival folds (LIPCOF), corneal staining and 
conjunctival staining for the right eye split into 3 clusters. N=150. 
 
 
A) Final Cluster Centres 
 Cluster 
1 2 3 4 5 
Age 40.56 77.82 25.67 54.51 69.03 
OSDI .18 .27 .16 .25 .24 
NIBUT 13.71 12.03 13.90 12.68 13.20 
NaFL TBUT 13.65 12.05 13.93 12.73 13.11 
NITBUT 7.60 7.38 6.62 8.12 6.91 
TMH .13 .11 .13 .12 .11 
PRT 13.28 10.93 12.86 13.64 12.59 
Corneal Staining .20 .54 .19 .26 .24 
Conjunctival Staining .56 1.32 .67 1.08 1.24 
LIPCOF .48 1.18 .67 .87 1.00 
Lipid 3.00 2.00 2.40 2.94 2.65 
Osmolarity 358.00 294.00 312.40 305.33 316.82 
 
B) ANOVA 
 Cluster Error F Sig. 
Mean Square df Mean Square Df 
Age 11244.847 4 24.356 145 461.683 .000 
OSDI .064 4 .031 145 2.068 .088 
NIBUT 15.372 4 3.977 145 3.865 .005 
NaFLTBUT 14.423 4 4.670 145 3.088 .018 
NITBUT 4.093 4 5.517 45 .742 .568 
TMH .002 4 .000 145 5.585 .000 
PRT 32.933 4 12.216 145 2.696 .033 
Corneal Staining .556 4 .444 145 1.251 .292 
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Conjunctival Staining 3.107 4 .914 145 3.399 .011 
LIPCOF 1.990 4 .672 145 2.964 .022 
Lipid 1.438 4 1.201 45 1.198 .325 
Osmolarity 1441.562 4 53.282 45 27.056 .000 
The F tests should be used only for descriptive purposes because the clusters have been chosen to 
maximize the differences among cases in different clusters. The observed significance levels are not 
corrected for this and thus cannot be interpreted as tests of the hypothesis that the cluster means are 
equal. 
Table 2.10: A) Final Cluster centres and B) Analysis of Variance (ANOVA) between 
cluster centres for Ocular Surface Disease Index (OSDI), non-invasive 
break-up time (NITBUT), fluorescein tear break-up time (NaFL TBUT), 
tear meniscus height (TMH), phenol red test (PRT), osmolarity and lipid 
pattern, lid-parallel conjunctival folds (LIPCOF), corneal staining and 
conjunctival staining for the right eye split into 5 clusters. N=150. 
 
 
2.3 Discussion 
There are batteries of tests which can be performed in optometric practice in order to 
evaluate the ocular surface and most importantly, to help diagnose and efficiently treat 
DED in practice. Despite the existence of all these dry eye tests, the clinical history of 
patients that has been regarded as a useful tool in uncovering this condition (O’Toole, 
2005; Heath, 2007; Doughty, 2010). Both dry eye symptoms and ocular signs are often 
do not correlate well, but both are believed to be essential in the diagnosis and 
management of dry eye, with the patient’s history and symptoms playing a crucial part 
(Smith et al., 2008). It is impractical to conduct every test on all dry eye patients, due to 
time restraints for both practitioner and patient. Therefore, it is important to justify if any 
of these tests are largely redundant in providing additional information compared to 
other tests and whether any have more diagnostic significance than others. 
 
Unfortunately, most dry eye tests and symptoms often do not correlate, conflict with 
each other, and display considerable variation making classification difficult (Nichols et 
al., 2004; De Gomes et al., 2012). The dry eye tests included in this study could be 
categorised in the following way, in order to evaluate DED. The tear stability is 
assessed by break-up tests, i.e. NIBUT, NaFL TBUT and NITBUT. Tear volume can be 
assessed by means of the PRT, TMH. Corneal and conjunctival staining and LIPCOF 
are tests which provide an extent of the irritation and physiological status of the ocular 
surface. The balance of the tear film constituents can be assessed by assessing the 
osmolarity of the tears.  Hence if the above mentioned groups are justifiable and the 
tests within a grouping are strongly correlated with one another, fewer tests would have 
to be performed. 
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Symptomology, assessed utilising the OSDI questionnaire, correlated with those tests 
investigating potential damage to the ocular surface i.e. LIPCOF; conjunctival and 
corneal staining as well as tests which assess both tear volume and stability as 
measured by the TMH and NIBUT. With age all these parameters were affected. Tear 
stability was significantly positively correlated with non-invasive and invasive tear 
break-up times. In this study, tear stability metrics were also correlated well with tear 
volume as measured by TMH and PRT, as well as corneal and conjunctival staining, 
and to a lesser degree LIPCOF. Both tear volume tests, as measured by the PRT and 
TMH, correlated well with corneal and conjunctival staining and LIPCOF; however the 
PRT test correlated less than the TMH for these tests. While several of the tear film 
metrics were statistically significant between those patients with and without LIPCOF, 
corneal and conjunctival staining (Table 2.6), it should be noted that some of the 
changes were small (such as 1 second difference in NITBUT) which are unlikely to be 
clinically significant. Tomlinson et al., (2001) reported a lack of correlation between 
TMH and the PRT, but their study had younger and fewer subjects than this one. 
Corneal staining was correlated to conjunctival staining, LIPCOF and osmolarity. 
Osmolarity was significantly positively correlated to corneal staining, unlike any of the 
other clinical tear film tests performed in the study. LIPCOF was significantly correlated 
to tear stability as well as conjunctival and corneal staining.  
 
Cluster analysis was introduced for the first time in dry eye to try to establish whether it 
represents a group of distinct conditions (which may partly explain different preferences 
to dry eye treatments in subsequent chapters) or whether it is a single condition with a 
spectrum of severity as has been suggested for non-infectious and microbial keratitis, 
under the umbrella of corneal inflammatory events (CIEs) by Morgan and colleagues 
(2005). Although the research in this chapter demonstrated that statistically distinct 
clusters of dry eye metrics defining the disease could be established, there was no 
clear end point to the number of subgroups that could exist, with three or five 
potentially indicated for this cohort. This usefulness in explaining preference to dry eye 
treatments will be explored in chapter 3. 
 
 
2.4 Conclusion 
Numerous dry eye tests have been applied to diagnose and monitor dry eye disease, 
either in a clinical setting or in clinical trials.  However, there are a number of studies 
that have been subject to several forms of bias (section 1.10.1 and 1.10.2); therefore 
the cut-off values that they recommend may be unreliable. Another important factor to 
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consider is several tests available are expensive and may not be available routinely in 
optometric practice (e.g. TearLab, LipiView®, Keratograph 5M). 
 
DEWS (2007), has suggested the following tests to diagnose dry eye disease in the 
series: symptomology; tear break-up time and ocular surface fluorescein staining; 
Schirmer test; lid and meibomian morphology and meibomian expression. 
 
It has been reported that the following tests are the most commonly used diagnostic 
tests for the initial assessment of dry eye disease, tear break up time (93%), corneal 
staining (85%), and tear film assessment (76%), conjunctival staining (74%), and 
Schirmer test (54%)(Serin et al., 2007). 
 
The use of questionnaires is used in order to ensure consistency in recording patients’ 
symptoms. One of the most widely used questionnaires is The Ocular Surface Disease 
Index (OSDI), as it is deemed more (Schiffman et al., 2000). The OSDI questionnaire 
has been suggested to be more useful for monitoring disease progression, despite the 
difference in symptoms in meibomian gland dysfunction (Tomlinson et al., 2011), based 
on a recent validation of the survey (Miller et al., 2010). A number of studies have been 
conducted in order to ascertain the correlation of different dry eye tests or the 
predictive ability of a dry eye test. A large multicentre study involving 314 subjects, 
conducted by Lemp and colleagues (2011) measured bilateral tear osmolarity, tear film 
break-up time, corneal and conjunctival staining, Schirmer test, and meibomian gland 
grading. They reported 73% sensitivity and 92% specificity for tear hyperosmolarity 
with a cut off value chosen 312 mOsms/L. Tests displaying poor sensitivity were 
(corneal staining 54%; conjunctival staining 60%; meibomian gland grading 61%). The 
tests presenting with poor specificity were tear film break-up time 45% and Schirmer 
test 51%.  They concluded that tear osmolarity is the best single metric in order to 
classify and diagnose dry eye disease. On the contrary it has also been reported that 
“tear osmolarity cannot be used as the sole indicator of dry eye disease’’ (Suzuki et al., 
2010). Traditionally tear stability has been observed with the instillation of fluorescein, 
in order to measure the tear break up time, however the legitimacy of the results obtain 
have been scrutinised (Norn 1969, 1986; Lemp et al., 1973; Mengher et al., 1985). 
Several studies have reported that fluorescein tear break up time values are generally 
higher than non-invasive tear break up time (Mengher et al., 1985; Patel et al., 1985). 
The phenol red thread is less invasive than the Schirmer test which is used in order to 
assess the tear volume and has been described as an index of tear volume (Tomlinson 
et al., 2001). A study leaving the thread in place for 120 seconds differentiated between 
aqueous deficient and evaporative dry eye using a cut-off of 20 mm (sensitivity, 86%; 
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specificity, 83%) (Patel et al., 1998).No correlation has been found between phenol red 
thread test and tear meniscus height in dry eye, although the Schirmer I test has 
showed a significant correlation when both tests were performed for one minute (Yokoi 
et al., 2000). The tear lipid layer can be observed by looking at the images produced by 
specular reflection using the Tearscope (Keeler Ophthalmic Instruments).  It has been 
reported that the tear lipid thickness and aqueous volume were interconnected after 
punctul occlusion (Goto et al., 2003). Corneal and conjunctival staining can be 
assessed by instilling dyes such as sodium fluorescein, rose bengal or lissamine green. 
However the repeatability of staining tests has been found to be poor (Nichols et al., 
2004), as well as lacking discriminatory power in mild to moderate cases of dry eye 
(Suliivan et al., 2010). It has been reported that the   strongest  predictor  of contact  
lens  induced  dry  eye  was  a  combination  of nasal LIPCOF and non-invasive break-
up  time (Pult et al., 2011). The OCT has recently been used in a study to grade 
LIPCOF, which correlated well with slit lamp evaluation (Veres et al., 2011). 
 
As the tear stability tests are strongly correlated, these results demonstrate that TBUT 
and NITBUT are both not necessary to perform in clinical practice. It would be more 
appropriate to observe the tear stability by performing NIBUT/NITBUT as fluorescein 
potentially disrupts the tear film structure (Mengher et al., 1985). The tear volume tests 
are also related and so any of the two can be used in clinical practice. It could be 
argued that conjunctival staining is linked to tear film stability and hence does to 
provide enough independent information to warrant the invasive and time consuming 
test. While lipid thickness lacks a severity rather than thickness grading scale, as some 
tear film supplements specifically target this layer and the lipid is so important for 
preventing evaporative loss (see section 1.6.9), lipid assessment should also be 
included in a dry eye test battery. Osmolarity and corneal staining provide similar 
information and the former, while more expensive to perform with the TearLab device, 
is linked to specific artificial tear treatments, and so could be preferred. Tear osmolarity 
has been reported to be the single best sign for dry eye disease (DEWS, 2007). 
 
It can be seen from these results that there is no consistent relationship found between 
signs and symptoms of DED. However, each measurement offers distinct information 
about the condition of the ocular surface. Symptoms alone are insufficient to diagnose 
DED (DEWS, 2007), and more than one test has to be carried out in order to achieve 
the desired results with treatment. Therefore the key tests for DED 
diagnosis/management that are suggested from the results of this chapter are:  
 
 Symptoms e.g. OSDI 
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 Stability e.g. NIBUT – which is linked with conjunctival staining. 
 Volume e.g. TMH, as measured with slit lamp. 
 Osmolarity e.g. TearLab – which is linked with corneal staining. 
 Lipid e.g. as measured with the Tearscope, LipiView®, Keratograph 5M. 
 
All these tests are easy to perform in optometric practice, but take some time and 
hence there is a necessity for specialist dry eye clinics conducting these specific tests 
for the diagnosis and monitoring of treatments of dry eye. This is considered to be a 
better alternative than practitioners ‘diagnosing’ and proposing inadequate treatments 
for DED on grounds of less relevant examinations carried out as a small subset of the 
full eye examination 
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CHAPTER 3 
 
Relative Effectiveness of Different Categories of Artificial Tear Supplements 
 
3.0 Introduction 
Practitioners are experiencing an increasing number of patients complaining of 
symptoms associated with ocular dryness (Atkins, 2008) and symptoms. Dry eye is a 
common disorder, typically dry eye is classified as either aqueous-deficient or 
evaporative (DEWS, 2007); however these aetiologies are not mutually exclusive, and 
increased evaporation has been reported to be the more significant factor, contributing 
to dry eye signs and symptoms in as many as 78% of patients (Heiligenhaus et al., 
1994, Lemp, 1995, Scaffidi et al., 2007). 
 
Dry eye is one of the most common conditions faced in clinical practice. It is estimated 
that clinical dry eye affects as many as 21.6% of the patient population between 43 to 
86 years of age (Moss et al., 2000). Based on data from studies by the Women’s 
Health Study (WHS), the Physicians’ Health Study (PHS) and other studies (Lemp et 
al., 1995; Miyawaki et al., 1995; Miljanovic et al., 2007; Schein et al., 1997; McCarty et 
al., 1998; Christen et al., 1998; Schein et al., 1999; Muñoz et al., 2000; Moss et al., 
2000; Christen et al., 2000; Lee et al., 2002; Chia et al., 2003; Schaumberg 2003; Lin 
et al., 2003) it has been estimated that 3.23 million female and 1.68 million male, 
Americans 50 years and older have dry eye (Schaumberg et al., 2003;  Miljanovic et 
al., 2007). Reddy et al., (2004), reported a prevalence of 11-17 per cent in the general 
population. 
 
A comparison of age-specific data on the prevalence of dry eye from large 
epidemiological studies reveals a range of 5% (McCarty et al., 1998) to greater than 
35% (Lin et al., 2003) at different ages. However, different definitions of dry eye were 
employed in these studies; hence caution is advised in interpreting direct comparisons 
of these studies. Even though, limited data exists on the possible effect of race or 
ethnicity on dry eye prevalence, data from the WHS imply that the prevalence of severe 
symptoms and/or clinical diagnosis of dry eye may be greater in Hispanic and Asian, as 
compared to Caucasian women (Schaumberg et al., 2003). The combined data from 
large population-based epidemiological studies indicates that the number of women 
affected with dry eye appears to surpass that of men (Schein et al., 1997; 1999; 
Christen et al., 1998; 2000; McCarty et al., 1998; Moss et al., 2000; Muñoz et al., 2000; 
Lee et al 2002; Chia et al., 2003; Lin et al., 2003; Schaumberg et al., 2003; Miljanovic 
et al., 2007). 
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The studies were conducted in different populations across the world, therefore, 
providing valuable information regarding potential differences in dry eye according to 
geographic location. Data from the two studies performed in Asia suggest the 
possibility of a higher prevalence of dry eye in those populations (McCarty et al., 1998; 
Lee et al., 2002). The weight of the evidence from large epidemiological studies 
indicates that female sex and older age increase the risk for dry eye; the Salisbury Eye 
Evaluation study is the most notable exception (Schein et al., 1997; Muňoz et al., 
2000). An overall summary of data suggests that the prevalence of dry eye lies 
somewhere in the range of 5-30% in the population aged 50 years and older. The 
prevalence of dry eye, using varying definitions, was tabulated for each epidemiologic 
study and is listed in table 3.1, along with the corresponding estimates of population 
prevalence (DEWS, 2007). 
 
 
Table 3.1: Summary of population-based epidemiologic studies of dry eye (Taken 
from DEWS, 2007). The number of patients in each study, age range, 
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dry eye assessments and the prevalence are summarised. The studies 
were carried out over different continents; USA, Australia and Asia. 
 
Ocular complaints, such as burning, dryness, stinging, and grittiness, are often 
reported in epidemiologic studies of indoor environments, especially in offices where 
highly demanding visual and cognitive tasks are performed (Skyberg et al., 2003). 
Typical symptoms of dry eye sufferers include photophobia, burning, itching, foreign-
body sensation, eye fatigue, and dryness (Ball, 1982). Ocular dryness may be due to 
increased tear evaporation and to low humidity, high room temperature and air velocity, 
decreased blink rate, or indoor pollution or poor air quality (Tsubota et al., 1993; 
Skyberg et al., 2003; Wolkoff et al., 2005; McCulley et al., 2006) and ultra-low humidity 
environments, such as aircraft cabins, have also been associated with dry eye 
symptoms (Lindgren et.al., 2002; Sato et al., 2003). The symptoms of patients tends to 
be diurnal, with symptoms becoming worse as the day progresses, and they are 
frequently aggravated in dry, warm environments where tear evaporation is highest 
(Kanski, 1989). 
 
The effect of contact lenses on exacerbating dry eye is indicted by the higher prevalent 
rate in this population (typically around 50%, DEWS, 2007). However, studies 
assessing contact lens wear in adverse environmental conditions such as dehydration 
(Fonn et al., 1999; Efron et al., 1999) and temperature / humidity (Morgan et al., 2004) 
have suggested contradictory effects on their impact on subjective comfort.  
 
Unfortunately, there is no known cure for dry eye disease and so treatment can be 
seen as management in order to supplement, preserve or stimulate tears to minimise 
ocular discomfort. The fundamental treatment goals in the management of dry eye are 
suitable healing, epithelialisation and the re-establishment of normal ocular surface 
(Gobbles et al., 1992). 
 
Even though dry eye disease in its milder form may react to treatments that lessen 
symptoms without altering the disease process, recent pharmacological approaches 
are directed toward reducing, stopping the disease process. Therefore tests are 
required to discriminate between dry eyes, quantify disease severity, and demonstrate 
the effect of disease on a patients’ quality of life. 
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Fig 3.1: Schematic illustration of the relationship between dry eye and other 
forms of ocular surface disease. OSD = Ocular surface disease; MGD = 
Meibomian gland dysfunction.  (Taken from DEWS, 2007) 
 
 
The most widely used therapy for dry eye is by the use of topical artificial tears and 
lubricants (Calonge, 2001).  There are numerous components used to formulate a vast 
number of commercially available preparations (table 1.6 and table 1.7).The main aim 
of using artificial tears in to improve the ocular lubrication (Calonge, 2001), ‘tear 
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replacement’ or ‘tear retention’ (Farrell, 2010) and are principally aimed at relieving the 
subjective symptoms of patients (Doughty, 2010; Farrell, 2010). 
 
However, there various treatment options for dry eye, rather than just using artificial 
tears. They are discussed briefly below:  
 
 Blink exercises- an incomplete blink will usually present as inferior punctate 
corneal epithelial staining (Heath, 2004). Blink modification exercise plan has 
been recommended by Schendowich (2003), for contact lens wearers with 
incomplete blinking.  
 
 Lid hygiene and warm compresses- Blepharitis may be seborrheic, 
staphylococcal or a combination of both (Kanski, 1989). Blepharitis can be 
observed as oily secretions, ‘dandruff’ or collarettes around the eyelashes and 
missing or misdirected eyelashes. Patients may complain of photophobia, 
tearing, pain, redness, blurred vision and/or discharge. Warm compresses of 
the lid may reduce tear evaporation by temporarily thickening the lipid layer 
(Gilbard, 2005). Korb et al., (1994) reported that patients with MGD with a daily 
regimen of eyelid scrubbing and warm compresses, as well as meibomian 
gland expression resulted in less solid meibomian secretions and significantly 
increased lipid layer thickness and patients reported improved dry eye 
symptoms. Craig and colleagues (1995) also showed that manual expression of 
the meibomian glands increases lipid layer thickness and tear film stability in 
normal subjects.  
 
 Autologous serum tears– are produced from the patient’s serum and have 
been used in severe DED. Autologous serum tears have biochemical and 
mechanical properties similar, to those of normal aqueous tears (Geerling et al., 
2004).  
 
 Punctal plugs- are the most commonly used means of occlusion (Lemp, 2008). 
A number of clinical studies have evaluated the efficacy of punctal plugs 
(Tuberville et al., 1982; Willis et al., 1987; Gilbard et al., 1989; Balaram et al., 
2001; Baxter et al., 2004) and their use has shown both objective and 
subjective improvement in patients with Sjögren and non-Sjögren aqueous tear 
deficient dry eye. It has been reported that, patients who are symptomatic of dry 
eyes, have a Schirmer test (with anaesthesia) result less than 5 mm at 5 
minutes, and appear to have ocular surface staining would benefit from punctal 
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plugs (Baxter et al., 2004). The complications of punctal plugs are conjunctival 
irritation, epiphoria where 5% of patients request plug removal (Taban et al., 
2006) and infection (DEWS, 2007). 
 
 Anti-inflammatory therapy- Disease of the tear secretory glands results in an 
alteration of the tears leads to changes in the tears, such as hyperosmolarity, 
which stimulate the production of inflammatory mediators on the ocular surface 
(Luo et al., 2004; 2005), this inflammation may cause dysfunction of cells 
responsible for tear secretion and / or retention (Niederkorn et al., 2006).  
 
 Essential fatty acids- can be obtained from dietary sources (DEWS, 2007). 
Several clinical trials have shown a clinical benefit of the effect of fish oil 
omega-3 fatty acids on rheumatoid arthritis (James et al., 1997; Kremer, 2000). 
In a study conducted by Barabino et al., (2003) showed a significant 
improvement in ocular irritation symptoms and lissamine green staining. 
 
 Environmental strategies- anything that may affect a reduction in tear 
production or increased tear evaporation e.g. Antihistamines or 
antidepressants, environmental factors such as air conditioning and low 
humidity should be reduced (Seedor et al., 1986; Mader et al., 1991; Moss et 
al., 2000). It has been advised that visual display units be lowered to below the 
eye level, in order to reduce the inter-palpebral aperture as well as patients 
taking regular breaks when working on a computer (Tsubota et al., 1993). 
 
Even though there are numerous topical lubricants, with varying viscosity, that may 
improve patient symptoms and clinical findings, there is no evidence that any particular 
artificial tear treatment is superior to another (DEWS, 2007). Generally clinical trials 
involving topical artificial tears will report some improvement of subjective symptoms 
and improvement in some clinical signs (Nelson et al., 1992). Therefore this study aims 
to investigate if any one artificial tear used in the trial is superior to another. 
 
3.0.1 The ideal artificial tear solution 
The ideal tear supplement can be said to require the following key features: 
 
 Provide immediate discomfort relief 
 Give prolonged residency of the tear film, for long lasting relief 
 Is non-toxic to the ocular surface 
 Is simple to instil 
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 Does not blur vision after instillation (Atkins, 2008). 
 
The ideal delivery system for such a solution can be said to have the following key 
features: 
 
 Easy/simple to use/instil 
 Small (measured) droplet size to avoid blurring/washing away the tear film 
 Helps maintain solution sterility between usage (with or without preservatives) 
 Affordable (Atkins, 2008). 
 
Currently there are multiple treatments available, however, the majority being tear 
supplements, but with little evidence as to their effectiveness and whether some work 
better for some patients than others. At present treatment goals are directed towards 
either ‘tear replacement’ or ‘tear retention’, and are aimed primarily at relieving the 
subjective symptoms associated with this condition (Farrell, 2010). Numerous 
formulations and active ingredients have been introduced over the years, with varying 
success, and these may broadly be classified as aqueous artificial tears, ocular 
lubricants and viscoelastics (Farrell, 2010). 
 
Artificial tears can be viewed as ‘simple’ or ‘complex’, and those that re-wet a ‘dry’ eye 
will provide at least a transient lubricating action. More complex eye drops labelled as 
true ocular lubricants are more likely to provide more substantial lubricating action 
(Doughty, 2010). Simple artificial tears are likely to be based on a normal saline 0.9% 
and usually a single polymer to assist any lubricating action. Whereas the complex 
artificial tears may contain two or more polymers, and the true lubricants category is 
limited either to products containing the highest concentrations of the polymers or 
special polymers, or have an ointment vehicle base rather than saline (Doughty, 2010). 
The main active ingredients are usually carboxymethylcellulose (CMC), polyvinyl 
alcohol (PVA), hyaluronic acid (HA), polyethylene glycol (PEG) and Poly Vinyl-
Pyrrolidone (PVP) (see section 1.7.1). Current artificial tears and ocular lubricants are 
presented in Table 1.6. 
 
3.0.2 Preservatives 
Topical ophthalmic solutions sometimes may cause toxic or allergic reactions resulting 
in iatrogenic ocular disease (Wilson, 1979). Toxic reactions relate to the direct chemical 
irritation of tissue, whereas allergic reactions imply sensitization and induction of ocular 
inflammatory processes by the patient’s immune system (Arffa, 1979). Bernal and 
colleagues (1991) concluded from their study that solutions containing preservatives 
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such as benzalkonium chloride, polyquad and thimersol caused corneal damage, whilst 
non preservative solution showed no damage to the cornea.  Likewise, Berdy and 
colleagues (1992) conducted a study to evaluate the corneal epithelium of rabbit eyes 
after administration of two preservative-free ocular lubricants: Hypotears PF and 
Refresh, and 0.02% benzalkonium chloride, and used a scanning electron microscopy 
to assess the corneal epithelial damage they came to the conclusion that with frequent-
dosage regimens, preservative-free artificial tear solutions used in the study were free 
of the toxic effects associated with preserved solutions. 
 
These adverse external ocular effects of ophthalmic therapy are due to the topically 
applied drug, or the excipients present in the preparation. Preservatives are among the 
excipients currently used in ophthalmic preparations (Furrer et al., 2002). Furrer and 
colleagues (2002) reviewed the ocular cytotoxic effects caused by preservatives and 
focused on the validity of the use of preservatives in ophthalmic solutions and the risks 
associated with their use. They concluded that the use of preservatives is the easiest 
way to prevent microbial spoilage of ophthalmic solutions. However, constitute a 
necessary compromise between what is legally required and necessary, and what is 
microbiologically efficacious on the one hand and possibly toxic on the other (Kilp et al., 
1984). In other words, preservatives are meant to destroy microorganisms across a 
broad spectrum and to protect the eye against possible secondary infection, but 
unfortunately their action is non-specific and they can damage ocular tissues (Lemp et 
al., 1988). Furrer and colleagues (2002) suggested that the use of preservatives in eye 
drops should be restricted to solutions that are used selectively during a short period of 
time and recommended that preservatives should be avoided, if possible, in cases 
where patients have chronic ocular surface disease (dry eye or allergy), because of the 
risk of worsening patient symptoms. In others cases, caution is urged in the use of 
preservative-containing topical ocular medications over an extended period in patients 
with extensive ocular surface diseases (Olson et al., 1990). The use of preservative-
free tear substitutes should be promoted as they are as effective as preserved artificial 
tears, and avoid adverse ocular effects induced by preservatives (Brewitt et al., 1991; 
Grene et al., 1992). 
 
Hence the future of artificial tears is likely to be preservative free therefore the solutions 
selected for this study were unpreserved. The aim of this chapter was to determine the 
relative effectiveness of the different categories of tear supplements as identified in the 
introduction (Chapter 1), namely two with different concentrations of hyaluronic acid, 
one marketed on its osmolarity balancing effects and the other being a liposomal spray.  
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3.1 Method 
 
3.1.1 Drops chosen for the study  
The drops chosen for the study were Clinitas Soothe, Hyabak, Tears Again and 
TheraTears. The reason for using these drops for the study as they all are preservative 
free causing no potential cytotoxic effect on the ocular surface and represented the 
different non-pharmaceutical eye drop options commercially available to manage dry 
eyes.  
 
3.1.1.1 Clinitas Soothe and Hyabak 
Clinitas Soothe is marketed as a rewetting/lubricating solution for dry eye patients and 
contact lens wearers containing 0.4 per cent Sodium Hyaluronate as a preservative 
free eye drops containing 0.5ml of solution. The container is an interesting 
development on the traditional single unit container (SUC) in that it incorporates a 
replaceable cap for leak-free disposal and breaking the seal of the vial leaves a smooth 
opening, unlike most conventional SUCs (Atkins, 2008). Hyabak uses the patented 
Abak preservative-free multi-dose eye drop dispenser. This uses a system of filters to 
ensure that each drop dispensed is preservative-free and calibrated to always be 30µl 
in size. The key lubricant is unpreserved 0.15% Sodium Hyaluronate. The ingredients 
and benefits of Hyabak can be seen in table 3.2. 
 
Several studies have reported that sodium hyaluronate is able to improve both 
symptoms and signs in patients with dry eye (Gill et al., 1973; Polack et al., 1982; De 
Luise et al., 1984, Stuart et al., 1985; Shimmura et al., 1995; Papa et al., 2001). 
Aragona and colleagues (2002) explored the effect of sodium hyaluronate containing 
eye drops on the ocular surface of patients with dry eye during long term treatment, 
concluding that sodium hyaluronate seems to effectively improve ocular surface 
damage associated with dry eye syndrome. Likewise a study conducted by Brignole et 
al., (2005) evaluated the efficacy and safety of 0.18% sodium hyaluronate in patients 
with moderate dry eye syndrome and superficial keratitis. They concluded sodium 
hyaluronate was well tolerated and tended to show a faster efficacy than did the CMC-
based formulation in patients with moderate dry eye and superficial keratitis. Sodium 
hyaluronate could therefore advantageously be prescribed from the early stages of dry 
eye disease. Mengher and colleagues, (1986) evaluated the effect of 0.1% sodium 
hyaluronate (unpreserved) in 10 patients with dry eyes. The pre-corneal tear film break-
up time was assessed by non-invasive technique, and the severity of symptoms was 
recorded before and after treatment on a 0 to +3 scale. Tear film stability was 
significantly increased (p<0.05) in eyes treated with sodium hyaluronate. The 
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symptoms of grittiness and burning were also significantly alleviated in the treated 
eyes. Sand and colleagues, (1989) investigated the effect of Sodium hyaluronate in the 
treatment of keratoconjunctivitis sicca (KCS). They evaluated this in a double masked 
crossover trial, comparing the effect of a 0.1% solution, a 0.2% solution and placebo in 
20 patients. The authors showed significantly decreased rose bengal staining and 
increased break-up time following 0.2% treatment compared to placebo. No significant 
difference was found in the Schirmer values and the cornea sensitivity. The patients 
significantly preferred sodium hyaluronate treatment over the placebo. Hence the 
consensus of studies is that hyaluronic acid based dry eye treatment should be 
effective, even in low concentrations. 
 
3.1.1.2 TheraTears 
TheraTears was developed by Gilbard at the Schepens Eye Institute. TheraTears is a 
preservative free hypotonic solution in unit dose, with the active ingredient 
Carboxymethylcellulose (CMC 0.25 %). CMC is negatively charged and binds to the 
corneal epithelial surface well. CMC also has a cyto-protective function against the 
insult from the preservatives present in contact lens disinfecting solutions (Vehinge et 
al., 2003; Sulley, 2004). It has been claimed that TheraTears may have beneficial 
effects on conjunctival goblet cell density, especially in patients fitted with punctal 
plugs, due to its hypotonicity and may help corneal healing by reducing the effects from 
the upper eyelid on blinking (Gilbard, 1999). 
 
TheraTears is designed to saturate dry eyes, and dilute down the high salt 
concentration that causes dry-eye irritation. Dry eye is a result of a loss of water from 
the tears on the eye surface that makes the tears hyper-osmotic. TheraTears has an 
osmolarity mean value of 181mmol/kg which is significantly lower than general ocular 
lubricants (Perrigin et al., 2004). The hypo-osmotic TheraTears help replace the lost 
water, lowering the high salt concentration, so that they not only wet but also rehydrate 
dry eyes, leading to an improvement in symptoms (Matheson, 2006). In addition the 
tears are an electrolyte solution specially designed to protect the eye surface. The 
ingredients and benefits of TheraTears can be seen in table 3.2. 
 
The importance of electrolyte balance has been reported extensively (Gilbard et al., 
2005, Schofield, 2004). The corneal epithelium derives its electrolytes and oxygen from 
the tear film (Matheson, 2006). Volker and colleagues, (2000) showed that unless an 
eye drop has an electrolyte balance that precisely matches that of the human tear film, 
there is a loss of conjunctival goblet cells (conjunctival goblet-cell density appears to be 
a sensitive indicator of ocular surface health, and goblet cells provide the natural 
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lubrication for the ocular surface). TheraTears has been shown to restore conjunctival 
goblet cells in dry eye seen after Lasik vision correction surgery (Lenton et al., 1998). 
 
3.1.1.3 Tears Again  
The tear lipid layer has long been recognised to play an important role in preventing 
tear film evaporation (Mishima et al., 1961). The tear lipid layer is a complex structure 
with a thin, inner polar layer, interfacing with the aqueous phase and reducing surface 
tension, and a thicker, outer, non-polar layer which is believed to inhibit tear 
evaporation (Korb et al., 2002, Bron et al., 2004). Meibomian gland dysfunction results 
in abnormal lipid production and has been identified as one of the major causes of 
ocular discomfort and ocular surface abnormality (Shimazaki et al., 1998, McCulley et 
al., 2003, Foulks, 2003).  
 
Traditionally, the focus of dry eye therapies has been to augment tear film volume to 
compensate for aqueous insufficiency but more recently, attention has been directed 
towards creating supplements that address deficiency in the tear film lipids. In the last 
decade, researchers have reported significant reductions in tear evaporation and 
improvements in lipid layer thickness with topical lipid emulsion eye drops containing 
neutral oils and castor oil (Goto et al., 2002; Di Pascuale et al., 2004; Khanal et al., 
2007; Scaffidi et al., 2007). 
 
Tears Again phospholipid liposomal spray is applied to the closed eyelids and the 
liposomes migrate, via the lid margins, into the tear film (Craig et al., 2010). An 
improvement in eyelid margin inflammation, symptomatology, tear production, visual 
acuity and lid parallel conjunctival folds have been documented with use of the lipid 
spray in patients with dry eye (Lee et al., 2004; Dausch et al., 2006; Khaireddin et al., 
2010; Craig et al., 2010), as well as in contact lens wear (Kunzel, 2008) and following 
cataract surgery (Reich et al., 2008). The effect of significantly improving tear film 
stability and lipid layer thickness in normal and mildly symptomatic eyes appears to last 
for between 60 and 90 minutes following a single application of a phospholipid 
liposomal spray to the closed eye (Craig et al., 2010). The ingredients and benefits of 
Tears Again can be seen in table 3.2. 
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Key Lubricant Size/For
m 
Other 
constituents  
Benefits Manufacturer 
and 
Distributor 
 
Clinitas Soothe 
Highest concentration of 
Sodium Hyaluronate 0.4% 
Molecular weight 1.2 million 
Daltons (Ds) 
 
20 
Resealabl
e 
droppers. 
0.5ml in 
each 
dropper 
(8-10 
drops) 
Monobasic 
sodium 
phosphate, 
dibasic sodium 
phosphate, 
sodium 
chloride, water 
for injection 
No 
preservativ
es 
8 to 10 
drops per 
dropper 
Each 
dropper is 
re sealable 
for 12 
hours 
Shelf life 2 
years (Atkin 
2008) 
Maximum 
expiry after 
opening : 
up to 2 
years 
single use 
(Atkin 
2008) 
Manufacturer: 
Farmigea 
S.p.A., Pisa 
Italy. 
 
Distributed by: 
Altcor Ltd, 
Cambridge, 
UK 
Hyabak 
Sodium Hyaluronate 0.15% 
 
10ml 
Bottle 
Sodium 
chloride, 
trometamol, 
hydrochloric 
acid, water for 
injection ad 
100mL 
No 
Preservativ
es 
Dispenser 
contains 
around 300 
drops 
 
Manufactured 
by: 
Laboratoires 
Théa, 
Clermont-
Ferrand, 
France.  
 
 
 
Distributed by: 
Spectrum 
Thea 
Pharmaceutica
ls Ltd, 
Macclesfield, 
UK 
TheraTears 
Sodium 
Carboxymethylcellulose 0.25 
32 single 
use 
container
s  per box 
Borate buffers, 
calcium 
chloride, 
Dequest®, 
No 
Preservativ
Manufacturer: 
Advanced 
Vision 
Research, Ann 
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% 
 
magnesium 
chloride, 
potassium 
chloride, 
purified water, 
sodium 
bicarbonate, 
sodium 
chloride, 
sodium 
perborate, and 
sodium 
phosphate 
 
es 
Patented 
so that 
each drop 
provides 
the special 
salt 
balance, 
the 
electrolyte 
balance, 
needed for 
the health 
of the eye 
surface 
Arbar, MI, 
USA. 
 
Distributor: 
Matheson 
Optometrists – 
3 West St, 
Alresford, 
Hants, SO24 
9AG 
 
Tears Again 
Phospho-lipid liposomes 
 
10ml 
Bottle 
1ml contains 
10mg soy 
lecithin, 8mg 
sodium 
chloride, 8mg 
ethanol, 5mg 
phenoxyethan
ol, 0.25mg 
vitamin A, 
0.02mg 
vitamin E, 
aqua purificata 
Apply to 
lids when 
closed 
3 Year 
shelf life 
Bottle 
contains 
100 
applications 
Manufacturer: 
Optima 
Pharmazeutisc
he GmbH, D-
85361, 
Moodburg/Wa
ng, Germany. 
Distributed by: 
Optrex, 
Damson Lane, 
Hull, HU8 
7DS, UK. 
(Optrex is an 
associate 
company of 
Reckitt 
Benckiser 
Healthcare 
Ltd.) 
Table 3.2:  Listing the key lubricants, size/ form, other constituents, manufacturer 
and benefits of the drops chosen for the study. (Clinitas Soothe Hyabak, 
TheraTears and Tears Again). 
 
3.1.2 Patients 
Fifty patients (average age 60.8 years, range 26-82 years; 35 females and 15 males) 
were recruited from the patients of a community optometric practice in the north west of 
England. The study was approved by the ethical committee of Aston University and 
conformed to the tenets of the Declaration of Helsinki. Patients signed a consent form 
after an explanation of the study and its possible risks had been given. 
 
The patients recruited, were advised of the purpose of the study which was to look 
more carefully at the signs and available treatments of dry eye and to be able to 
identify the best treatment for future patients with dry eye without the need to trial 
several possible treatments. Subjects were excluded if they had diabetes; Sjögren’s 
Syndrome, recent ocular infection, hay fever, used any eye drops or ocular 
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medications, were currently on medications known to affect the eyes, wore contact 
lenses or were pregnant. Patients included in the study had subjective symptoms 
indicative of dry eye. The patients that met the inclusion and exclusion criteria and 
consented to take part in the research were advised that they would undergo clinical 
assessment of their tears and were then given artificial tears to use for one month. The 
patients were advised to continue without a ‘wash out’ period on the next set of tear 
supplements in order to ease ocular comfort, however, were asked not to use their 
artificial tear supplements on the day of the clinical observation. The same tests would 
be repeated in consecutive months. They were advised that there would be required to 
attend the practice a total of five times over a four month period and to use only the 
drops given to them at each visit.  
 
Patients were asked to record how many drops they used on a daily basis. It was 
stressed to subjects that this was a single blinded study where the researcher was 
unaware of which drops were used and at which month, so total discretion with respect 
to this was required. In order for the researcher not to be involved with the actual 
handing over of the eye drops key staff members in the clinical practice were selected 
to distribute the drops out and facilitate the follow up appointments of the patients 
before they saw the researcher. The participants were free to discontinue with the trial 
at any time and were reassured that their information would be fully confidential. A 
copy of the consent form can be found in Appendix D. 
 
3.1.3 Clinical evaluation  
It has been recommended, that when a battery of tests is performed, they should be 
performed in an arrangement that best preserves their reliability (DEWS, 2007), and 
intervals should be left between the tests (Bron, 2001; Foulks and Bron, 2003). 
 
Therefore, on these recommendations, the tear film metrics for this study were 
assessed in the following order due to the invasive nature of some tests. These dry eye 
tests were conducted on the right eye of every patient at every visit.  
 
 Symptoms – the OSDI questionnaire measures the severity of dry eye disease 
using 12 questions scored on a scale of 0-4. The OSDI score was calculated by 
multiplying the total score by 25 and dividing by the total number of questions 
answered generating a result between 0 and 100. Subjects were assigned 
normal (≤10) or symptomatic (>10) status based upon the OSDI score. The 
OSDI is well validated and can differentiate dry eye severity with a limited time 
(Schiffman et al., 2000). 
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 Non-invasive Break-up Time (NIBUT) – was measured by observing the 
stability of the keratometer mire projected onto the front of the corneal surface 
(Patel et al., 1985). The one position Bausch and Lomb keratometer with 
circular mires was used to measure the NIBUT in this study. The portion of the 
image mire used in keratometry is not reflected from the exact centre of the 
cornea, but from two small areas on either side of the axis of the instrument, 
separated by about 3mm (Henson, 1983). Subjects were instructed to blink 
normally and then keep their eyes open for as long as possible The NIBUT was 
recorded with a stop watch to the nearest second when distortion is first seen in 
any part of the mire pattern. 
 
 Tear Meniscus Height (TMH) - the total volume of aqueous tears comprised 
within the upper and lower tear meniscus is approximately 75-90 per cent of the 
total volume of the aqueous component (Mainstone et al., 1996). The tear 
formation is controlled by the size and shape of the tear meniscus along the 
tear margin, (Holly et al., 1977). It has been reported that the height of the tear 
meniscus is reduced by half in the presence of KCS (Lim et al., 1991), as well 
as an irregular edge or intact temporal area of the lower tear meniscus being 
consistent with dry eye (Holly et al., 1977, Terry, 1984, Port et al,. 1990). The 
method used to quantify TMH was to rotate the slit beam (under 25 times 
magnification) until it was horizontal and to adjust the width of the slit until it 
matched the height of the tear prism. The tear meniscus height (TMH) was 
measured directly below the pupil centre. 
 
 Lid Parallel Conjunctival Folds (LIPCOF) - are folds in the lower conjunctiva 
parallel to the lower lid margin (Pult and Sickenberger, 2000). It is understood 
that friction between the upper eyelid and bulbar conjunctiva interferes with 
conjunctival lymphatic flow resulting in dilation and ultimately folds (Meller and 
Tsang, 1998). They were observed using a 2-3 mm wide vertical slit beam 
located along the temporal, viewed at 25 times magnification. The numbers of 
folds were counted and graded using the approach outlined in table1.2 (Höh et 
al., 1995). LIPCOF graded ≥ grade 2 is likely to be associated with dry eye 
symptoms (Pult et al., 2011). 
 
 Fluorescein Break up Time (NaFL TBUT) - was measured with the slit lamp 
bio-microscope (magnification 10 times) with a diffuse cobalt blue light at 
maximum brightness. A single drop of sterile saline was applied to a fluorescein 
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sodium impregnated paper strip (Fluorets, 1mg fluorescein sodium, Chauvin 
Pharmaceuticals, Essex, UK) and the excess shaken off before applying it to 
the subjects’ eye. The lower lid of the right eye was lowered and the moistened 
strip was swiftly but gently applied to the temporal lower tarsal conjunctiva. The 
subject was then instructed to blink normally after application to circulate the 
fluorescein. Subjects were then asked to look in primary gaze without blinking. 
NaFL TBUT was defined as the interval of time between the last complete blink 
and the first appearance of a dry spot or disruption (black/dark blue area) in the 
tear film (Lemp et al., 1995) measured with a digital stop clock. Three 
measurements were taken and averaged. A yellow filter (Kodak Wratten 12) 
was used to enhance contrast and improve the visibility of breaks in the tear 
film (Bron et al., 2003). 
 
The established NaFL TBUT cut-off for dry eye diagnosis has been <10 
seconds in Caucasian subjects (Lemp et al., 1973). Values between ≤5 and <10 
seconds have been adopted, possibly based upon the report by Abelson et al 
(2002), which suggested that the diagnostic cut-off falls to <5 seconds when 
small volumes of fluorescein are instilled in the conduct of the test (e.g. clinical 
trials pipetting 5µl of 2.0% fluorescein  dye). Selecting a cut off below <10 
seconds will tend to decrease the sensitivity of the test and increase its 
specificity (Lemp et al., 1973). 
 
 Corneal Staining - Corneal staining was assessed using fluorescein sodium 
(Fluorets) impregnated paper strips. A single drop of sterile saline was applied 
to a fluorescein sodium impregnated paper strip (Fluorets, 1mg fluorescein 
sodium, Chauvin Pharmaceuticals, Essex, UK) and the excess shaken off 
before applying it to the subjects’ eye. The lower lid of the right eye was 
lowered and the moistened strip was swiftly but gently applied to the temporal 
lower tarsal conjunctiva. The subject was then instructed to blink normally after 
application to circulate the fluorescein. The cornea of each eye was examined 
use a cobalt blue light source (10 times magnification) with the excited 
fluorescein dye contrast enhanced using a yellow filter. The presence of 
staining on the cornea of both eyes was recorded. 
 
After a 5 minute break the following tests were performed as recommended by 
Bron, (2001). 
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 Phenol Red Thread (PRT) – the use of cotton thread for absorbing the tears 
was originally advocated by Kurihashi (1975). In order to make the wetting 
observation easier, Hamano and colleagues (1982) impregnated the cotton 
thread with phenol red dye that acts as a pH indicator. On contact with the tear 
film, the thread changes colour from yellow to red in response to the pH of the 
tear fluid. The phenol red thread is very fine, and should not stimulate reflex 
tears. In theory the measurement should therefore represent basal tear 
production without interference from reflex tearing. It is an alternative to the well 
validated Schirmer strip, which is more invasive and hence is more likely to 
stimulate tearing. 
 
Even though the thread is in contact with the ocular surface, although for a brief 
period, it may only be assessing the presence of tear volume in the lower 
conjunctival sac rather than overall tear production (Blades et al., 1996, 
Mainstone et al., 1996). In normal eyes, wetting values have been reported to 
be on average 15.4 + 4.9mm while dry eyes average at 6.9 (no standard 
deviation reported; Cho et al., 1996; Mainstone et al., 1996). Whereas Little and 
Bruce (1994a) proposed that a PRT value of less than 11mm be used as the 
diagnostic criterion for low tear secretion and a value of less than 16mm for 
borderline cases. This diagnostic cut-off is affected by patient ethnicity. For 
example, Sakamoto and colleagues (1993) examined the results of the phenol 
red thread tear test in a cross-cultural comparison, and reported the mean wet 
length of the thread for patients in the United States was 23.9 +9.5mm whereas 
the mean for patients from Japan was 18.8+8.6mm. There was a significant 
difference between the two countries (P<0.05). There were no overall 
differences between the right and left eye means for either country (P > 0.05) as 
well as no differences between the eyes for any particular age group. Right and 
left results showed a moderate positive correlation for both countries (United 
States n=500 r=0.74; Japan n=500 r=0.65) and males subjects having a 
significantly longer wet length than females was noted (P<0.05).  
 
The Zone-Quick (Showa Yakuhin Kako Co., Tokyo, Japan) version of the 
Phenol Red test was used which has a length of 70mm. A 3mm end of the 
thread was bent over and placed between the lower eyelid and the ocular 
surface approximately one fifth of the way in from the temporal canthus. The 
thread was left in position for 15 seconds while the patient is instructed to keep 
their eyes open and blink normally. After removal, the length of wetting was 
measured from the end of the thread in millimetres using a ruler. 
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 Conjunctival Staining – Lissamine green is primarily a conjunctival dye which 
does not stain healthy cells, but only dead and degenerate cells (Feenstra et al., 
1992) and areas of the conjunctiva not protected by mucus. Uchiyama and 
colleagues suggested in 2007 that conjunctival staining with Lissamine Green 
could show up prior to corneal staining with fluorescein in patients with early dry 
eye. Lissamine Green (Green Glo, 1.5mg Lissamine Green, HUB 
Pharmaceuticals, USA) strips were used to evaluate the conjunctiva, where a 
single drop of sterile saline was applied to the strip. The wetted strip was quickly 
but gently applied to the lower tarsal conjunctiva after lowering the lower lid. The 
subject was then instructed to blink normally after application to distribute the 
Lissamine Green, before the conjunctiva of each eye was studied using a slit 
lamp bio-microscope (white light, 10 times magnification; Feenstra et al., 1992) 
and the presence of staining on conjunctiva in both eyes was recorded. 
 
Further details on all of the above tests can be found in the section 1.6. Figure 3.2 
represents the order in which the tear film metrics were assessed due to in the invasive 
nature of some tests. 
 
Figure 3.2: Represents the order in which the tear film metrics were assessed due 
to in the invasive nature of some tests. 
•Ocular Surface Disease Index (OSDI)  
•Non Invasive break up time (NIBUT) 
•Tear Meniscus Height (TMH) 
•Lid Parrallel Conjunctival Folds (LIPCOF) 
•Fluorescein break up time (NaFL TBUT) 
•Corneal Staining 
•Five minute break 
•Phenol red thread test (PRT ) 
•Lissamine Green Staining 
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Unfortunately, the tear lipid layer of the participants could not be observed for the 
whole period of the trial, as the tearscope had to be returned to the university clinic. Slit 
lamp observation of the lipid layer utilising the slit lamp via specular reflection would not 
have given satisfying results. The tear osmolarity was also not measured for the length 
of the study as the TearLab was only loaned for collecting the baseline measurements.  
 
Patients were also asked to rate the drops that they had just been trialling out of 10. 
They were also asked more specifically to rate the overall comfort, ease of insertion of 
the eye drops and the clarity of the vision after having instilled the eye drops.  
 
3.1.4 Sample size and statistical analysis 
Sample size estimation was performed in order to obtain ethical clearance and to justify 
the number of subjects recruited. Conducting a sample size calculation is important in 
order to detect a real statistical difference and also having an ethically acceptable 
sample size and saves on resources and time for the practitioner. For repeated 
measures statistical comparisons such as ANOVA it is recommended that there are 15 
or more degrees of freedom (Armstrong et al., 2000; 2010). Hence for this study four 
solutions were compared, so n-1 degrees of freedom are equal to 3. Hence with 5 or 
more subjects this criterion is met. When comparing 2 groups, such as those who 
preferred one solution compared to the rest of the subjects, the typical mean value, the 
size of the difference one wants to detect and the standard deviation of the 
repeatability are required. Therefore, this information was inputted into a sample size 
calculator:  
(https://www.dssresearch.com/knowledgecenter/toolkitcalculators/samplesizecalculator
s.aspx). 
 
Assessment of normal distribution conducted in chapter 2 using one-Sample 
Kolmogorov-Smirnov Tests showed that only NITBUT of the metrics used in this study 
was normally distributed. Where data was normally distributed, the analysis of variance 
between tear metrics was evaluated using parametric analysis, with related-samples 
Friedman’s two-way analysis of variance by ranks. The data were analysed using 
SPSS 20 software (IBM Corporation, New York, USA).  
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3.2 Results  
 
3.2.1 Artificial Tear Comparison 
 
3.2.1.1Ocular Comfort 
OSDI was similar after treatment with each of the four artificial tear supplements 
(Hyabak: 23.6 ± 18.8; Tears Again; 27.7 ± 20.9; TheraTears: 28.9 ± 18.4; Clinitas 
Soothe: 28.8 ± 21.2; p = 0.521), however, all of the treatments showed an 
improvement from baseline comfort (33.9 ± 20.0; p = 0.002). 
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Baseline Hyabak Tears Again Theratears Clinitas Soothe
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Figure 3.3: Ocular comfort as measured by the OSDI questionnaire with the four 
different artificial tears used. N= 50. Error bar = 1 S.D 
 
3.2.1.2 Non-invasive break-up time 
The NIBUT was similar after treatment with each of the four artificial tear supplements 
(Hyabak: 13.6 ± 2.4s; Tears Again; 13.2 ± 2.2s; TheraTears: 13.3 ± 2.4s; Clinitas 
Soothe: 13.3 ± 2.6s; F = 1.315, p = 0.272) and did not improve from baseline (13.2 ± 
1.9s; F = 0.959, p = 0.431). 
 
3.2.1.3 Tear Meniscus Height 
Tear meniscus height was similar after treatment with each of the four artificial tear 
supplements (Hyabak: 0.11 ± 0.02mm; Tears Again; 0.11 ± 0.01mm; TheraTears: 0.11 
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± 0.01mm; Clinitas Soothe: 0.11 ± 0.01mm; p = 0.443) and showed no improvement 
from baseline (0.11 ± 0.02mm; p = 0.184). 
 
3.2.1.4 Phenol Red Thread 
Phenol red test tear volume was similar after treatment with each of the four artificial 
tear supplements (Hyabak: 14.0 ± 4.4mm; Tears Again; 14.0 ± 4.2mm; TheraTears: 
14.0 ± 4.5mm; Clinitas Soothe: 14.1 ± 4.6mm; p = 0.724) and showed no improvement 
from baseline (14.1 ± 5.1mm; p = 0.797). 
 
3.2.1.5 Lid Parallel Conjunctival Folds 
The presence of LIPCOF was similar after treatment with each of the four artificial tear 
supplements (Hyabak: 1.2 ± 0.9; Tears Again; 1.3 ± 0.7; TheraTears: 1.4 ± 0.7; Clinitas 
Soothe: 1.4 ± 0.8; p = 0.688) and while there was no improvement from baseline (1.6 ± 
0.8; p = 0.055), this approached statistical significance.  
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Figure 3.4: LIPCOF with the four different artificial tears used. N= 50. Error bars = 1 
S.D. 
 
3.2.1.6 Invasive Break-up Time 
The NaFL TBUT was similar after treatment with each of the four artificial tear 
supplements (Hyabak: 13.7 ± 2.7s; Tears Again; 13.7 ± 2.4s; TheraTears: 13.8 ± 2.4s; 
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Clinitas Soothe: 13.5 ± 2.7s; p = 0.225) and showed no improvement from baseline 
(13.2 ± 2.4s; p = 0.588).  
 
3.2.1.7 Corneal Staining 
The presence of corneal staining was similar after treatment with each of the four 
artificial tear supplements (Hyabak: 0.08 ± 0.40; Tears Again; 0.00 ± 0.00; TheraTears: 
0.12 ± 0.44; Clinitas Soothe: 0.04 ± 0.30; p = 0.137) and showed no improvement from 
baseline (0.08 ± 0.27; p = 0.218).  
 
3.2.1.8 Conjunctival Staining 
The presence of conjunctival staining was similar after treatment with each of the four 
artificial tear supplements (Hyabak: 0.92 ± 0.99; Tears Again; 0.88 ± 0.98; TheraTears: 
1.02 ± 1.00; Clinitas Soothe: 0.88 ± 1.00; p = 0.752) however, all of the treatments 
showed an improvement from baseline (1.64 ± 0.75; p = 0.000).  
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Figure 3.5: Conjunctival Staining with the four different artificial tears used. N= 50. 
Error bars = 1 S.D. 
 
 
3.2.1.9 Overall Subjective Rating 
 
3.2.1.9.1 Overall Comfort comparing the drops preferred 
Each of the four artificial tear supplement treatments had similar results of overall 
comfort of the drops (Hyabak: 8.6 ± 1.0; Tears Again; 8.3 ± 1.0; TheraTears: 8.2 ± 1.5; 
Clinitas Soothe: 8.3 ± 1.2; p = 0.117).  
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3.2.1.9.2 Overall Ease of Insertion the drops preferred 
In totality the ease of insertion of the drops was comparable after treatment of each of 
the four artificial tear supplements (Hyabak: 9.0 ± 1.3; Tears Again; 8.5 ± 1.1; 
TheraTears: 8.1 ± 1.7; Clinitas Soothe: 8.6 ± 1.1; p = 0.233).  
 
3.2.1.9.3 Clarity of vision after use the drops preferred 
The overall result of clarity of vision after instilling drops was similar upon treatment 
with each of the four artificial tear supplements (Hyabak: 9.2 ± 1.2; Tears Again; 8.4 ± 
1.1; TheraTears: 8.1 ± 1.7; Clinitas Soothe: 8.4 ± 1.5; p = 0.091). 
 
Figure 3.6: Average score out of 10 for the overall comfort, ease of insertion and 
clarity of vision, for the patients who preferred for Clinitas Soothe, 
TheraTears, Tears Again and Hyabak. N=50. 
 
 
3.2.2 Treatment Effect with Time 
3.2.2.1 Ocular Comfort 
OSDI was showed a significant treatment effect with time (p = 0.041) between the first 
2 months (end of month 1: 29.1 ± 20.1; end of month 2; 30.4 ± 19.1) and second 2 
months (end of third month: 24.9 ± 19.4; end of fourth month: 24.8 ± 20.3). 
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Figure 3.7: Ocular comfort as measured by the OSDI questionnaire over treatment 
months. N = 50. Error bars = 1 S.D. 
 
 
3.2.2.2 Non-invasive break-up time 
NIBUT showed no treatment effect with time (end of first month: 13.2 ± 2.4s; end of 
second month; 13.3 ± 2.3s; end of third month: 13.4 ± 2.5s; end of fourth month: 13.6 ± 
2.4s; F = 1.584, p = 0.196). 
 
3.2.2.3 Tear Meniscus Height 
Tear meniscus height showed no treatment effect with time (end of first month: 0.11 ± 
0.01mm; end of second month; 0.11 ± 0.01mm; end of third month: 0.11 ± 0.01mm; 
end of fourth month: 0.11 ± 0.01mm; p = 0.289). 
 
3.2.2.4 Phenol Red Thread 
Phenol red tear volume showed no treatment effect with time (end of first month: 14.3 ± 
4.7mm; end of second month; 14.2 ± 4.2mm; end of third month: 14.2 ± 4.3mm; end of 
fourth month: 13.4 ± 4.2mm; p = 0.221). 
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3.2.2.5 Lid Parallel Conjunctival Folds 
Lid parallel conjunctival folds showed a treatment effect with time (end of first month: 
1.5 ± 0.8; end of second month; 1.3 ± 0.8; end of third month: 1.3 ± 0.7; end of fourth 
month: 1.1 ± 0.8; p =0.038) with the significant different being from the first to the fourth 
month of treatment only (p = 0.014). 
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Figure 3.8: LIPCOF over treatment time. N = 50. Error bars = 1 S.D.  
 
3.2.2.6 Invasive Break-Up Time 
Invasive break-up time showed no treatment effect with time (end of first month: 13.3 ± 
2.7 seconds; end of second month; 13.6 ± 2.4 seconds; end of third month: 13.9 ± 2.5 
seconds; end of fourth month: 13.9 ± 2.5 seconds; p = 0.259). 
 
3.2.2.7 Corneal Staining 
Corneal staining showed no treatment effect with time (end of first month: 0.06 ± 0.24; 
end of second month; 0.02 ± 0.14; end of third month: 0.04 ± 0.20; end of fourth month: 
0.02 ± 0.14mm; p = 0.629). 
 
3.2.2.8 Conjunctival Staining 
Conjunctival staining showed a treatment effect with time (end of first month: 0.98 ± 
0.94; end of second month; 0.80 ± 0.90; end of third month: 0.66 ± 0.80; end of fourth 
month: 0.52 ± 0.76; p = 0.012) with the significant different being from the first to the 
fourth month of treatment only (p = 0.002). 
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Figure 3.9: Conjunctival Staining over treatment time. N = 50. Error bars = 1 S.D. 
 
 
3.2.2.9 Overall subjective Rating 
 
3.2.2.9.1 Overall Comfort 
The overall comfort of the drops significantly improved with time (end of first month: 5.2 
± 2.9; end of second month; 5.5 ± 2.8; end of third month: 6.26 ± 2.6; end of fourth 6.5 
± 2.2; p =0.003; Figure 3.10). 
 
3.2.2.9.2 Overall Ease of Insertion 
The overall ease of insertion of the drops was similar over the 4 month treatment 
period (end of first month: 6.8 ± 2.4; end of second month; 6.4 ± 2.4; end of third 
month: 6.6 ± 2.2; end of fourth 6.8 ± 2.1; p =0.339; Figure 3.10).  
 
3.2.2.9.3 Clarity of vision after use 
The overall clarity of vision after instilling the drops improved with time (end of first 
month: 6.3 ± 2.6; end of second month; 6.5 ± 2.3; end of third month: 6.9 ± 2.2; fourth 
6.9 ± 1.9; p =0.036; Figure 3.10). 
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Figure 3.10: Average score out of 10 for the overall comfort, ease of insertion and 
clarity of vision, when rated at the end of each month, by all patients. 
N=50. 
 
 
3.3 Discussion 
The aim of this chapter was to determine the relative effectiveness of the different 
categories of tear supplements as identified in the introduction (Chapter 1) as none or 
very little work has been done on determining the most effective treatment for an 
individual at diagnosis for dry eye disease. Dry eye disease was previously considered 
candidly as a nuisance to some patients, and was managed with various forms of 
soothing treatments (Volker-Dieben et al., 1987). However, dry eye is presently 
considered a condition worthy of substantial attention with regards to patient well-being 
and a considerable patient benefit can be achieved from active and timely intervention 
(Reddy et al., 2004). 
 
On the whole, dry eye treatments are available as general sales list (GSL) products or 
pharmacy (P) medicines and therefore Optometrists registered in the UK can sell and 
supply these products to their patients (Doughty, 2007). Therefore with such great 
access to various artificial tear supplements and ocular lubricant products, it is 
important to know what the relative effectiveness of different product types as well as 
the evidence demonstrating that the treatment has actually improved the dry eye 
condition for the patient. Previous studies have generally only compared a single tear 
supplement to a placebo i.e. saline (Mengher et al., 1986; Condon et al., 1999; Craig et 
al., 2010). Some studies have only compared more than one artificial tear supplement 
in the same category (in terms of key ingredient), but not cross-category (Aragona et 
al., 2002; Aragona et al., 2002; Dieter et al., 2006; Pult et al., 2012). The number of 
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patients used in the trials have also been varied from as little as 10 patients (Mengher 
et al., 1986) to 80 (Pult et al., 2012). The period of application of these various 
treatments has also ranged widely from as little as 10 minutes (Pult et al., 2012) to 3 
months (Aragona et al., 2002). Table 3.3 represents a comparison of these trials.  
 
The greatest advantage of this study in comparison to the ones that have been 
represented in table 3.3 is that a total of 4 different artificial eye drops were used by the 
patients in a randomised order. A total of 3 different categories of key ingredients were 
examined (Sodium Hyaluronate, Liposomal Spray and Sodium 
Carboxymethylcellulose). The patients were asked to trial these drops for 1 month at a 
time and the total time of the study was 4 months.  The number of tests performed at 
baseline and subsequent visits was greater than previous studies measuring 
symptomology as measured by OSDI, and evaluation of dry eye signs with NIBUT, 
NaFL TBUT, TMH, PRT wetting, LIPCOF, corneal and conjunctival staining. Patients 
were also advised to ‘rate their favourite drops’ in order to ascertain if subjective and 
objective preferences were the same for these subjects. 
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Study Drops Used Tests compared Method Number
& type 
of 
patients 
Period of 
application 
Conclusions 
Mengher et al., 
1986. 
Sodium Hyaluronate 
(0 1%) Vs Sodium 
Chloride (0 .9 %) 
Non Invasive tear film 
stability (NIBUT)& 
symptoms 
A cross over double masked clinical 
trial. 
10 dry 
eyes 
 Tear film stability significantly 
increased and symptoms 
decreased in eyes treated with 
sodium hyaluronate. 
Condon et al., 
1999. 
Sodium Hyaluronate 
0.1%   Vs Saline 
0.9% 
Schirmer, Rose Bengal 
Staining, 
Subjective assessment 
A randomised, double blind, 
crossover clinical trial  
70 dry 
eye 
28 days  Clear benefit of hyaluronan 
over saline, in both subjective 
and objective assessment. 
Hyaluronan well tolerated 
Aragona et al., 
2002. 
Hypotonic 0.4% 
Hyaluronate eye 
drops; & isotonic 
0.4% Hyaluronate  
Subjective symptoms, 
break up time (BUT), 
corneal fluorescein 
staining, conjunctival 
rose bengal staining, 
Schirmer I test, & 
conjunctival impression 
cytology 
Non- crossover but masked 
observer 
40 
Sjögren’
s 
90 days Pronounced hypo tonicity 
formulation showed better 
effects on corneo conjunctival 
epithelium than the isotonic 
solution 
Aragona et al., 
2002. 
Sodium Hyaluronate 
Vs Saline 
Bulbar impression 
cytology, slit lamp 
examinations, and 
subjective symptoms 
Non- crossover randomised double 
blind study  
86 
medium 
to 
severe 
dry eye 
3 months Sodium hyaluronate improved 
ocular surface damage 
associated with dry eye 
syndrome 
Dieter et al., 
2006. 
Liposomal eye 
spray Tears Again®,  
Vs eye gel 
containing 
triglycerides 
Liposic® 
LIPCOF, BUT, 
Schirmer-I Test, tear 
meniscus, eyelid edge 
inspection, visual 
acuity, subjective 
feelings 
The randomised, controlled, multi 
centre cross-over study 
74 dry 
eye 
6 weeks Phospholipid-liposomes out 
performed viscous gels.  
Table 3.3: Representing a comparison of studies trialling different artificial eye drops. The studies trialled different eye drops; comparing various 
dry eye tests utilising different methodology, with varying ages; varied levels of dry eye; with different treatment periods. 
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The DEWS report (2007) has suggested that the ideal artificial lubricant should be 
preservative-free, contain potassium, bicarbonate, and other electrolytes and have a 
polymeric system to increase its retention time (Gilbard et al., 1989; Holly et al., 1971; 
Grene et al., 1992; Ubels et al., 1995). The physical properties should include a neutral 
to slightly alkaline pH. Osmolarities of artificial tears have been measured to range 
from 181 to 354 mOsms/L (Perrigan et al., 2004). It is a requirement of the FDA that 
multi dose artificial tears contain preservatives to prevent microbial growth (Kaufman et 
al., 2003). However, preservatives such as Benzalkonium Chloride (BAK), which is the 
most frequently, used preservative in topical ophthalmic preparations and lubricant has 
epithelial toxic effects (Gasset et al., 1974; Wilson, 1979; Burstein 1980; 1984; 
Brubaker et al., 1985; Smith et al., 1991). BAK can damage the corneal and 
conjunctival epithelium, affecting cell-to-cell junctions and cell shape and microvilli, 
eventually leading to cell necrosis with sloughing of 1-2 layers of epithelial cells (Smith 
et al., 1991). Therefore preservative-free formulations are necessary for patients with 
severe dry eye (DEWS, 2007). Hence this study examined non-preserved drops with 
the key component categories identified in the introduction chapter (See section 1.7). 
 
The literature suggests that each of the types of artificial tears used in this study should 
have a beneficial effect on dry eyes. Viscous agents such as hyaluronic acid contained 
in Clinitas Soothe and Hyabak protect the ocular surface epithelium. Agents such as 
hydroxymethycellulose (HMC), which decrease rose bengal staining in dry eye 
subjects, (Versura et al.,1989) may either “coat and protect” the surface epithelium or 
help restore the protective effect of mucins. Artificial tear solutions containing 
electrolytes and or ions such as TheraTears have been shown to be beneficial in 
treating ocular surface damage due to dry eye (Gilbard et al., 1989; 1992; Bernal et al., 
1993; Nelson et al., 1994; Ubels et al., 1995). Potassium and bicarbonate seem to be 
the most critical (DEWS, 2007). Potassium is important to maintain corneal thickness 
(Grene et al., 1992). In a dry eye rabbit model, a hypotonic tear-matched electrolyte 
solution (TheraTears® [Advanced Vision Research, Woburn, MA]) increased 
conjunctival goblet cell density and corneal glycogen content, and reduced tear 
osmolarity and rose bengal staining after 2 weeks of treatment (Gilbard et al., 1992). 
Bicarbonate containing solutions promote the recovery of epithelial barrier function in 
impaired corneal epithelium and aid in maintaining normal epithelial ultra-structure. 
They may also be important for maintaining the mucin layer of the tear film (Ubels et 
al., 1995).  
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Most clinical trials involving topical lubricant preparations will document some 
improvement (but not resolution) of subjective symptoms and improvement in some 
objective parameters (Nelson et al., 1992) as was found in this study. However, there 
are no studies suggesting whether tear drops which have different key ingredients, are 
similar in performance or not. However, Doughty and Glavin (2009) objectively 
reviewed the outcome of clinical studies where rose bengal (RB) stain was used as an 
outcome measure to assess the efficacy of artificial tears (AT) in patients with dry eye. 
Information was searched for on dry eye status, as reported using a grading scheme, 
after use of RB as a diagnostic test, before and after use of a specific regimen of 
artificial tears or ocular lubricants for approximately 30 days. The mean baseline scores 
and post-treatment scores were calculated, along with the net change and the 
percentage change in the RB scores (Doughty and Glavin, 2009). There is far less 
published information on how treatment with artificial tears or ocular lubricants might 
alter or improve any other staining of the conjunctiva or cornea with an alternative to 
RB stain (e.g. lissamine green) (Doughty and Glavin, 2009). While lissamine green 
might be being considered for routine use (Versura et al., 2006), there is a lack of 
similar analyses and work still to be done to establish normal values for lissamine 
green staining and its use as a measure for treatment outcomes (Doughty and Glavin, 
2009). Rose Bengal is no longer widely available and was toxic to the eye, so previous 
studies of effectiveness will prove difficult to compare with future research. Doughty 
and Glavin, (2009) also reported that with RB grading schemes used by numerous 
different clinicians over the years, the treatment of dry eye with artificial tears or ocular 
lubricants can be expected to improve the condition of the exposed ocular surface. 
Assuming no improvement without treatment, the evidence from their review of the 
literature suggests 30 days treatment period can be projected to produce an overall 
improvement of around 25%, but with no unambiguous statistical differences between 
product types. 
 
In Chapter 2, it has been shown that Lid Parallel Conjunctival Folds (LIPCOF) and 
conjunctival staining as measured by lissamine green are significantly correlated to one 
another, corneal staining, tear osmolarity and is significantly correlated to tear stability 
as measured by NIBUT, NaFL TBUT and tear volume measured by TMH and PRT test. 
 
In this study, the patients were asked to continue using their artificial tears 
continuously, without a ‘wash out’ phase; in order to prevent the patients from 
discomfort without the use of artificial eye drops. The results identified that the LIPCOF 
showed a treatment effect with time, with a significant difference being from the first 
month to the fourth month of treatment, suggesting an improvement over time of the 
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conjunctival surface. The presence of conjunctival staining as measured by Lissamine 
green was found to be similar with each of the different artificial eye drops, however 
this dry eye metric showed a statistical improvement from baseline measurements, 
suggesting that the conjuctival ocular surface improves significantly with time with the 
use of artificial eye drops. These two measures (LIPCOF and conjunctival staining) 
appear to be the most sensitive measures of ocular surface dry eye related damage 
may be this remarkable as patients with low grades of conjunctival staining and 
LIPCOF were excluded. Certain percentage of patients with low degrees of LIPCOF 
and conjunctival staining who mentioned the improvement was much lower than of 
those with higher degrees of LIPCOF and conjunctival staining. Furthermore, not 
having observed the lipid layer with the tearscope, or the lids and meibomian glands 
with slit lamp, may be some weakness of this study, especially in terms of the use of 
Tears Again liposomal spray. The stability of the tear film may improve with better 
conjunctival tissue in terms of mucins as well as the tear lipid layer. The tear lipid layer 
can improve when meibomian gland secretion is treated, but not using a liposomal 
spray solely. The stability of the tears did not appear to show much improvement 
possibly due to the fact that the tear lipid layer contributes to the stability of the tear 
film.  The tear film volume did not improve with time; the tear volume normally does not 
increase due to drops when observing the tear film the day after instillation. 
 
It does not seem to matter much which drops are being used by the patients, as there 
appeared to be a significant difference (improvement) in appearance of the conjunctival 
tissue from the first month to the fourth and final month and an improvement from 
baseline measurements regardless of which drops were being used. These results 
show that long term use of artificial eye drops have an improvement on the ocular 
surface.  
 
 
3.4 Conclusion  
Therefore from the results it can be deduced that artificial tear supplements do work for 
ocular comfort, and by observing the ocular surface an improvement in the conjunctival 
tissue as observed by the presence of LIPCOF and conjunctival folds. However, there 
does not seem to be an improvement in the tear film quality or volume despite the fact 
that the conjunctival tissue appears to show an improvement, which one would expect 
would provide better mucus layer which should in turn support the tear film. The 
stability of the tears also relies on a healthy tear lipid layer, which can improve with 
meibomian gland treatment and not just the Liposomal spray. The tear volume does 
not normally increase due to the use of artificial eye drops when observing the tears 
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the day after instillation. However, this study was only conducted over a four month 
period and if it was continued for a longer period the tear stability and volume would be 
expected to improve. It would also be beneficial to have a four day ‘wash out’ period 
before patients starting treatment of the next set of artificial tear supplements. 
Observation of the lids and meibomian gland dysfunction would also be greatly 
beneficial. 
 
There does not seem to be any strong evidence of one class of artificial tear 
supplement treatment, being more effective than the others. The ocular comfort 
appeared to improve and so did the presence of conjunctival folds; however this was 
between all four treatments not between any specific treatments. The patients used 
these drops for one month and then carried on to use another tear supplement for the 
next month, with no wash-out period as it is difficult ethically to leave dry eye patients 
with no treatment. The data suggests that these improvements can be more due to the 
time rather than the specific drops. 
 
The positive effect of the treatment appears to be significant within the first month, and 
the ocular signs of the conjunctival tissue, is significant over the four month trial period.  
This chapter looks at overall effect for a subject group, though the most important 
factor is that the practitioner can identify whether the patient that he / she is treating 
might benefit more from one treatment than another which will be investigated in 
chapter 4. 
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CHAPTER 4 
 
Ability to Predict Patient Preference for Artificial Tears 
 
4.0 Introduction 
Dry eye disease is a common ocular disease resulting in visual disturbances, ocular 
discomfort and that result in affecting the quality of life of patients (Lin et al., 2014). Dry 
eye disease has several different factors involving tear film instability, increased tear 
film osmolarity and inflammation of the ocular surface causing potential damage to the 
ocular surface (DEWS, 2007). There are different classifications and diagnostic 
approaches for dry eye as discussed in detail in chapter 1.   
 
There are currently a few therapies available for dry eye patients (DEWS, 2007). As the 
aims of dry eye treatment is to improve patient symptoms and signs there are a few 
treatment options available in order to achieve this. They are listed below: 
 
 To improve tear volume by use of aqueous supplements (DEWS, 2007; 
Matheson, 2007; Farrell, 2010) 
 To improve the quality of the tear mucous layer by TheraTears (Matheson, 
2007) 
 Improve the tear film lipid layer by diet, lid hygiene, hot compresses, 
tetracyclines, liposomal sprays (Dieter et al., 2006; DEWS, 2007; Matheson, 
2007; DEWS, 2007; Geerling et al., 2011) 
 Reduce tear drainage by punctal plugs (Dieter et al., 2006; DEWS, 2007; 
Matheson, 2007; Lin et al., 2014) 
 Reduce tear evaporation by improvements to the tear lipid layer and paraffin 
ointment (DEWS, 2007, Matheson, 2007; Farrell, 2010) 
 Reduce inflammation by the use of Omega 3, steroids, NSAIDs, anti-allergy 
products (DEWS, 2007; Matheson, 2007; Lin et al., 2014) 
 
Other dry eye therapies include hormonal therapy which has reported an increase in 
tear production and tear lipid layer thickness and reduced symptoms by patients (Sator 
et al., 1998; Worda et al., 2001). Autologous serum has been indicated in the 
application of severe dry eye disease (Yoon et al., 2007) as it contains substances 
which support the proliferation and maturation of the normal ocular surface (Celebi et 
al., 2014). Acupuncture as a treatment for dry eye disease, has been based on reports 
which claim that acupuncture modulates both the autonomic nervous and immune 
systems (Kavoussi et al., 2007; Bäcker et al., 2008) which result in regulating the 
141 
 
function of the lacrimal gland. It is possible that salivary submandibular gland 
transplantation can replace deficient mucin and the aqueous tear film (DEWS, 2007). 
Patients have reported a subjective relief in their dry eye symptoms immediately after 
surgery (Soares et al., 2005). 
 
It has been recommended that the primary factor for the therapeutic management of 
dry eye patients should be considered according to patients’ symptoms and signs, not 
clinical tests and the best combination of medications to avoid symptoms (Behrens et 
al., 2006).  
 
A cure for dry eye disease has still to be found (Farrell, 2010). Currently treatment 
objectives are directed towards either ‘tear replacement’ or ‘tear retention’, and are 
aimed principally at relieving the subjective symptoms associated with this condition 
(Farrell, 2010). Nevertheless, the underlying treatment goals will always be aimed at 
appropriate healing, epithelialisation, and the reestablishment of a normal ocular 
surface (Göbbels et al., 1992). In order to select the most appropriate treatment option 
the cause and severity of the dry eye should be established, and the management plan 
chosen to effectively target the nature of the condition.  
 
An assessment  of  dry  eye  in  patients  wanting  to  wear contact lenses  should  be  
used  as  an  indicator  of  when  to  strongly  promote enhanced  wetting  lenses  and  
to  warn  patients  of  potential  issues, prompting  a  more  frequent  review  schedule 
(Wolffsohn, 2014). Individual  clinical  dry  eye  tests  such  as  non-invasive  tear 
break-up  time (NIBUT),  tear  meniscus  height (TMH),  phenol  red  test (PRT) and lid-
parallel conjunctival  folds  (LIPCOF) are  moderately  related  to  self-rated  ocular  
surface  symptoms  (as evaluated by  the  ocular  surface  disease  index),  but  the  
strongest  predictor  of contact  lens  induced  dry  eye  was  a  combination  of  NIBUT  
and  nasal  LIPCOF (Pult et al., 2011). 
 
There are few peer review journal articles investigating the efficacy of numerous dry 
eye treatments with artificial tears or ocular lubricants (see table 3.3 in the previous 
chapter which reviews the pertinent studies). However, Doughty and Galvin (2009) 
objectively reviewed the outcome of clinical studies where rose bengal stain has been 
used as an outcome measure to assess the efficacy of artificial tears in patients with 
dry eye. They identified 33 suitable data sets when searching for journals from 1947 to 
2008, and chose to use the rose bengal test for these analyses because of the long 
history of its use, hence providing the maximum chance of obtaining enough published 
data to see if any consistent differences could be seen between products. They 
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concluded that based on rose bengal grading schemes used by numerous different 
clinicians over the years, treatment of dry eye with artificial tears or ocular lubricants 
can be expected to improve the condition of the exposed ocular surface. Assuming no 
improvement without treatment, a 30 days treatment period can be projected to 
produce an overall improvement of around 25%, but with no un-ambiguous statistical 
differences between product types. 
 
The U.S. Food and Drug Administration (FDA) have been interested in understanding 
the full extent of a patient’s treatment experience as it applies to their day-to-day life 
and assessing their quality of life (Marquis et al., 2003). Clinicians, pharmaceutical 
companies and the scientific community are involving their patients when they evaluate 
their treatment and the value of the treatment that they are receiving (Mertzanis et al., 
2005). It has been reported that dry eye patients can become frustrated with the 
development of their treatment with regular specialist visits and seeking treatment 
changes, and may well persue alternative treatments (Thomas et al., 1998; Schiffman 
et al., 2000). Additionally, these dry eye patients have reported not attending for work, 
often losing approximately 5 working days per year with their dry eye symptoms 
(Schiffman 2000). 
 
Optometrists in the UK have various prospects to develop their own interests and skills 
in the diagnosis and management of dry eye. The Clinical Management Guidelines 
(CMGs) of the College of Optometrists lists this condition as Tear Deficiency 
(Keratoconjunctivitis sicca) (accessed at www.college-optometrists.org). Therefore, this 
management will allow for optometrists with suitable re-imbursement, to undertake 
detailed assessments of dry eye and to be in an excellent position care for these 
patients (Doughty, 2010). 
 
Currently there are three diplomas offered by the College of Optometrists which allow 
optometrists to prescribe additional medications (Needle et al., 2008). They are:  
 
 Independent prescribing 
 Supplementary prescribing  
 Additional supply 
 
Optometrists who have qualified to be an independent or supplementary prescriber can 
now have formalised prescribing rights (i.e. having a medicines prescription pad). 
Optometrists can, therefore encourage patient acceptance that their optometrists can 
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be their regular source of dry eye products. Optometrists can sell these dry eye 
products to their patients along with instructions on use of these products. 
 
There are currently various co-management schemes in the community of patients with 
glaucoma, diabetes and cataracts by optometrists as well as the management of low 
vision (Margrain et al., 2005) and paediatric optometry (Karas et al, 1999).  A survey 
conducted by Mason et al., (2002), reported that 26% of referrals by optometrist to the 
hospital eye service was due to anterior eye conditions (conjunctivitis, blepharitis and 
dry eyes), indicating a strong case to develop a co-management community dry eye 
scheme. Other reasons for referral in to the hospital eye service were suspected 
cataract (33%), glaucoma (13%) and retinopathy (10%) (Mason et al., 2002). 
 
There is no evidence currently indicating whether patients would be willing to pay for a 
community based dry eye service. However, funding from the local clinical 
commissioning groups (CCG) could be sought in order to provide a better service for 
patients in the community. Evidence also suggests having once received care from 
optometrists, 55% of patients favoured to consult with their optometrist in future 
compared with 15% of patients who preferred to consult a GP (Chambers and Fisher, 
1998). On the other hand, research conducted in the older population recognised that a 
worry about the costs would prevent them from attending for regular sight tests, 
although they are entitled to a free eye examination under the NHS (Smeeth, 1998). 
The lack of patient knowledge with regards to eye health, not understanding an 
optometrists’ role as well as affordability of spectacles (Jessa  et al, 2007), these could 
stop patients from seeking the care they require for their dry eye condition in a 
community based optometric practice. As a community based practice, it is always the 
aim to provide a great customer journey and experience. Boulding et al., (1993) 
reported that if customers are happy with their overall experience in the practice they 
would remain loyal customers.  
 
There are foreseen complications in trying to investigate the cost of a consultation for a 
dry eye assessment, as the demographics age of the area in which the study was 
conducted was mainly over 60 years old. Patients entitled to free NHS sight tests 
include, over 60 years old, diabetics, glaucoma patients, low income patients, those 
with family history of glaucoma and complex prescriptions (College of Optometrists, 
2010). 
 
This chapter will investigate the preferred artificial tear drop chosen by the fifty subjects 
from the drops used in the study, namely; Clinitas Soothe, TheraTears, Tears Again 
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and Hyabak, and to see whether this could have been predicted from their presenting 
signs and symptoms or whether their choice is based on their signs and/or symptoms 
standing better with their preferred artificial eye drops compared to the three other 
artificial drops trialled. It will also investigate whether patients would be willing to pay 
for a dry eye community based service if it were available, and if so how much would 
they pay for their consultation.  
 
 
4.1 Methods 
As advocated by DEWS (2007), that when a battery of tests is performed, they should 
be performed in an arrangement that best preserves their reliability, and intervals 
should be left between the tests (Bron, 2001; Foulks and Bron, 2003). The tear film 
metrics were assessed in the following order due to the invasive nature of some tests. 
At baseline measurements were observed for the right eye followed by the left eye for 
every patient, after which on subsequent visits, only the right eye measurements were 
taken.  
 
Prior to the 1 month usage of each of the artificial tears as described in chapter 3 
(section 3.1.1); patients attended a baseline visit at which the same tests that were 
performed at the end of each month were conducted:  
 
 Symptoms (OSDI) 
 Non-invasive break-up time (NIBUT) 
 Tear meniscus height (TMH) 
 Lid Parallel Conjunctival Folds (LIPCOF) 
 Fluorescein break up time (NaFL TBUT) 
 Corneal staining 
 Phenol red thread (PRT) 
 Conjunctival staining 
 
In addition, some more specialist tests of tear film composition and stability were 
performed at baseline: 
 
 Non-invasive Tearscope break up time (NITBUT) - was measured using the 
Tearscope Plus (Keeler Ltd, Windsor, UK) in conjunction with a fine grid pattern 
insert mounted on a slit lamp bio-microscope (magnification 25 times) to 
produce an image of the fine grid pattern over the entire cornea via specular 
reflection. Subjects were instructed to blink normally and then keep their eyes 
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open for as long as possible. The NIBUT was defined as the time period 
between the last complete blink and the appearance of a break or distortion in 
the fine grid pattern (Guillon, 1998), measured using a digital stop-clock. This 
was repeated 3 times and the results were averaged to give a mean NITBUT 
value.  
 
 Lipid Layer Thickness - was measured using the Tearscope Plus (Keeler Ltd, 
Windsor, UK) on a slit lamp bio-microscope. After blinking, the tear lipid layer is 
observed via specular reflection. Subjects were instructed to blink normally and 
then keep their eyes open for as long as possible. The observation patterns 
formed after a blink were compared with the pictures as provided by Keeler, as 
shown in figure 1.20. 
 
 Osmolarity – osmolarity was measured by The TearLab (TearLab Ltd, San 
Diego, CA, USA). It requires only a very small volume of tears, therefore can be 
used in subjects with relatively dry ocular surfaces. Osmolarity is determined by 
measuring the impedance of an electric current passed through a very small 
sample of tears (< 50 nanolitres) (Sullivan, 2005). The TearLab Osmolarity 
System Pen was placed lightly onto the subjects lower tear meniscus from 
where it draws tears into the test card. An audible sound allows the practitioner 
to identify sufficient tears have been gathered. The "pen" was then transferred 
to the "TearLab Osmolarity System Reader" which analyses the collected tear 
sample, determining its osmolarity which it displays on its liquid crystal display 
(LCD; Tomlinson et al., 2006). The single use test card contains a microfluidic 
channel that is gently placed on the tear meniscus in the corner of the eye on 
the inner lower lid margin, and via passive capillary action, less than 50 
nanoliters of tear sample is instantly and automatically collected when it comes 
in contact with tear fluid. The TearLab osmolarity test utilizes a temperature 
collected impedance measurement to provide an indirect assessment of 
osmolarity. After applying a lot specific calibration curve, osmolarity is 
calculated and displayed and a quantitative numerical value. 
 
146 
 
 
Fig 4.1: Summary of the tear film metrics, in the order represented due to the 
invasive nature of certain tests. 
 
At the end of the study, participants were asked to state which drop of the four trialled 
was preferred. In addition patients were asked whether they would be willing to pay for 
an exclusive dry dye consultation, in their community practice, involving all the tests 
that were carried out in the study and then be advised appropriately on the most 
relevant eye drop that would grant them relief and successful treatment. 
 
4.1.2 Statistical Analysis 
The baseline characteristics of those patients that preferred each eye drops were 
compared with the values of those patients who preferred the other eye drops in order 
to determine whether their preference could have been predicted on presentation to the 
practice. Assessment of normal distribution conducted in chapter 2 using one-Sample 
Kolmogorov-Smirnov Tests showed that only NITBUT of the metrics used in that 
chapter was normally distributed. Of the additional measures used at baseline, 
osmolarity (Z=0.723, p=0.672) was normally distributed whereas lipid grade (Z=1.634, 
p=0.010) and Tearscope derived NITBUT (Z =3.134, p < 0.001) was not.  
 
For those patients that preferred each treatment type, their signs and symptoms with 
that treatment was compared with the treatments they did not prefer. Where data was 
•Ocular Surface Disease Index (OSDI)  
•Non Invasive break up time (NIBUT) 
•Tear Meniscus Height (TMH) 
•Lid Parrallel Conjunctival Folds (LIPCOF) 
•Non Invasive Teascope break up time (NITBUT) 
•Lipid Pattern as observed by Tearscope 
•Fluorescein break up time (NaFL TBUT) 
•Corneal Staining 
•Five minute break 
•Phenol red thread test (PRT)  
•Lissamine Green Staining  
•Tear Osmolarity 
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normally distributed, the analysis of variance between tear metrics was evaluated using 
parametric analysis, with related-samples Friedman’s two-way analysis of variance by 
ranks where it was not. The data were analysed using SPSS 20 software (IBM 
Corporation, New York, USA). 
 
4.2 Results 
 
4.2.1 Drops preferred 
The table below shows the total number of patients who preferred each artificial tear 
drops.  
 
Drop Preferred by Patient Number of Patients Number of patients in 
% 
Clinitas Soothe 17 33 
TheraTears 15 31 
Tears Again 11 22 
Hyaback 7 14 
Table 4.1: The table shows the number of patients who preferred each artificial eye 
drop.  
 
4.2.2 Can the drop Preferred be predicted from Baseline Measures? 
Table 4.2, compares the baseline characteristics of patients who preferred each drop 
compared to the patients who preferred other treatment. Clinitas Soothe (p = 0.03) and 
Hyabak (p = 0.05) were preferred by those with a higher Tearscope NITBUT. 
TheraTears (p = 0.01) was preferred by those with a lower tear volume. Tears Again 
was preferred by those with a keratometer derived (p = 0.03) or fluorescein higher 
TBUT (p = 0.01), or a thinner (lower grade) lipid film layer (p = 0.04).   
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Clinitas Soothe 
 
Preferred 
Drop  
(n =17) 
58.
4 + 
17.
1 
31.2 
+ 
19.8 
13.5 + 
2.0 
0.11 + 
0.02 
16.4 + 
5.1 
1.8 + 
0.6 
13.3 + 
2.7 
304.7 
+ 11.2 
8.0 + 
2.5 
2.7 + 
0.8 
Remaining 
Subjects  
(n = 33) 
62.
0 + 
12.
5 
35.3 
+ 
20.3 
13.1 + 
1.9 
0.11 + 
0.02 
13.0 + 
4.7 
1.5 + 
0.8 
13.1 + 
2.3 
308.0 
+ 
14.30 
7.1 + 
2.2 
2.5 + 
1.2 
TTest 0.2
8 
0.12 0.54 0.95 0.09 0.06 0.55 0.49 0.03 0.86 
TheraTears 
 
Preferred 
Drop 
(n=15) 
64.
1 + 
9.5 
35.2 
+ 
16.7 
12.3 + 
2.0 
0.11 + 
0.03 
11.3 + 
4.8 
1.7 + 
0.7 
12.8 + 
2.5 
305.6 
+ 12.5 
6.3 + 
2.2 
2.7 + 
1.2 
Remaining 
Subjects 
(n=35) 
59.
4 + 
15.
7 
33.3 
+ 
21.5 
13.6 + 
1.8 
0.11 + 
0.02 
15.3 + 
4.8 
1.5 + 
0.8 
13.3 + 
2.4 
307.4 
+ 13.8 
7.9 + 
2.2 
2.5 + 
0.9 
TTest 0.6
2 
0.85 0.31 0.39 0.01 0.27 0.85 0.95 0.44 1.00 
Tears Again 
 
Preferred 
Drop 
(n=11) 
60.
6 + 
14.
0 
33.6 
+ 
24.5 
13.4 + 
1.5 
0.11 + 
0.02 
14.1 + 
3.6 
1.0 + 
0.9 
13.0 + 
2.0 
305.8 
+ 10.6 
7.9 + 
2.4 
2.4 + 
1.2 
Remaining 
Subjects 
(n=39) 
60.
8 + 
14.
4 
33.9 
+ 
18.8 
13.1 + 
2.1 
0.11 + 
0.02 
14.2 + 
5.5 
1.8 + 
0.7 
13.3 + 
2.5 
307.2 
+ 14.2 
7.3 + 
2.3 
2.7 + 
1.0 
TTest 0.9
4 
0.46 0.01 0.57 0.77 0.05 0.03 0.51 0.08 0.04 
Hyabak 
 
Preferred 
Drop (n=7) 
64.
8 + 
11.
0 
40.5 
+ 
24.2 
14.0 + 
2.0 
0.12 + 
0.02 
16.8 + 
6.2 
1.8 + 
0.8 
13.7+ 
2.7 
311.3 
+ 23.1 
8.12 + 
1.87 
2.2 + 
0.8 
Remaining 
Subjects 
(n=43) 
60.
2 + 
14.
6 
32.9+ 
19.6 
13.1 + 
1.9 
0.11 + 
0.02 
13.8+ 
4.9 
1.6 + 
0.8 
13.1 + 
2.4 
306.2 
+  11.7 
7.3 + 
2.4 
2.7 + 
1.1 
TTest 0.1
8 
0.31 0.12 0.14 0.34 0.47 0.08 0.90 0.05 0.53 
Table 4.2: Table showing the Age, Ocular Surface Disease Index (OSDI), Non-Invasive 
break up time (NIBUT sec), Tear Meniscus Height (TMH mm), Phenol Red 
Thread (PRT mm), Lid Parallel Conjunctival Folds (LIPCOF),  Invasive break up 
time (NaFL TBUT sec), Tear Lab (mOsms/L), Tear scope break up time (sec) 
and lipid pattern for the 50 baseline subjects and then for the respective drops 
preferred by the subjects; Clinitas Soothe, TheraTears, Tears Again, Hyabak. 
(Average ± S.D.). 
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4.2.3 Does the preferred drop fit with the dry eye cluster subgroup? 
Looking at the results from the cluster analysis performed for 5 clusters as described in 
chapter 2, it was found that the distribution of preference for each particular drop taken 
did not appear differ between the individual clusters (Table 4.3). 
 
 
 
 
Preferred 
Drops 
  
Cluster 
Total 1 2 3 4 5 
  
Amounts of subjects in each cluster 
Clinitas 
Soothe 
17 0 3 3 5 6 
Tears Again 11 0 2 1 6 2 
TheraTears 15 0 3 0 6 6 
Hyabak 7 1 1 1 1 3 
TOTAL 50 1 9 5 18 17 
Table 4.3: The total number of patients for each preferred treatment in their 
relevant cluster. 
 
 
Thirty five percent (6) of subjects who preferred Clinitas Soothe were grouped in cluster 
5 followed by 29 % (5) in cluster 4. There were no subjects in who fell in cluster 1 and 
an equal percent of subjects in clusters 2 and 3 of 17.65% (3). 
 
From the 11 subjects who preferred Tears Again 35% of these (6) were grouped in 
cluster 4. There were no subjects who fell in cluster 1 and only 18% (2) subjects who 
fell in clusters 2 and 5, and only 1 patient in cluster 3. 
 
For the 15 subjects who preferred TheraTears there were an equal number of subjects 
falling in cluster 4 and 5 of 40% (6). However, there were no subjects who preferred 
this drop falling in clusters 4 and 3. There was 20% (3) of these subjects who fell in 
cluster 2.  
 
For the 7 subjects who preferred Hyabak 43% (3) fell into cluster 5 and 14 (1) fell into 
clusters 1, 2, 3 and 4.  
 
It should be noted that the majority of subjects enrolled in the randomised controlled 
trial of dry eye treatments were categorised from the larger group of 150 subjects 
studied in chapter 2, as falling in clusters 4 or 5, which were the patients with more 
symptoms. 
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 Cluster 
 1 2 3 4 5 6 7 
 Number of patients in each cluster 
 3 4 6 12 9 4 12 
 Symptomology as measured by OSDI (%) 
 (Ave + SD)    24.97 + 
4.96 
22.12 + 
11.51 
22.36 + 
16.87 
16.83 + 
16.42 
30.47 + 
18.46 
49.67 + 
3.96 
31.91 
+ 
26.62 
Table 4.4:  The total number of patients who participated in the study for each 
cluster group and their symptomology as measured by the OSDI. (N = 
50). 
 
It can be seen from table 4.4, that from the fifty subjects who participated in the study, 
12 patients were grouped in cluster 4 with an average OSDI score of 16.83 + 16.87.  
There were 9 patients who were grouped together in cluster 5 with an average OSDI 
score of 30.47 + 18.46. 
 
From the 25 patients who recorded their symptoms, 4 patients were grouped in cluster 
4 and 8 patients were grouped in cluster 5.  The average OSDI of the patients who fell 
in cluster 4 was 34.86 + 17.06 and those who fell in cluster 5 was 33.03 + 17.95.  
 
It can be noted from this that the majority of these subjects who preferred the relevant 
drops fell in either clusters 4 and 5. 
 
4.2.4 Did the preferred artificial drop give patients better signs or symptoms 
compared to the other drops trialled? 
 
Table 4.5 compares the characteristics of patients who preferred each drop to those 
not preferred by the same patients.  
 
There were 17 patients who preferred Clinitas soothe over the other drops trialled and 
for these patients there were no significant changes in the OSDI, NIBUT, TMH, 
LIPCOF and NaFL TBUT. However there was a significant difference in the patients 
overall comfort (p = 0.048), ease of insertion (p = 0.014) and clarity of vision (p = 
0.041). 
 
There were 15 patients who preferred TheraTears over the other drops trialled and for 
these patients there were no significant changes in the OSDI, NIBUT, TMH, LIPCOF 
and NaFL TBUT. However there was a significant difference in the patients overall 
comfort (p = 0.002), ease of insertion (p = 0.022) and clarity of vision (p = 0.013). 
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There were 12 patients who preferred Tears Again over the other drops trialled and for 
these patients there were no significant changes in the OSDI, NIBUT, TMH, LIPCOF 
and NaFL TBUT. However there was a significant difference in the ease of insertion (p 
= 0.036) and clarity of vision (p = 0.036). There did not appear to be any significant 
difference in patients overall comfort (p = 0.081). 
 
There were 6 patients who preferred Hyabak over the other drops trialled and for these 
patients there were no significant changes in the OSDI, NIBUT, TMH, LIPCOF and 
NaFL TBUT. There was a significant difference in the patients overall comfort (p = 
0.042) and no significance in clarity of vision (p = 0.068), ease of insertion (p = 0.066). 
 
 
A
g
e
 
(y
rs
) 
O
S
D
I 
 
N
IB
U
T
 
(s
e
c
) 
 
T
M
H
 (
m
m
) 
P
R
T
 (
m
m
) 
L
IP
C
O
F
 
(g
ra
d
e
) 
N
a
F
L
 T
B
U
T
 
(s
e
c
) 
O
v
e
ra
ll
 
C
o
m
fo
rt
 
E
a
s
e
 o
f 
In
s
e
rt
io
n
 
C
la
ri
ty
 o
f 
V
is
io
n
 
Clinitas Soothe 
(N=17) 
Preferred 
Drop 
 
58.4 
+17.
1 
25.1 + 
18.4 
13.7 
+2.1 
0.11+0.
01 
15.5 
+4.6 
1.4 +0.9 13.8 
+2.4 
8.3 +1.2 8.6 +1.0 8.4 +1.5 
Average 
with Non-
Preferred 
drops 
58.4 
+17.
1 
25.2 
+18.5 
14.1 
+2.1 
0.11 
+0.01 
15.6 
+4.4 
1.2 +0.8 14.2 
+2.3 
6.1 +2.8 7.1 +2.4 7.2 +2.0 
ANOVA  0.756 0.408 0.053 0.924 0.689 0.932 0.048 0.014 0.041 
TheraTears 
(N=15) 
Preferred 
Drop 
 
64.1 
+9.5 
35.6 
+19.1 
12.4+2.
5 
0.11 
+0.02 
12.8 
+4.5 
1.7 +0.7 12.7 
+2.6 
8.2 +1.5 8.1 +1.7 8.1 +1.7 
Average 
with Non-
Preferred 
drops 
64.1 
+9.5 
28.1 
+19.2 
12.5 
+2.7 
0.11 
+0.02 
12.4 
+3.8 
1.5 +0.8 12.8 
+2.9 
5.5 +2.5 6.4 +2.1 6.4 +2.0 
ANOVA  0.256 0.703 0.749 0.932 0.887 0.589 0.002 0.022 0.013 
Tears Again 
(N= 11) 
Preferred 
Drop  
 
60.6 
+  
14.0  
22.3 + 
18.2 
13.3 
+2.3 
0.11 
+0.01 
13.6 
+4.1 
1.3 +0.6 13.7 
+2.3 
8.3 +1.0 8.5 +1.1 8.4 +1.1 
Average 
with Non-
Preferred 
drops 
60.6 
+  
14.0 
27.7 
+21.0 
13.3 
+2.4 
0.11 
+0.01 
13.3 
+4.3 
1.1 +0.7 13.8 
+2.8 
5.8 +2.7 6.2 +2.2 5.9 +2.6 
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ANOVA  0.937 0.788 0.516 0.637 0.271 0.969 0.081 0.036 0.036 
Hyabak 
(N=7) 
Preferred 
Drop  
 
59.8 
+17.
1 
24.8 
+26.8 
15.1 
+2.0 
0.11 
+0.01 
14.8 
+3.5 
1.0 +0.9 14.9 
+1.5 
8.6 +1.0 9.0 +1.3 9.2 +1.2 
Average 
with Non-
Preferred 
drops 
59.8 
+17.
1 
30.7 
+24.2 
13.9 
+1.7 
0.11 
+0.01 
14.7 
+4.2 
1.3 +0.6 14.5 
+1.6 
6.2 +3.0 7.5 +2.1 7.6 +2.1 
ANOVA  0.042 0.278 0.102 0.785 0.234 0.674 0.042 0.066 0.068 
Table 4.5: Table showing the Age, Ocular Surface Disease Index (OSDI), Non-Invasive 
break up time (NIBUT sec), Tear Meniscus Height (TMH mm), Phenol Red 
Thread (PRT mm), Lid Parallel Conjunctival Folds (LIPCOF),  Invasive break up 
time (NaFL TBUT sec), Tear Lab (mOsms/L), Tear scope break up time (sec) 
and lipid pattern for the subjects who preferred their specific drops and then for 
the remaining drops not preferred by the same subjects; the respective drops 
preferred by the subjects; Clinitas Soothe, TheraTears, Tears Again, 
Hyabak.(Average ± S.D.). 
 
4.2.5 Did the preferred drop relate to the greatest improvement in clinical signs? 
The percentage of cases where the preferred drop of a patient was also the one that 
gave patients the largest improvement in subjective ocular surface symptoms, tear film 
stability / volume and clinical signs can be seen in figure 4.2. 
 
 
Figure 4.2: Patients whose artificial tear preference matched the drop that gave the 
largest improvement in subjective ocular surface symptoms, tear 
stability / volume and clinical signs.  
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The most improvement in OSDI score matched patient’s preferred artificial tear for 
around one quarter of patients across all the drops trialled for OSDI, NIBUT, LIPCOF 
and NaFL TBUT. The greatest improvement is TMH and PRT matched patient’s 
preference for Clinitas Soothe (48% and 38% respectively) whereas this was less likely 
to be the case for the other artificial tears trialled. Table 4.6 shows the average 
improvement in each of the metrics compared to baseline levels showing 
improvements, on average, of 45% for OSDI, 108% for NIBUT, 112% for PRT, 197.5% 
for LIPCOF and 111% for NaFL TBUT, but no improvement in TMH. 
 
  OSDI 
 
NIBUT 
(sec) 
TMH 
(mm) 
PRT 
(mm) 
LIPCOF NaFL TBUT 
(sec) 
Ave 
Baseline 
33.86 13.20 0.11 14.02 1.58 13.17 
SD 
Baseline 
20.04 1.92 0.02 5.14 0.51 2.41 
Ave 
Improved  
15.36 14.27 0.11 15.71 0.80 14.64 
SD 
Improved 
14.70 2.31 0.01 4.69 0.81 2.30 
Table 4.6: Showing the average and standard deviation of the various tear metrics 
for baseline measurements for 50 patients and the average and 
standard deviation of the improved results. 
 
4.2.6 Would they pay? 
On completion of the study, the subjects were asked if they would be willing to pay for 
a dry eye service if it were available. Interestingly, only 2 subjects (4%) were not willing 
to pay for the service if available. 
 
4.2.7 How much would they pay? 
The most that a patient was willing to pay for the service was £50. The average that the 
subjects were willing to pay was £17.00 with a standard deviation of £9.30. This data is 
represented in figure 4.3. 
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Figure 4.3: The amount each of the patients was willing to pay for a dry eye 
consultation in their area. N = 50. 
 
 
4.3 Discussion 
The eye drops used in this study were commercially available, unpreserved eye drops, 
currently used for the treatment of dry eye. Artificial eye drops have been designed with 
a focus on physical properties relating to wetting of the ocular surface and usually 
contain hydrophilic polymers, which lubricate the eye during blinking (Lemp, 1973). The 
ideal tear replacement should have a composition which is compatible with the 
maintenance of a normal ocular surface epithelium (Aragona et al., 2002). In the 
presence of ocular damage, the artificial tear solution should provide an environment in 
which the epithelium can recover the normal structure and function (Aragona et al., 
2002). 
 
Amongst the 50 patients participating in the study, the most frequently preferred 
artificial eye drop was Clinitas Soothe (17 patients), followed by TheraTears (15 
patients), Tears Again (11 patients) and lastly Hyabak (7 patients). The patients rated 
these taking in to consideration the overall ease of insertion of the drops, overall 
comfort after using the drops and the clarity of their vision after having used the drops. 
It was important to investigate whether the patients’ preferred drops could be predicted 
from the initial baseline measurements taken. Therefore, the baseline characteristics of 
patients who preferred each drop were compared to the patients who preferred the 
other treatments.  
 
0
5
10
15
20
25
30
35
£0-£10 £11-£20 £21-£30 £31-£40 £41-£50
Number of patients 10 33 3 3 1
N
u
m
b
e
r 
o
f 
P
at
ie
n
ts
 
155 
 
Clinitas Soothe and Hyabak were preferred by those with a higher Tearscope NITBUT 
which seems counterintuitive. The key lubricating ingredient in these two eye drops is 
sodium hyaluronate, which is a naturally occurring glycosaminoglycan of the 
extracellular matrix that plays an important role in development, wound healing and 
inflammation (Inoue et al., 1993). Sodium hyaluronate eye drops have shown efficacy 
in several trials for the treatment of dry eye (Sand et al., 1989; Shimmura et al., 1995; 
Hamano et al., 1996; Avisar et al., 1997; Yokoi et al., 1997; Papa et al., 2001; Aragona 
et al., 2002). Sodium hyaluronate has been used in the treatment of dry eyes because 
of its long ocular surface residence time (Graue et al., 1980; De Luise et al., 1984; 
Snibson et al., 1990; Shimmura et al., 1995; Aragona et al., 2002). Experimental data 
show that sodium hyaluronate eye drops do not alter the normal conjunctival 
epithelium, as may happen with other lacrimal substitutes. In fact, eye drops primarily 
containing this constituent do not interfere with secretory processes of goblet cells and 
do not damage the intercellular junctions as may happen with other tear substitutes 
(Aragona et al., 2002). Sodium hyaluronate eye drops increase pre-corneal tear film 
stability and corneal wettability; reduce the tear evaporation rate, and the healing time 
of corneal epithelium (Tsubota et al., 1992; Nakamura et al., 1993; Shimmura et al., 
1995; Hamano et al., 1995).   
 
Experiments in animals have shown that sodium hyaluronate promotes corneal 
epithelial wound healing by stimulating the migration, adhesion and proliferation of the 
corneal epithelium (Stuart et al., 1985; Nishida et al., 1991; Inoue et al., 1993). The 
mechanism of action of sodium hyaluronate on these cell functions remains 
controversial (Nishida et al., 1991; Nakamura et al., 1993; Fitzsimmons et al., 1992; 
Lindquist et al., 1993). Human studies have been confined to the in-vivo topical 
instillation of sodium hyaluronate drops in eyes with epithelial problems (Norn, 1981; 
Yokoi et al., 1995). The trans-membrane cell surface adhesion molecule (CD44) 
receptor which has been identified on healthy human corneal epithelial cells 
demonstrates an increase in inflammation proposing its significance in corneal 
epithelial cell physiology (Aruffo et al., 1990; Zhu et al., 1997). Its expression has also 
been found to correlate with corneal re-epithelialisation, suggesting its involvement in 
cell to cell and cell to substratum interactions that mediate cell migration during re-
epithelialisation (Yu et al., 1998). Studies have also shown that CD44 expression is 
associated with proliferation of epithelial cells (Abbasi et al., 1993; Günthert et al., 
1993; Lesley et al., 1993; Mackay et al., 1994); however, the reason for this association 
is not known. Sodium hyaluronate is said to form a compound with CD44 (Zhu et al., 
1997). Conflicting results have been obtained regarding the efficacy of sodium 
hyaluronate on ocular surface damage. Wysenbeek et al., (1988), indicated that 
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hyaluronate is able to protect the corneal epithelium and Condon et al., (1999), have 
reported a reduction in cell degeneration as assessed by rose bengal. On the other 
hand, Nelson et al., (1988), have published a report stating that sodium hyaluronate did 
not change significantly the degree of squamous metaplasia of the bulbar conjunctival 
surface, as shown by impression cytology during a short term treatment period. 
 
A topical application of sodium hyaluronate has been shown to confer both subjective 
and clinical improvement in patients with dry eye syndrome (Gill et al., 1973; Polack et 
al., 1982; De Luise et al., 1984; Stuart et al., 1985; Shimmura et al., 1995; Papa et al., 
2001). A study conducted by Aragona et al., (2002), showed that for the tests 
considered (tear film break up time, fluorescein staining, rose bengal staining, and 
Schirmer test) there was no statistical significant difference between their treatment 
groups (i.e. the two groups were patients being treated with preservative free sodium 
hyaluronate or saline). However, they appeared to be an improvement over baseline 
for all. They concluded that sodium hyaluronate may effectively improve ocular surface 
damage associated with dry eye syndrome. Another study also conducted by Aragona 
et al., (2002), also confirmed that symptoms were statistically significantly improved as 
well as the BUT and fluorescein, and Rose Bengal scores from baseline. Gomes et al., 
(2004), investigated the effect of sodium hyaluronate on human corneal epithelial cell 
migration, proliferation, and CD44 receptor expression. They concluded that sodium 
hyaluronate promotes migration but not proliferation or CD44 expression on human 
corneal epithelial cells in vitro. The beneficial effect of sodium hyaluronate in corneal 
wound healing is likely to be related to rapid migration of cells leading to rapid wound 
closure. This may be facilitated by the adhesion between CD44 on the cells and 
hyaluronic acid. 
 
TheraTears was preferred by those with a lower tear volume. A study by Matheson 
(2006) reported that 87.5 per cent of patients were free of dry eye symptoms at 1 week 
after treatment and 100 percent of the patients were free of dry eye symptoms after 
being treated with TheraTears. TheraTears is hypotonic and has been shown to 
produce sustained lowering of the elevated tear film osmolarity with continued 
treatment (Gilbard et al., 1992). TheraTears precisely matches the electrolyte balance 
of the human tear film (Gilbard, 1988; 1994; Gilbard et al., 1989). Therefore by lowering 
the elevated tear film osmolarity and providing this electrolyte balance TheraTears has 
been shown to lessen symptoms and restore conjunctival goblet cells in dry eye 
patients following LASIK (Lenton et al., 1998). Perrigin and colleagues (2004), 
examined 21 different lubricating agents; with one-third being preservative free and the 
remaining containing preservatives, concluding that from the 21 common ocular 
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lubricants tested, TheraTears has an osmolality value statistically significantly lower 
than all other products tested. 
 
The patients who preferred Tears Again appeared to have lower tear lipid layer 
observation, and a significant improvement in keratometer derived TBUT, an increase 
NaFL TBUT, and a thinner (lower grade) lipid film layer. Dieter et al., (2006), found an 
improvement in LIPCOF, NIBUT, Schirmer, visual acuity and inflammation of the lid 
margin. The patients reported their subjective evaluation concerning efficacy and 
compatibility of the eye spray turned out to be more favourable with 74.6 % of the 
patients favouring the liposomal spray. Research conducted by Craig et al., (2010), 
concluded that subjective reports were consistent of improved comfort, statistically and 
clinically significant improvements in lipid layer thickness and tear film stability are 
observed in normal eyes for >1 hour after a single application of a phospholipid 
liposomal spray. Comfort improved relative to baseline in 46% of those treated at 30 
min post-application and 68% preferred the liposomal spray.  
 
The artificial tear which gave the most improvement in subjective ocular comfort, tear 
film stability or volume and clinical signs did not match patient’s preferred artificial tear 
for the majority of patients except for TMH and PRT for Clinitas Soothe and even then, 
this was only the case in less than half of patients. Hence, preference for an artificial 
tears must be based on a more complex decision making process. Greater preference 
for an artificial tear could be expected to give better patient compliance, but 
unfortunately this may not relate to the formulation that is best for the patient’s ocular 
physiology. 
 
The tests identified in chapter 2 as contributing individually to the diagnosis and 
monitoring of dry eye would take no longer than 20 minutes including the advice given 
to the patient and any special instructions. The average cost of the materials including 
the staining dyes and the Tearscope chips and the lease of the equipment would cost 
no more than £25 (chips for Tearscope ~ £17.00 per pair, staining strips ~ £0.80, PRT 
~ £2.00, equipment lease ~ £5.00) and this is not taking in to consideration the 
optometrists time which would estimate at £24 for a 20minute appointment. However, 
the average cost that patients from this trial were only willing to pay £17.00, the cost of 
a private sight test at the practice is £20. It has been reported that in order to know the 
‘true cost’ of an optometrists’ clinical time can range from approximately £50 for a 20 
minute appointment in a busy practice, to £150 or more for a 30 minute appointment in 
a part time practice (Russ, 2008).  The current NHS sight test fee (1st April 2014 to 
31st March 2015) is £21.10 (FODO.com), whereas the average private sight test fee of 
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£21.30 (FODO, 2011), which do not cover an optometrists’ clinical time and overheads 
of the practice. The survey conducted by Mason and Mason, (2002), concluded that 
41% of optometrists were dissatisfied and 44% very dissatisfied with present methods 
for the GOS and other co-managements schemes. Customarily the profit from 
spectacles and contact lens sales at an optical practice has been utilised to finance the 
true cost of professional optometrist fees, such as eye examinations (Calver, 2010). 
 
The reimbursement of the cost of the assessment of these dry eye patients could be 
discussed with the local health authorities who have consortium called the First Choice 
Eye care group, in order for the local health authority to either subsidise these 
payments or fund them for patients in the community.  Currently the co management 
fees for optometrists’ caring for post cataract patients; under the first choice eye care 
scheme is £40 per test. Also under this scheme, patients who present at the request of 
their GP or other health care professionals for conditions such as, ectropion, entropion, 
dry eye, red eye, photopsia, sudden loss of vision, sub conjunctival haemorrhage and 
any other eye condition; would get a fee of £50 on the initial visit and £25 on 
subsequent visits if the patient requires to be reviewed by the optometrist.  
 
Doughty (2010) reported that at the time for 39 dry eye products currently marketed in 
2010 the UK the recommended retail prices range from just £1.50 per bottle to as much 
as £36.20 for a multi-pack of a preservative-free product; the average cost per product 
(as packaged for retail sale) was approximately to £7.50. The average retail cost of 
multi-dose eye drop bottles were closer to £5.00 (range £1.50 to £13.80), while 
preservative-free eye drop products were much higher, averaging £13.00 (range £3.99 
to £36.20). Patients using the preservative-free eye drops on an average of six times 
per day instead of QDS, due to moderate or severe dry eye, their estimated costs 
would range from £12.00 per month to as high as £56.85 per month, for an average of 
£32.18 per month (Doughty, 2010). Therefore patients would be paying for these drops 
if not eligible on the NHS. If a drug company wants to enlist its drug in order to have it 
prescribed on the NHS, it would have to apply to the DOH prescribing department who 
would analyse the evidence for the drug and the price the NHS would pay for it and is 
then agreed. Tears Again spray and TheraTears are currently unavailable on the NHS, 
and therefore cannot be prescribed to patients on the fp 10 (NHS prescription) from 
their GP. This is due to the drug company and DOH not agreeing on the price the NHS 
would pay for these artificial eye drops. 
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4.4 Conclusion 
When trying to predict patient preference for artificial tears from baseline 
measurements, each individual category of artificial tears appeared to have a 
significant improvement in at least one tear metric test performed. However, the 
artificial tears were only used for one month and if patients had used them for a longer 
period there could be a significant difference from baseline in more than one test for 
each category of eye drop.  
 
Undoubtedly from the study the patients preferred the artificial drops because their 
subjective responses were statistically significant than the signs. They rated the 
preferred drops much higher than the other drops.  
 
The cost of specialist services is an arduous factor to explore in an optometric clinical 
setting, due to the patients being entitled to free NHS examinations due to low income 
or health reasons, as well as receiving help towards the cost of spectacles or contact 
lenses.  
 
Even though patients are willing to pay for a dry eye service in their community, the 
average cost involved in charging them would be no less than £25, which would be a 
challenge as the average that they were willing to pay was £17. The cost of this type of 
specialist service may have an effect on patients expectations of the services received. 
However, we are entering in to talks with the local First Choice Eye care consortium 
financed by the CCG, to either get this cost financed completely or partially if referred 
by the GP.  
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CHAPTER 5 
 
Final Summary and Future Direction 
 
Dry eye is a significant problem where we are beginning to understand the mechanism. 
As outlined in chapter 1 there are various tests aimed at diagnosis and this should lead 
to effective treatment. There are numerous treatment options for dry eye disease e.g. 
blink exercises, lid hygiene and warm compresses, autologous serum tears, punctal 
plugs, anti-inflammatory therapy, essential fatty acids, environmental strategies and 
artificial eye drops.  
 
Although there are many topical lubricants available, that may improve patient 
symptoms and ocular surface improvement, there is no evidence that any particular 
artificial tear treatment is superior to another (DEWS, 2007). Clinical trials involving 
topical artificial tears have reported some improvement of subjective symptoms and 
improvement in some clinical signs (Nelson et al., 1992).  As there is currently no study 
investigating which treatment works best for different patients; the try and see 
approach of patients who have symptoms can’t be much improved upon. However, 
patients are likely to give up on treatment and live with the long term reduction in 
quality of life caused by dry eye (Atkins, 2008; Doughty, 2009; Rogers, 2009), if their 
initial treatments are ineffective. Hence, from the various clinical treatments available 
for dry eye, it would help if practitioners not only knew which dry eye tests were the 
most effective to diagnose dry eye, but also indicated which treatment (artificial tears) 
should be attempted initially from evidence basis. Therefore, this thesis initially 
examined how clinical tests of dry eye were interrelated and whether distinct clusters of 
dry eye patients could be identified. 
 
Dry eye disease is a common clinical condition whose aetiology and management 
challenges clinicians and researchers alike. Patients may attend the practice 
mentioning that they suffer from gritty, burning, irritated, eyes. Other symptoms include, 
foreign body sensation, blurred vision and photophobia, or uncomfortable feeling eyes 
particularly in the evening (Begley et al., 2003). 
 
There are multiple clinical tests to evaluate the tear film, which either help evaluate the 
stability of the tear film, the volume of the tears or the tears’ osmolarity. These tests 
include: non-invasive break up time (NIBUT), tear meniscus height (TMH) and 
regularity, phenol red thread test (PRT), sodium fluorescein tear break up time (NaFL 
TBUT) and tear lipid analysis. Other tests help to evaluate the effect of dry eye on the 
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ocular surface; these tests include: corneal staining, lissamine green conjunctival 
staining and lid parallel conjunctival folds (LIPCOF). Symptomology is also very 
important in order to diagnose correctly as well as to try and help with dealing with 
patient expectations of their treatments and as a measure of how the patients are 
feeling with their current dry eye treatment or dry eye condition.  
 
A successful cure for dry eye disease has still to be found.  At present treatment goals 
are directed towards either ‘tear replacement’ or ‘tear retention’, and are aimed 
primarily at relieving the subjective symptoms associated with this condition (Farrell, 
2010). Artificial tears remain the essential agent used in the treatment and 
management of dry eye regardless of the cause or type (Farrell, 2010). There is 
currently a variety of products available on the market for the ‘dry eye’ patient to 
choose from. The various artificial tear supplements available are aqueous artificial 
tears, liposomes, ocular lubricants or viscoelastics. Each of these categories has an 
active ingredient and may or may not contain preservatives. Even though the primary 
principle of successful dry eye treatment is to improve the ocular surface and prevent 
damage to the cornea, it is also important to try to provide relief of symptoms and so 
offer the patient some degree of satisfaction (Asbell et al., 2010). The final point for 
relief or provision of satisfaction is, however, likely to vary between patients and the 
practitioners managing the patient. A patient with a dry eye is likely to suffer from some 
symptoms; hence, successful treatment may just be that the frequency of symptoms 
has subsided. Patient satisfaction with treatment may, also, be related to the cost, i.e. 
relief from the use of an inexpensive product may be considered adequate in 
comparison to gaining slightly more relief from use of a more expensive product. 
 
The aim of chapter 2 was to find the correlation of dry eye tests in clinical practice. A 
large cohort typical of clinical optometric practice of 150 subjects was recruited. There 
was sampling bias as the patients were recruited from optometric practice and not from 
the general population and only one site in the UK was used. However, the population 
was relevant to patients likely to be managed by optometrists, at least in that location in 
the UK. A cluster analysis technique was conducted in order to appreciate if there was 
a presence of any groups of tear film metrics using cluster analysis. When investigating 
the correlation of the various tests conducted in practice in chapter 2, it was concluded 
that the tear stability tests are correlated. These results demonstrate that NIBUT and 
NaFL TBUT are both not necessary to perform in clinical practice. It is proposed it 
would be more appropriate to observe the tear stability by performing the NIBUT as the 
potential for fluorescein disrupting the tear film structure as has been suggested by 
other authors (Mengher et al., 1985; DEWS, 2007). The tear volume tests are also 
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related and so any of the two (tear meniscus height and phenol red test) can be used in 
clinical practice. In addition to a tear stability and tear volume test, it is worth 
performing: a validated questionnaire to assess patient symptomology such as the 
OSDI (self-completed so it need not consume consultation time and is a good 
symptomology metric to monitor and communicate to patients); LIPCOF, lissamine 
green conjunctival staining, corneal fluorescein staining and a measurement of the tear 
osmolarity. This combination test was found in chapter 2 to provide independent 
information towards the definition of dry eye and therefore its diagnosis and potentially 
optimal treatment (not just diagnosis as reviewed by DEWS (2007)). 
 
Two factors influenced the DEWS (2007) recommendations of diagnostic tests for dry 
eye disease. Formerly, numerous tests derived from studies that were subject to 
various forms of bias i.e. spectrum bias where bias due to differences in the features of 
different populations e.g., sex ratios, age, severity of disease, which influences the 
sensitivity and/or specificity of a test and selection bias where bias built into an 
experiment by the method used to select the subjects who are to undergo treatment, 
meaning that the cut offs that they proposed may be unreliable. Secondly, several tests 
with excellent credentials are not available outside of specialist clinics. Therefore, 
offering a practical approach to the diagnosis of dry eye disease based on the quality of 
tests currently available and their practicality in a general clinic. It has also been 
suggested that practitioners appraise for themselves the credentials of each test by 
referring to the report (DEWS, 2007). 
 
There are seven sets of validated questionnaires of differing length which practitioners 
can adopt for routine screening in their clinics, taking in to consideration the qualitative 
differences between the tests (DEWS, 2007). These tests have been summarised in 
table 5.1 below.  
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Table 5.1: A number of symptom questionnaires in current use (Taken from 
DEWS, 2007). 
 
The dry eye component of the international classification criteria for Sjögren syndrome 
requires one ocular symptom (out of three) and one ocular sign (out of two) to be 
satisfied.  
 
For ocular symptoms: a positive response to at least one of the following questions: 
 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 
months?  
2. Do you have a recurrent sensation of sand or gravel in the eyes?  
3. Do you use tear substitutes more than 3 times a day? 
 
For ocular signs: that is, objective evidence of ocular involvement defined as a 
positive result for at least one of the following two tests:  
 
1. Schirmer I test, performed without anaesthesia (≤5 mm in 5 minutes)  
2. Rose bengal score or other ocular dye score (≥4 according to Van 
Bijsterveld’s scoring system) (Vitali et al., 2002). 
 
Tear Evaluation  
 
Tear osmolarity: Tear hyperosmolarity may reasonably be regarded as the signature 
feature that characterizes the condition of “ocular surface dryness” (DEWS, 2007). In 
several studies, as illustrated in Table 1.8, development of a diagnostic osmolar cut-off 
value has utilized appropriate methodology, using an independent sample of dry eye 
patients. Hence, the recommended cut-off value of 316 mOsms/L can be said to be 
well validated (Tomlinson et al., 2006). As an objective measure of dry eye, 
hyperosmolarity is attractive as a signature feature, characterizing dryness (DEWS, 
2007). 
 
Non-invasive break-up time: If the studies shown in Table 1.8 that are potentially 
susceptible to selection or spectrum bias are ignored, the simple clinical alternative for 
dry eye diagnosis might be non-invasive TFBUT measurements that give moderately 
high sensitivity (83%) with good overall accuracy (85%)(DEWS, 2007). 
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DEWS (2007), has further recommended that an improved test performance can be 
achieved when tests are used in combination, either in series or in parallel. Taking this 
advice in consideration for the purpose of this study symptomology as measured by the 
OSDI, LIPCOF, TMH, NIBUT, TBUT, corneal staining, lissamine green staining and 
tear osmolarity (Details of all these tests have been described in detail in chapter 1). 
 
It can also be concluded from our study that there is no consistent relationship found 
between signs and symptoms of DED. However, each measurement offers distinct 
information about the condition of the ocular surface. Symptoms alone are insufficient 
to diagnose DED, and more than one test should be carried out in order to achieve the 
desired results with treatment. All these tests are not common in standard optometric 
practice, although within the competencies of most optometrists. Hence the necessity 
for specialist dry eye clinics conducting these specific tests is merited, rather than 
practitioners ‘diagnosing’ and proposing inadequate treatments for DED on grounds of 
less relevant examinations carried out as a small subset of the full eye examination.  
 
Chapter 3 reports on a randomised clinical trial which aimed to find the relative 
effectiveness of different categories of tear supplements. The choice of products were 
categories aimed to improve lipid, increase viscosity and the osmolarity of the tears, so 
should have generality to dry eye products currently on market. It was concluded that 
artificial tear supplements do work for ocular comfort, and by observing the ocular 
surface improvement in the conjunctival tissue as observed by the presence of LIPCOF 
and conjunctival staining. However there does not seem to be an improvement in the 
tear film quality or volume despite the fact that the conjunctival tissue appears to show 
an improvement, and one would think that in turn that would provide a better mucus 
layer which should in turn support the tear film. However, this study was only 
conducted over a four month period and if it was continued for a longer period 
improvement in the tear stability and volume might become evident.  
 
There does not seem to be any strong evidence of one class of artificial tear 
supplement being more effective than the others when categorised as moisture 
retaining, lipid based or osmolarity based. The patients used these drops for one month 
and the carried on to use another tear supplement for the next month, with positive 
effects observed with visit regardless of treatment order. This suggests that 
improvements can be more due to the time rather than the specific drops. In practice 
this suggests the importance of explaining to patients that while there might be 
immediate relief to symptoms, further benefits to comfort and ocular surface damage 
can be gained by longer term use and aftercares should be scheduled accordingly. A 
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wash-out period between drops was considered in the study design, but as the patients 
were symptomatic of dry eye, a period without treatment was unlikely to be complied 
with and the ethics could be challenged. However, the masked, counter balanced 
sequence of drop use overcame bias between the examinations of the effectiveness of 
the different drops. The conjunctival signs of dry eye such as LIPCOF and lissamine 
green staining improved beyond the first month period. Hence, this suggests that these 
are particularly sensitive indicators of dry eye damage that can be restored in a 
relatively short time interval with treatment, even though an immediate association with 
comfort is not seen. 
 
Few other studies have compared multiple treatments; however a lot of the authors 
have conducted studies with similar drops to saline or other drops in the category of the 
artificial tear supplements being trialled.  Studies conducted by Mengher et al., 1986; 
Condon et al., 1999 and Aragona et al., 2002 all showed a benefit in the ocular surface 
and symptomology by using Sodium Hyaluronate. Dieter et al., (2006); Craig et al., 
(2010) and Pult et al., (2012), investigated the ocular effects with liposomal sprays and 
the results of these studies showed an improvement in ocular surface and ocular 
comfort. Therefore, for future work, a longer duration of treatments should be 
considered. It would also be beneficial to use the TearLab at each visit in order to 
observe the osmolarity results and calculate whether there is any correlation between 
the treatment and osmolarity (not undertaken in this study due to the cost).  
 
The final part of this thesis (chapter 4) examined the ability to predict patient preference 
for artificial tears. If designed correctly a lipid based treatment should work best for 
those with higher lipid deficiency and so on. It was concluded that when trying to 
predict patient preference for artificial tears from baseline measurements, each 
individual category of artificial tears appeared to have a significant improvement in at 
least one tear metric test performed. It can be noted from this study that patients who 
preferred a particular artificial eye drop was mainly due to the fact that their eyes felt 
better, (i.e. it was subjective in that their eyes ‘felt’ comfortable, and objectively their 
eyes may not have appeared to look any better or have improved physiology). These 
patients obviously rated their preferred drops higher in overall performance to the rest 
of the drops used in the study (see section 3.2.2.9 and figure 3.10). Therefore there 
was some prediction of preference, but preference was not related to improvement in 
signs. Cluster grouping of dry eye signs and symptoms did not assist in predicted 
preference of treatment. 
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Patients were asked at the end of the study if they were willing to pay for a dry eye 
service in their community. This is because in the area in which the studies were 
conducted, many patients were going to their GPs for dry eye problems that could be 
effectively treated in the community. The average cost that the patients were willing to 
pay for this ‘dry eye community service’ was £17, but the minimum that would be 
feasible to charge for this service is £25. The LOCAL Optical Committee Support Unit 
(LOCSU) welcomed comments from the head of NHS England which promote 
community-based services as the future of UK healthcare (O’Hare, 2014). Sir David 
Nicholson, spoke of the need for increased investment to help the NHS move away 
from an ‘unsustainable’ hospital-based treatment system. He added that the extra 
money would be used to move to a new model of community-based services, without 
which the NHS will see a decline in the level of care and public support for the health 
service. He told the Guardian: ‘A large proportion of hospital care should be delivered 
in community settings if the NHS is to cope with the pressures posed by the ageing 
population, the rise in the number of patients with one or more long-term conditions 
such as asthma or diabetes, and demand for new treatments’ (O’Hare, 2014). 
 
Managing director of LOCSU, Katrina Venerus, commented that there was a ‘real 
urgency for fundamental change’ in how eye health services are delivered in the UK. 
She said ‘Innovation funding to support the development of community services would 
enable [Clinical Commissioning Groups (CCGs)] to succeed in reducing what Sir David 
referred to as its ‘outmoded reliance on hospital-based care’. And also added ‘We 
know that, despite the fact that research shows that nearly four out of five people 
attending eye casualty have conditions that can be deemed ‘non-serious’, just over 
10% of CCGs have commissioned community-based minor eye condition services’ 
(O’Hare, 2014). Therefore, in order for the public to seek expert advice about eyes from 
an optometrist, it would be greatly beneficial working with LOCSU and CCGs to 
develop the business case for dry eye clinics run by qualified optometrists.  
 
In conclusion, this thesis has added to the academic literature on the most appropriate 
current clinical tests to conduct as part of a dry eye work-up to aid the choice of the 
optimum artificial tears treatment. Cluster analysis was performed for the first time on 
such a cohort, but was not found to aid the optimisation of treatment. All artificial 
treatments assessed offered similar benefits in signs and symptoms, despite being 
chosen to represent the range of formulations currently available. On the individual 
patient level, preference was predictable to some degree by the individual tear film 
tests prior to treatment which could inform practitioner treatment choices. Treatment 
effects continued for the full 4 month period that patients were using the different drops, 
167 
 
an improvement particularly in conjunctival tissue assessments, but tear stability 
improvements were not detected over this period. Therefore, in order to answer the 
question ‘What is the optimum artificial treatment for dry eye?’, there is no optimum 
artificial treatment to dry eye, as all the various drops used in the study presented 
similar benefits in signs and symptoms of the patients over the period of the study. 
Hence patients should be encouraged to have perseverance in the use of artificial tears 
and regular aftercares to encourage compliance. In addition, further research is 
warranted to determine the natural history of the benefits and whether this is 
predictable in individual patients. Finally this thesis has informed the need for and cost 
effectiveness of a local optometrist based dry eye service to manage this chronic 
condition.    
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APPENDIX A:  ETHICS FORM 
 
 
ETHICS FORM 
 
All parts of the Ethics Application must be written concisely using terminology that would be 
understandable to an educated lay person on an ethics committee.   
 
Title: Optimising the Treatment of Dry Eyes 
 
Principal Investigator: Prof James Wolffsohn 
Contact Details: j.s.w.wolffsohn@aston.ac.uk x4160 
Other Staff / Students involved: Laika Essay (OD student) 
 
A. PROJECT OBJECTIVES / BACKGROUND  
A1.  What are the primary research questions / objective? 
To determine the optimum pharmaceutical treatment for dry eye from pre-treatment clinical tear 
film assessment 
A2.  Where will the study take place? 
Clinical Optometric Practice Specsavers Opticians, 83 Victoria Road west, Thornton – Cleve leys, FY5 
1AJ, Lancashire. Tel: 01253 864 130 
 
A3.  Describe the statistical methods and/or other relevant methodological approaches to be used in the 
analysis of the results (e.g. methods of masking / randomization) 
Randomized order, investigator masked, repeated measure treatment. The subjects will not be 
masked as this would not affect the sterility of the solutions.  
A4.  List the clinical techniques to be conducted on patients as part of the study and indicate whether they 
fall within the scope of normal professional practice of the individual to perform them 
Tear film will be assessed using the tearscope (lipid thickness and break-up time, tear meniscus 
height, lid wiper epitheliopathy, lissamine green and fluorescein staining, phenol red test, a dry 
eye questionnaire and comfort/use diary. 
 
ENCLOSE AN OUTLINE OF THE STUDY RATIONALE AND METHODOLOGY Attached 
 
B. RESEARCH PARTICIPANTS 
B1.  How many participants will be recruited? Please provide justification (power analysis software 
available from http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/) 
50 patients will be recruited allowing at least 15 degrees of freedom if the clinical measures are 
grouped into 3 categories. 
 
B2.  What restrictions will there be on participation (age, gender, language comprehension etc.)? 
Self-reported dry eye for at least a year with no seasonal element and a desire for treatment 
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No reaction to previous solutions applied to the ocular surface. 
On stable medication or not taking any medication known to affect the tear film 
Non-contact lens wearers 
Not had eye surgery within the previous 3 months 
No active ocular surface pathology 
At least 18 years of age 
Willing to take part in the study 
B3.  How will potential research participants in the study be (i) identified, (ii) approached and (iii) recruited?  
If research participants will be recruited via advertisement then attach a copy of the advertisement in the 
appendix of the ethics report. 
Patients meeting the inclusion criteria assessed as part of their normal clinical eye examination 
will be given the information sheet and may agree to take part in the study at any time after this 
by contacting the practice. 
B4.  Will the participants be from any of the following groups? Tick as appropriate and justify any 
affirmative answers. 
Children under 16:                                                                                    
Adults with learning disabilities:                                                                  
Adults who are unconscious or very severely ill:                                         
Adults who have a terminal illness:                                                             
Adults in emergency situations:                                                                  
Adults with mental illness (particularly if detained under Mental Health Legislation):  
Adults suffering from dementia:                                                                  
Prisoners:                                                                                                  
Young Offenders:                                                                                      
Healthy volunteers:                                                                                       other than dry eyes 
Those who could be considered to have a particularly dependent relationship 
with the investigator, e.g. those in care homes, students:                     patients 
Other vulnerable groups:                                                                           
Participants will need to be healthy patients (other than dry eyes) to enable recruitment. It will 
be made clear to them that choosing not to take part will not affect their clinical treatment. 
B5.  What is the expected total duration of participation in the study for each participant? 
4 months  
B6.  Will the activity of the volunteer be restricted in any way either before or after the procedure (e.g. diet 
or ability to drive)? If so then give details. 
No, although patients will be asked to report possible large changes in lifestyle over the duration 
of the study 
B7.  What is the potential for pain, discomfort, distress, inconvenience or changes to life-style for research 
participants during and after the study? 
Lissamine green instillation, fluorescein instillation and phenol red testing can be slightly 
uncomfortable for a short period. The tear film supplements should assist rather than hinder 
comfort. The patients will be required to attend additional visits to assess the health of their 
eyes, but these will be free and the free comfort drops should compensate for this 
inconvenience.  
B8.  What levels of risk are involved with participation and how will they be minimized? 
A reaction to the preservative in a tear supplement, in which case the drop can be stopped 
immediately and the optometrist consulted if desired. The Phenol Red thread and tear lab are 
highly unlikely to significantly damage the cornea or conjunctiva, there are no known cases of 
clinically significant damage or lasting symptoms.  
B9.  What is the potential for benefit for research participants? 
Free dry eye treatment for 4 months and the identification of the optimum treatment for them. 
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B10.  If your research involves individual or group interviews/questionnaires, what topics or issues might 
be sensitive, embarrassing or upsetting?  Is it possible that criminal or other disclosures requiring action 
could take place during the study? 
No upsetting or disclosure questions  
C. CONSENT 
C1.  Will a signed record of informed consent be obtained from the research participants?  If consent is not 
to be obtained, please explain why not.  
Yes 
ENCLOSE A PARTICIPANTS INFORMATION SHEET (including a clear statement of what will happen to 
a volunteer) & CONSENT FORM Attached 
 
C2.  Who will take consent and how it will be done?  
The optometrist – Laika Essa BSc (Hons) 
 
C3.  How long will the participant have to decide whether to take part in the research? Justify your answer. 
As long as they need – the subjects can be considered as non – participants after a month has 
elapsed  
C4.  What arrangements are in place to ensure participants receive any information that becomes 
available during the course of the research that may be relevant to their continued participation? 
The practice holds contact details on all patients 
C5.  Will individual research participants receive any payments/reimbursements or any other incentives or 
benefits for taking part in this research?  If so, then indicate how much and on what basis this has been 
decided? 
Free tear supplements. Subjects will not be reimbursed for any additional travel required for 
multiple visits.  
C6. How will the results of research be made available to research participants and communities from 
which they are drawn?  
By publication on completion of the study. The participant will be offered a summary sheet of 
their individual findings at the end of the study. 
D.  DATA PROTECTION 
D1.  Will the research involve any of the following activities? Delete as appropriate and justify any 
affirmative answers.  
Examination of medical records by those outside the NHS, or within the NHS 
by those who would not normally have access:  
Electronic transfer of data by e-mail:  
Sharing of data with other organizations:  
Use of personal addresses, postcodes, faxes, emails or telephone numbers:  
Publication of direct quotations from respondents:  
Publication of data that might allow identification of individuals:  
Use of audio/visual recording devices:  
The data spreadsheet will be password protected with Microsoft encryption 
D2.  Will data be stored in any of the following ways? Delete as appropriate and justify any affirmative 
answers.  
Manual files:  
Home or other computers:  
University computers:  
The data spreadsheet will be password protected with Microsoft encryption 
D3. What measures have been put in place to ensure confidentiality of personal data? Give details of 
whether any encryption or other anonymisation procedures will be used, and at what stage.  
The data spreadsheet will be password protected with Microsoft encryption. Patient contact 
details will not be recorded as can be linked to patient files 
D4. If the data is not anonymised, where will the analysis of the data from the study take place and by 
whom will it be undertaken? 
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At the university/practice and by the investigators. 
D5. Other than the study staff, who will have access to the data generated by the study? 
No one 
D6. Who will have control of, and act as the custodian for, the data generated by the study? 
Prof J Wolffsohn 
D7. For how long will data from the study be stored [minimum 5 years]? Give details of where and how the 
data will be stored. 
5 years in a locked data storage room and on computer storage in encrypted pass worded form 
E.  GENERAL ETHICAL CONSIDERATIONS 
E1.  What do you consider to be the main ethical issues or problems that may arise with the proposed 
study, and what steps will be taken to address these?  
Patients’ time to take part in the study, but this is voluntary and they benefit from free 
consultation and free tear film supplements. 
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APPENDIX B:  ETHICS APPROVAL 
 
 
 
 
Response from AOREC 
25
th
 March 2010 
Project title: Optimising the Treatment of Dry Eyes 
 
Reference Number: Essa OD 
Researchers: Laika Essa and Prof James Wolffsohn 
 
I am pleased to inform you that the Audiology / Optometry Research Ethics Committee has 
approved the above named project. 
 
The details of the investigation will be placed on file. You should notify The Committee of any 
difficulties experienced by the volunteer subjects, and any significant changes which may be 
planned for this project in the future.  
 
 
Yours sincerely 
 
 
 
Chair AOREC 
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APPENDIX C:  OSDI QUESTIONAIRE 
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Appendix D:  PATIENT CONSENT FORM 
     
   
 
 
 
Personal Identification Number for this study: ____________ 
 
CONSENT FORM 
 
 
Title of Project:  Optimising the Treatment of Dry Eyes 
 
Research Venue: Clinical Optometric Practice 
 
Name of Investigator(s): Laika Essa and James Wolffsohn 
 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet dated ............................ 
  (version ............) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
  without giving any reason, without my legal rights being affected. 
 
3. I agree to take part in the above study.    
 
 
 
 
________________________ ________________
 ____________________ 
Name of Research Participant Date Signature 
 
 
 
 
_________________________ ________________
 ____________________ 
Name of Person taking Consent Date Signature 
 
 1 copy for research participant; 1 copy for practice. 
 
 
